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ABSTRACT 
Adverse drug reactions remain a major health issue with delayed type hypersensitivity reactions 
developing in a high number of individuals. The cellular immunological processes that underlie 
drug-specific responses in hypersensitive patients have been previously described; however the 
involvement of the humoral immune system has not been studied in great detail. Consequently, 
this thesis explores the nature of the piperacillin-specific B cell response in hypersensitive 
patients and compares the cellular and humoral immune response that develops in patients with 
cystic fibrosis (CF) exposed to repeated courses of the drug.   
Initial studies involved characterization of B cell proliferation, B cell phenotype and the nature of 
total and drug-specific IgG antibody secretions using peripheral blood mononuclear cells (PBMC) 
from hypersensitive patients. For comparison PBMCs from 2 groups of individuals were assessed: 
piperacillin naïve healthy volunteers and piperacillin tolerant patients with CF. ELISA, and ELISpot 
were used to detect piperacillin-specific B cells responses and IgG secretion. T lymphocyte 
proliferation was assessed with the lymphocyte transformation test (LTT). T lymphocytes from 
hypersensitive patients, but not tolerant patients or naïve donors were stimulated to proliferate 
in the presence of the drug. The peak concentration for T cell activation was 1 mM. Phenotypic 
assessment of hypersensitive patients B-cells revealed an increase in CD19+CD27+ expression in 
response to piperacillin treatment in vitro. IgG secreting immortalized B-cell lines also expressed 
a pure CD19+CD27+ phenotype. Piperacillin stimulation of hypersensitive patient PBMC also led to 
an increase in the secretion of IgG. In contrast, IgG secretion was not detectable following 
piperacillin stimulation of PBMC from tolerant patients and healthy controls.    
Western blotting and mass spectrometric methods were applied to characterize -lactam-protein 
covalent binding. Bovine serum albumin (BSA) binding was time- and concentration-dependent 
with hapten densities (i.e., the extent of selective lysine residue modification) and anti-
piperacillin antibody binding affinity increasing with increasing molar ratios. Lysine residues in 
BSA at positions 4, 12, 131, 132, 136, 211, 431, 524, and 537 were modified by piperacillin. Epitope 
profiles also showed similar lysine residues were modified with amoxicillin, benzylpenicillin and 
flucloxacillin though the extent of ionisation at each site of modification was drug-dependent. A 
hapten inhibition ELISA used to assess the specificity of the antidrug antibodies revealed the 
total antibody binding to aztreonam, amoxycillin, benzylpenicillin and penicillin V BSA adducts. 
This indicates a lack of cross-reactivity with piperacillin-specific IgG antibodies. 
Subsequently, LTT and ELISA were employed to screen the piperacillin-specific T cell response 
and IgG antibodies during piperacillin therapy. It was established that piperacillin-specific T cells 
were detectable on and following clinical diagnosis of hypersensitivity. Moreover, piperacillin-
specific T cell responses were detected in a small number of patients currently classified as drug 
tolerant. A significant difference in piperacillin-specific IgG was observed when plasma form LTT 
positive and negative blood samples were compared. LTT positivity was associated with higher 
levels of piperacillin-specific IgG. Furthermore, a significant decrease in piperacillin-specific IgG 
was seen 24 h post-desensitisation (graded drug challenge).  
Piperacillin-specific T cell clones isolated from hypersensitive patients were used to explore the 
effect of plasma bearing anti-piperacillin IgG on the T cell response. Eleven piperacillin-specific 
CD4+ and CD8+ T-cell clones were generated from 2 hypersensitive patients. All clones were 
stimulated to proliferate with piperacillin in a concentration-dependent manner.  IFN-γ and IL-5 
secretion was seen to predominate following piperacillin stimulation. There were no differences 
in piperacillin-specific T-cell proliferation when piperacillin-specific antibody bearing plasma and 
plasma from naive volunteers were compared. However, attenuation in IFN-γ secretion was 
observed with plasma bearing anti-piperacillin antibodies alone.  
Collectively, the data presented in this thesis begins to describe the different components of the 
drug-specific humoral and cellular immune response that develops in piperacillin hypersensitive 
patients with CF.  
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1.0 Introduction  
 
The growth in the repertoire of pharmaceutical agents used in the treatment of disease 
has ensured that adverse drug reactions (ADRs) remain a major health issue, with recent 
studies in the UK indicating that ADRs are a common clinical problem accounting for 2 - 
6% of all hospital admissions (Pirmohamed, James et al. 2004). ADRs have been found to 
affect the skin, liver, blood, kidney and lungs (Mockenhaupt and Schopf 1996, Kudo 2007, 
Uetrecht and Naisbitt 2013) and have been shown to contribute significantly to an 
increase in healthcare costs due to an extended length of hospital stay and the 
requirement of additional clinical investigations in more serious cases (Suh, Woodall et al. 
2000, Pirmohamed, James et al. 2004, Sultana, Cutroneo et al. 2013). In other cases the 
outright withdrawal of the offending agents from distribution and clinical use such as the 
selective serotonin reuptake inhibitor (SSRI) Zelmid withdrawn from clinical use in 1983 
due to adverse neurological effects (Mulinari 2015), and the appetite suppressant FEN-
PHEN (Fenfluramine ("fen") and phentermine ("phen")) withdrawn due to adverse 
cardiovascular effects in 1997 by regulatory agencies (Connolly, Crary et al. 1997, FDA 
1997) led to huge financial losses for the pharmaceutical companies involved (Schindler 
2011).  
The clinical impact of ADRs has thus necessitated the development of ADR monitoring 
and reporting systems collectively referred to as pharmacovigilance. Pharmacovigilance 
as defined by the world health organization is ‘The science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other 
drug related problem’ (WHO). ADRs are a complex disease requiring a multidisciplinary 
approach to understand their pathomechanisms. Basic and clinical pharmacology, 
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chemistry, immunology, clinical medicine, toxicology, epidemiology, and 
pharmacogenetics have all contributed to our understanding of the disease pathogenesis 
(Biffignandi 2009). 
The objective in this chapter is to review current pharmacological, immunological and 
chemistry literature relevant to the study of drug-induced hypersensitivity reactions.  
1.1 Adverse drug reactions: Definitions 
 
An adverse drug reaction (ADR) may be defined according to the WHO as “a response to 
a drug that is noxious and unintended and occurs at doses normally used in man for 
prophylaxis, diagnosis or therapy of disease, or for modification of physiological function 
(WHO, 1972). Edwards and Aronson in their definition of an adverse reaction tried to take 
into account the fact that while some unpleasant reactions may be mild in nature, errors 
in medication, contaminants and supposedly inactive excipients may be responsible for 
the adverse effects being observed. They thus defined ADRs as “an appreciably harmful 
or unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the product.”  
(Edwards and Aronson 2000)  
1.1.1 Epidemiology and risk factors 
Adverse reactions to drugs occur frequently, and in many cases are difficult to avoid. 
Data has shown that a sizeable proportion of hospitalized patients experience a form of 
ADR, which also constitutes one of the most important reasons for hospital admission (2-
6%) with a substantial increase in the elderly. Drug-related hospital admissions in 
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individuals aged over 75 accounts for approximately 30% of all hospitalized patients.  
(Runciman, Roughead et al. 2003, Gamboa 2009). Due to the resultant significant 
morbidity, mortality and socioeconomic impact of ADRs, several studies have been 
carried out to quantify the impact of ADRs. The incidence of ADRs in hospitalized 
patients has been estimated to range from 1.8% in a study conducted at the LDS Hospital 
in Salt Lake City, which identified 731 reactions among 36,653 hospitalized patients 
during an eighteen month period, 6.5% in the United Kingdom, to a maximum of 15.1%  in 
a meta-analysis of thirty three studies conducted in the USA over a thirty year period, 
from 1966-1996 (Classen, Pestotnik et al. 1991, Lazarou, Pomeranz et al. 1998, 
Pirmohamed, James et al. 2004). Epidemiologic data regarding the prevalence of drug 
allergies suggested a varied prevalence among different populations, which could be 
attributed primarily to the different criteria for inclusion and methodologies employed 
(Gomes and Demoly 2005). The apparent lack of reliable data generally obtained from 
respondents by self-reporting from the general population prevents the direct 
comparison of the prevalence between hospitalized and ambulatory patients (Gomes, 
Cardoso et al. 2004, Ensina, Amigo et al. 2010).  
Several classes of drugs including the beta lactams, the non-steroidal anti-inflammatory 
agents, and anti-seizure drugs are associated with a high incidence of ADRs.  -lactam 
antibiotics have been recognized as the most frequent cause of immunological reactions 
(Rodriguez-Pena, Antunez et al. 2006).  
Various factors may play a role in the development of adverse drug reactions, with a 
majority typically due to an extension of the expected pharmacological activities of these 
pharmaceuticals. While this may be the case in a large proportion of reactions, inter-
patient pharmacokinetic and pharmacodynamic variability, pharmacological, 
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immunological and genetic factors are also involved in the development of ADRs. These 
factors could be related to the patient age or sex, the drug employed, and environmental 
or social related issues, as well as disease related factors (Alomar 2014) and genetic 
predisposition (Pirmohamed 2006, Park, Kim et al. 2014).  
Patients at the extremes of age have been shown to be predisposed to the development 
of certain forms of ADRs. Elderly patients that have multiple disease states are exposed 
to multiple drugs and thus are particularly susceptible to the development of ADRs. 
Infants and very young children are also at risk due to their low level of organ and tissue 
development such as immature renal tubular function, physiologic hypoalbuminemia, 
low body fat, and immature blood brain barrier in neonates below the age of 8 weeks 
(Anderson and Lynn 2009, De Gregori, De Gregori et al. 2009, Ibanez, Lopez-Bermejo et 
al. 2009, Schoderboeck, Adzemovic et al. 2009). This leads to an inability to readily 
metabolise a host of drugs. Like in infants, the elderly patients the mechanism of drug 
absorption, distribution, metabolism, and elimination is less likely to be studied widely 
(Kaushal, Bates et al. 2001, Gamboa 2009).  
Gender differences play a role in the action of many drugs and thus affect the way the 
body deals with the drugs, altering drug pharmacokinetics and pharmacodynamics in the 
process. Sex differences have been implicated in the severity and frequency of ADRs to 
antiretroviral agents (Ofotokun and Pomeroy 2003). Moreover hepatic enzyme activity, 
specifically CYP3A4 leading to the enhanced metabolism of midazolam in Chinese women 
when compared to men (Labbe, Sirois et al. 2000, El-Eraky and Thomas 2003), and in the 
effect of colchicine which may selectively affect fertility in males but not in females 
(Sternberg and Hubley 2004) are poignant examples.  Pregnancy, menopause and 
menstruation which are issues confined specifically to females could also have profound 
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drug effects (Mitchell, Smith et al. 2009).  
Alcohol consumption and smoking affects the metabolism of many drugs, and in turn are 
capable of altering susceptibility to ADRs. Chronic alcohol consumption activates 
enzymes that transform drugs and are able to alter the predicted actions of these agents 
hence producing effects capable of causing damage to the liver and other organs 
(Alomar 2014) . Smoking also affects liver enzyme activity as it is a potent inducer of the 
hepatic cytochrome P-450 (CYP) isoenzymes 1A1, 1A2, and, possibly, 2E1 (Tomlinson, 
McMahon et al. 2005).  
There is evidence to suggest that ethnicity controlled by genetic factors exerts a 
substantial influence on drug response and action. In the evaluation of risk factors for 
ADRs in patients on angiotensin converting enzyme (ACE) inhibitors, ACE related 
angioedema was found to be more prevalent in African Americans when compared with 
other ethnic groups (Morimoto, Gandhi et al. 2004). In another study the risk of cough 
with blood pressure lowering drugs was three times greater in black patients than non-
black patients (Grouzmann, Livio et al. 2009). Recently, the human leukocyte antigen 
(HLA) genes have been identified as genomic markers of predisposition to several forms 
of ADRs; for example abacavir hypersensitivity is associated with HLA-B*57:01 (Mallal, 
Phillips et al. 2008). Further associations include allopurinol and HLA-B*58:01 in Hong 
Kong Han Chinese and Portuguese (Somkrua, Eickman et al. 2011, Chiu, Hu et al. 2012, 
Goncalo, Coutinho et al. 2013), carbamazepine and HLA-B*15:02 (Chung, Hung et al. 
2004), or HLA-A*31:01 in the Han Chinese and European populations respectively 
(McCormack, Alfirevic et al. 2011, Ozeki, Mushiroda et al. 2011, Yip, Marson et al. 
2012).  
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1.1.2 Classification of ADRs 
ADRs are usually classified into two types A and B based on their perceived dose 
dependence and predictability. Further classifications have been proposed to include a 
combination of dose and time related reactions associated with cumulative dose, time-
related reactions alone, withdrawal-induced reactions and reactions attributable to the 
failure of drug therapy usually due to inadequate dosing and drug interactions (Edwards 
and Aronson 2000, Aronson and Ferner 2003). 
i. Type A ADRs: are due to exaggerations in the drugs known pharmacological effect and 
are usually dose dependent, predictable and account for a majority of ADRs. Type A 
reactions make up approximately 85% of all ADRS and include reactions like GIT bleeding 
after treatment with NSAIDs, and interactions with other drugs and/or any underlying 
illnesses. Generally type A ADRs are dose-dependent and are related to the 
pharmacokinetic properties of the drug. A reduction in the dose or withdrawal of the 
offending drug usually leads to a resolution of the ADR (Pirmohamed, Breckenridge et al. 
1998).  
ii. Type B ADRs: These reactions are usually idiosyncratic and unrelated to the drugs 
known pharmacology. They are less common and tend to be more serious than type A 
reactions, comprising about 10-15% of all ADR (Hausmann, Schnyder et al. 2010). Type B 
reactions were previously thought to be unrelated to the dose, and unpredictable as the 
mechanism was ill-defined. Many type B reactions provoke the host immune system as a 
part of the disease profile. The involvement of drug-specific immunoglobulins, T-
lymphocytes and other components of the adaptive immune system have been identified 
as important mediators in the pathogenesis of the ADRs (Naisbitt, Farrell et al. 2003).  
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1.2 Drug hypersensitivity reactions 
 
Drug hypersensitivity reactions make up about one sixth of all ADRs (Pichler, 2007). 
These reactions have been earlier classified pathophysiologically by Gell and Coombs into 
four types namely; Type I, Type II, Type III, and Type IV. This classification did not take 
into account the large body of drug reactions that have now been defined clinically such 
as pseudo-allergic reactions, primarily antibody-mediated reactions and T cell mediated 
reactions which serve as a basis for more recently proposed classifications. The most 
recent classification utilizes the basic structure proposed by Gell and Coombs, and also 
goes further to include those that were excluded earlier (Descotes and Choquet-
Kastylevsky 2001, Posadas and Pichler 2007). 
1.2.1 Type I hypersensitivity reactions   
Type I hypersensitivity is also known as immediate or sometimes anaphylactic 
hypersensitivity. The reaction may involve skin (urticaria and eczema), eyes 
(conjunctivitis), nasopharynx (rhinorrhea, rhinitis), bronchopulmonary tissues (asthma) 
and the gastrointestinal tract (gastroenteritis). Responses usually occur within 30–60 
min but can be extremely quick (within a few minutes) and may result in anaphylaxis 
(systemic type I hypersensitivity). A late onset reaction may occur in some cases, 3 or 4 
hours after allergen exposure. Symptoms could range from minor itching and 
inflammation to death. The effector mechanism has as its primary component mast cells 
and basophils and the response could be modified by platelets, neutrophils or 
eosinophils, though a biopsy of the reaction site has revealed mainly mast cell and 
eosinophil involvement. 
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Figure 1.1. Type I hypersensitivity reactions. Diagram showing the pathway of Type I hypersensitivity 
reactions which involves the release of IgE from activated B cells, mast cell degranulation and the 
subsequent release of mediators of inflammation leading to type I reaction manifestations. 
 
Type I reactions are mediated by IgE, which is preferentially produced by most cells in 
response to specific allergens. These antigen specific IgE are able to bind high affinity Fc-
IgE receptors on mast cells that at are able to bind antigen or drug-specific IgE to a high 
degree. The binding of IgE antibodies to complementary FcεRI receptors on mast cells via 
their Cε3 region leaves both antibody combining sites free to interact with the 
complementary allergenic determinants. This leads to cross-linking of the cell bound 
antibodies, degranulation of the anchoring mast cells and and triggers the release of 
preformed and newly formed mediators of hypersensitivity such as proteoglycans, serine 
proteases, leukotrienes (Yamasaki & Saito, 2005) and a host of other factors.  
Drugs implicated in the pathophysiology of type I allergic reactions include antibiotics 
(penicillins, cephalosporins, quinolones), neuromuscular blocking drugs, some 
nonsteroidal anti-inflammatory drugs such as pyrazolones, trimethoprim, 
sulphamethoxazole, proton pump inhibitors, heparin, insulin, L-asparaginase, etanercept, 
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and chimeric human–animal monoclonal antibodies used for therapy. Diagnosis of Type I 
hypersensitivity reactions is traditionally carried out using provocation testing which 
involves a topical challenge with certain antigens closely followed by observation  of the 
response of the patients dermis to the challenge. This test is associated with some risk as 
some antigens result in severe anaphylaxis (Smith 1992). Alternative methods which 
could be employed to determine hypersensitivity include skin prick or patch test, 
radioallergosorbent tests (RASTs), leukocyte histamine release assays, surface markers 
for basophil activation, and leukotriene release tests (Williams, Dolen et al. 1992, Primeau 
and Adkinson 2001). 
In the determination of the likelihood of a culprit drug to cause immediate 
hypersensitivity, the basophil activation test (BAT) and the fluorescence enzyme 
immunoassay were found to be less sensitive than the skin prick test, with the BAT being 
the least specific (Khan, Ueno-Yamanouchi et al. 2012). The RAST is also not as sensitive 
as the skin prick test and produces high variability between tests (Roberts-Thomson, 
McEvoy et al. 1993, Yunginger, Ahlstedt et al. 2000) 
1.2.2 Type II hypersensitivity reactions 
 Type II hypersensitivities are also known as cytotoxic hypersensitivity and antibody-
dependent cytotoxicity. They are rare reactions with serious and potentially life 
threatening implications. These reactions are mediated by IgG and IgM antibodies which 
bind to self-cell surface molecules forming complexes which activate the complement 
system, this triggers  opsonisation, red blood cell agglutination, cell lysis and death 
(Warrington, Watson et al. 2011). Due to the involvement of multiple underlying 
mechanisms, a host of tissues and organs may be involved, and while endogenous 
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antigens are those generally involved in the induction of the reaction, drugs are also 
known to provoke their own forms of type II hypersensitivity which include immune 
haemolytic anaemia, thrombocytopenia and granulocytopenia. Reaction times can range 
from minutes to hours, but drug-induced immune thrombocytopenia generally manifests 
after 5 to 8 days of exposure to the culprit drug, or after a single exposure in patients 
previously exposed to the same drug (Pichler, Adam et al. 2010). Drugs which have been 
found to cause type II hypersensitivities include antibiotics (penicillins, vancomycin, and 
some cephalosporins), sulphonamides, quinidine, quinine, α-methyldopa, 
propylthiouracil, gold salts, and acetaminophen.  
                  
Figure 1.2.  Type II hypersensitivity reactions. The binding of IgG and IgM antibodies to cell surface 
molecules forms complexes capable of activating the complement system. The end result being cell 
termination via phagocytes and NK cells. 
 
1.2.3 Type III hypersensitivity reactions  
They are also referred to immune complex deposition hypersensitivity. They are 
mediated by soluble immune complexes of antigen with antibodies generally of the IgG 
isotype. The similarity between type II and III hypersensitivity reactions lie in the 
dependence of both reactions on the formation of immune complexes, but their target 
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structures and physiological effects are distinct. A consequence of immune complex 
deposition in tissues is a reaction which may lead to mast cell degranulation, leukocyte 
chemotaxis, and inflammation induced by the cell influx.  
After exposure, reactions can develop to antigens which can be endogenous (DNA/anti-
DNA/complement) or exogenous (filarial worms, dengue virus, microbial antigens, drugs) 
in nature. Post exposure, reactions may develop over a period of-about 3–10 h against 
antigens. Drugs implicated include dapsone, (erythema nodosum leprosum in the skin of 
leprosy patients), penicillins (Jarisch–Herxheimer reaction in syphilitic patients), β-
lactams which induce hypersensitivity vasculitis , cotrimoxazole, NSAIDs and some 
monoclonal antibodies (Alomar 2014). 
                           
 
 
Figure 1.3. Type III hypersensitivity reactions. IgG antibody forms immune complexes and are targeted by 
phagocytes leading to either mast cell degranulation, leukocyte chemotaxis or inflammation. 
 
 
There remains controversy as to the ultimate effector molecules in both Type II and III 
hypersensitivity reactions. Generally the roles of drug-specific effector T cells have not 
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been studied. It is theoretically possible that IgG antibodies play a bystander effector role 
and that T-cells are responsible for the tissue injury through the release of cytokines. 
Alternatively IgG antibodies might exert a regulatory function. The latter is discussed in 
detail later in this chapter. 
1.2.4 Type IV hypersensitivity reactions  
Also referred to as T-cell-mediated, delayed drug hypersensitivity reactions. Unlike the 
other types of hypersensitivity reaction, which involve antibodies, type IV reactions are 
mediated by antigen-specific T-cells. Type IV hypersensitivity refers to a number of clinical 
reactions, with the cellular immune base being their main common factor. These 
reactions are caused by the overstimulation of T cells and monocytes/macrophages 
leading to the release of cytokines that cause inflammation, cell death and tissue 
damage. They are the second most common type of hypersensitivity reaction. The 
cellular response generally develops 2 or more days after antigen exposure which led to 
the inclusion of the term ‘delayed’ and also distinguishes the response from immediate 
reactions, which develops considerably earlier, within minutes and peaking after a few 
hours. Four subdivisions based on effector cells and mediators involved and the resulting 
cutaneous manifestations have recently been proposed. These include; Type IVa which is 
mediated by macrophage activation characterized with Th1 involvement and high IFN-
γ/TNFα secretion.  Type IVb reactions are mediated by eosinophils and Th2 secreting T-
cells with high IL-4/IL-5/IL-13 secretion. Type IVc reactions are mediated by CD4 and 
cytotoxic CD8 cells which are relied upon as effector cells, and appear to occur in all drug-
related delayed hypersensitivity reactions. Finally type IVd reactions are mediated by T-
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cells, which secrete IL-8 when activated by drug, that recruit neutrophils (Pichler, W.J 
2007).  
Representative cutaneous reactions range in severity from maculopapular rash to 
Stevens Johnsons syndrome and toxic epidermal necrolysis (SJS/TEN), although the 
response is generally heterogeneous with the tendency for reactions to overlap which 
blurs the clinical picture. Primary methods used to establish a Type IV hypersensitivity in 
susceptible individuals are via delayed skin testing (Ahmed and Blose 1983), the 
lymphocyte transformation test (Pichler and Tilch 2004, Earnshaw, Pecaric-Petkovic et al. 
2014) and the enzyme-linked immunospot (ELISPOT) assay which is a technique that 
permits the analysis of the frequency of antigen-specific, cytokine producing cells (El-
Ghaiesh, Monshi et al. 2012, Naisbitt, Nattrass et al. 2014).  
 
                              
 
Figure 1.4. Type IV hypersensitivity reactions. These reaction are mediated via antigen specific T cells 
activation. CD4+ or CD8+ T-cells are activated, and  monocytes and macrophages may be activated to 
release cytokines. The ensuing inflammation leads to tissue damage and cell death. 
 
Drug hypersensitivity resulting in end organ effects has been demonstrated with the 
development of drug-induced kidney damage manifested as interstitial nephritis, lung 
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involvement and in murine models of drug-induced liver injury (Neilson 1989, Naisbitt, 
Farrell et al. 2005, Erhardt, Biburger et al. 2007, Pichler 2007, Erhardt and Tiegs 2010). 
These hypersensitivity reactions have shown mononuclear cell involvement with drug-
specific activation of T cells featuring prominently in the immune regulatory and effector 
phases of the delayed hypersensitivity reactions. The end organ damage associated with 
these reactions differentiates them from current classifications which focus primarily on 
the cutaneous manifestations. Hence, with T cells playing a prominent role the 
recommendation is to define a new class as Type IVe specifically for these reaction types. 
                      
Table 1.1 Revised Gell and Coombs classification of hypersensitivity reactions. All reactions are T cell 
regulated but differ in their effector functions. Type I to III reactions being mediated by antibodies while 
Type Iva to IVd are mediated by more T cell/cytokine dependent functions (Adapted from; Drug 
hypersensitivity, Pichler WJ, 2007). 
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1.2.5 Clinical manifestations of cutaneous drug hypersensitivity 
Although the clinical manifestations of ADRs are varied and involves many organs, the 
skin remains the major organ affected during the course of drug hypersensitivity 
reactions (Merk, Baron et al. 2007, Merk 2009). Cutaneous manifestations of ADRs 
include maculopapular exanthema, acute generalised exanthematous pustulosis, drug 
reactions with eosinophilia and systemic symptoms, Stevens Johnsons syndrome and 
toxic epidermal necrosis. 
i. Maculopapular Exanthema (MPE):  Maculopapular exanthema is a common cutaneous 
manifestation of drug hypersensitivity, and as a response to viruses and bacterial agents. 
In fact they have been estimated to account for approximately 95% of all drug-induced 
eruptions (Bigby 2001). Viruses such as cytomegalovirus (CMV), and several types of 
herpes (varicella zoster, HHV6 and the gamma herpes virus), bacterial diseases, 
lymphoma and graft versus host disease are also not excluded from the precipitation of 
exanthemas (Fernandez, Canto et al. 2009).  
Skin presentations include erythematous macular or papular eruptions which often start 
on the trunk and subsequently spread to the extremities. Individuals also present with 
lesions which may also be found at the extremities. Studies have shown that the cell 
migration in drug-induced MPE generally favours drug-specific T cells which are capable 
of promoting the skin inflammatory reactions through the release of cytokines such as IL-
5, TNF-α, IFN- and certain chemokines such as eotaxin (Yawalkar 2005). MPE symptoms 
which arise due to drug administration usually have an acute onset then resolve 
spontaneously, after a period which may range from hours, or up to 2 or 3 weeks after 
drug exposure. Continuation of drug administration after the onset of symptoms will 
lead to persistence and possible exacerbation of the reaction. These symptoms tend to 
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appear again after resolution and re-administration of the drug even after extended 
periods. 
ii. Acute Generalized Exanthematous Pustulosis (AGEP): Is an acute skin eruption which 
is characterized by fever and the appearance of pustules that overlay edematous 
erythema. AGEP is induced in 90% of cases by drugs (Beltraminelli, Lerch et al. 2005) with 
an incidence of 3 to 5 cases per million per year and a mortality rate of 5%. There is a 
predominance of antibiotics as the causative agent in the development of AGEP, 
constituting over 80% of cases, though other drugs may be implicated such as 
hydroxychloroquine, cotrimoxazole, diltiazem, terbinafine and carbamazepine. Time of 
onset to resolution of the rash can be from as short as 24 hours. Resolution takes 
approximately 2 weeks. Activated drug-specific cytotoxic T cells are involved in tissue 
destruction (Schmid, Kuechler et al. 2002). 
iii. Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS). Also referred to 
as hypersensitivity syndrome or drug-induced hypersensitivity syndrome (DIHS) is a 
severe life- threatening adverse drug reaction. Clinical manifestations in skin reactions 
can be similar to MPE and AGEP but a visceral involvement with damage to internal 
organs and extended period of disease symptoms from the time of drug exposure (after 
2-8) weeks are distinguishing features of DRESS. The incidence of DRESS ranges from 
1:1000 to 1:10000 with a majority of patients presenting a prominent eosinophilia (Lopez-
Rocha, Blancas et al. 2014). Viruses have also been implicated in the pathogenesis of 
DRESS with a rise in reactivation of herpes viruses, a rise in anti-HHV-6 IgG titers and the 
presence of HHV-6 DNA 2–3 weeks after the onset of rash noted in many patients (Baldo 
and Pham 2013).  
 19 
 
CD8+ T lymphocyte activation, enhanced secretion of TNF-α and IFN-γ and increased 
cutaneous homing have been identified as hallmarks of HHV-6 induced DRESS. DRESS 
inducers sulfamethoxazole, carbamazepine and allopurinol encourage viral proliferation 
and have been hypothesized as culprits that profile the kinetics of HHV-6 induced DRESS 
and the DRESS flare-ups which occur after switching from a culprit anticonvulsant to 
another structurally unrelated anticonvulsant (Picard, Janela et al. 2010, Joshua, N. et al. 
2012). 
iv. Stevens Johnsons Syndrome and Toxic epidermal necrolysis (SJS/TEN): These 
hypersensitivity  conditions collectively referred to as (SJS-TEN) are both potentially fatal. 
Reactions are rare with incidences of usually less than two per million per year (Harr and 
French 2010) and involve damage to both the skin and mucus membrane. The extent of 
skin involvement remains the main distinguishing factor between the two. In SJS skin 
detachment is usually less than 10% of the total body surface while TEN patients manifest 
necrosis to at least 30% of their cutaneous tissue (Bastuji-Garin, Rzany et al. 1993).   
Patients show ocular, buccal and genital mucosa involvement, with the probability of 
respiratory and gastrointestinal tract involvement.  
The drugs which predominate in the pathogenesis of SJS-TEN are divided into two 
groups; those that provoke a hypersensitive response after short term administration 
and those that require a longer period to provoke a response (Roujeau, Kelly et al. 1995, 
Harr and French 2010).The former includes the antibiotics trimethoprim–
sulphamethoxazole, sulphonamides, aminopenicillins, cephalosporins, quinolones, and 
chlormezanone, while the antiseizure drugs carbamazepine, phenytoin, phenobarbitone, 
and valproic acid, NSAIDs of the oxicam type, allopurinol, and corticosteroids all fall into 
the latter group (Roujeau, Kelly et al. 1995). Allopurinol has been identified as the drug 
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most commonly implicated in the development of SJS/TEN in Europe and Israel (Halevy, 
Ghislain et al. 2008) Infectious diseases have been shown to have a marked effect on SJS 
and TEN. This has been observed with HIV patients where the annual incidence is about 
1,000 times higher when compared to the general population (Mittmann, Knowles et al. 
2012) and with M. pneumoniae and H. simplex where SJS-TEN hypersensitivity reactions 
have been observed in rare cases without apparent drug use (Harr and French 2010).  
Genetic associations have also been identified in the pathogenesis of these reactions and 
this has been demonstrated by the expression of HLA-B *15:02 alleles which had strong 
associations with carbamazepine induced SJS in Han Chinese. Their restriction to a 
particular ethnic grouping is indicative of an obvious relationship between ethnicity and 
SJS (Tassaneeyakul, Tiamkao et al. 2010, Chung and Hung 2012).  
Provocation tests and skin testing are not considered with SJS-TEN patients because the 
risk of inducing a fresh episode or worsening an existing case is too high. Thus, clinical 
presentation and histology are currently the main diagnostic tools employed in SJS-TEN 
(Baldo and Pham, 2013). Primary treatment generally consists of discontinuation of the 
causative drug(s). Other modes of treatment which have been employed include the use 
of systemic corticosteroids and immunosuppressive agents such as cyclosporine and 
cyclophosphamide (Ghislain and Roujeau 2002). The use of intravenous immunoglobulins 
has been suggested but there is currently a lack of randomized control trials to assess 
the benefits and risks and to ultimately standardize the optimal treatment protocol 
(Momin 2009). 
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1.3 The immune system 
 
The immune system is a consortium of biological structures and processes within an 
organism specifically designed for protection against disease. The ability to selectively 
detect a diverse range of pathogenic organisms remains a must for optimal functioning 
of this system. This is essential to enable the differentiation of self from pathogenic 
tissue. 
The earliest mention of immunity was during the plague of Athens in 430 BC (Retief and 
Cilliers 1998). Later Louis Pasteur exploited Pierre-Louis Moreau de Maupertuis’s findings 
of the 18th century to lay down the fundamental principles of vaccination (Plotkin 2005). 
Rapid advances were then made towards the end of the 19th century, and Paul Erlich was 
able to explain the specificity of the antigen-antibody reactions. This has formed the 
basis of a host of immunological assays to this date, a feat for which he was jointly 
awarded the Nobel Prize in Physiology or Medicine 1908 with Ilya Ilyich Mechnikov.  
The two main components of the immune system are the innate immune system which is 
the first line of defence of the body against infection, and the more highly specialised 
adaptive immune system. All cells of the immune system originate in the bone marrow, 
but the differentiation of some may occur at a distant immunological site.  
1.3.1 Innate immunity 
This first line of defence is a part of the comprehensive immune system that consists of 
the cells and mechanisms responsible for the protection of the host from infection by 
other organisms, by eliciting their protective responses usually in a generic manner. This 
response is shared by both plant and animals (Janeway and Medzhitov 2002) 
 22 
 
The innate immune system consists of anatomical barriers to infection which include 
epithelial surfaces that are impermeable to most pathogenic organisms. Skin exuviation, 
the peristaltic movement of the gastrointestinal tract, flushing action of tears and saliva 
are other mechanical ways employed to prevent infection. Chemically, fatty acids in 
sweat, lysozyme and phospholipase found in some secretions are also capable of 
inhibiting unwanted cell growth. If the anatomical barriers are unable to stop the 
progression of an infection, humoral barriers come into play in the form of an acute 
inflammatory reaction. This reaction is characterized by edema, the recruitment of 
phagocytic cells and the activation of the complement system. Cellular barriers to 
infection are evidenced by the involvement of polymorphonuclear cells as a part of the 
inflammatory response where they are recruited to the site of infection. Initial paradigms 
describe the non-specificity of the innate response. However some form of specificity is 
exerted via activation of a limited number of germline pattern-recognition receptors 
(PRRs) with the ability to recognize pathogen-associated molecular patterns (PAMPS) 
(Akira, Uematsu et al. 2006).  
1.3.1.1 Cells of the innate immune system 
 
(i) Macrophages. These are important phagocytic immune effector cells derived 
from monocytes, which also play vital homeostatic roles independent of their immune 
function (Mosser and Edwards 2008). Macrophages, sometimes referred to as 
‘professional phagocytes’ are renowned for the uptake and degradation of infectious 
agents and senescent cells, participation in development, tissue remodeling, the immune 
response, and inflammation (Aderem and Underhill 1999).  
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Recent studies have demonstrated that resident macrophages are established during 
embryonic development and persist during adulthood, but independent of blood 
monocytes (Sawyer, Strausbauch et al. 1982, Volkman, Chang et al. 1983, Hashimoto, 
Chow et al. 2013, Yona, Kim et al. 2013, Epelman, Lavine et al. 2014). Though monocytes 
are able to enter steady-state non-lymphoid organs they recirculate to lymph nodes 
without differentiation to macrophages (Jakubzick, Gautier et al. 2013).  
The molecular mechanisms underlying phagocytosis by macrophages is very complex 
due to the diversity of receptors and also the ability of some micro-organisms to 
influence their fate in unpredictable ways as they are internalized. In the midst of all this 
complexity a few shared features exist which include the initiation of particle interaction 
via interactions between specific surface receptors in the macrophage with ligands on 
the particle and the involvement of actin modelling (Aderem and Underhill 1999). 
Agents capable of activating macrophages include components of the immunoglobulin 
and complement systems, products of activated lymphocytes and non-immunological 
agents. Studies on bacterial endotoxin-induced macrophage activation has suggested 
the involvement of various kinases like Protein kinase A, protein kinase C, MAPKs etc., 
and numerous inflammatory cytokines  such as NF-kB, AP-1,TNF-α, IL-1, IL-6, IL-8, and IL-12  
(Ogmundsdottir and Weir 1980, Klimpel 1996, Fujihara, Muroi et al. 2003). Macrophages 
have also been shown to present antigen to T cells in a primary response (Hume 2008). 
(ii) Granulocytes 
(a) Neutrophils. Neutrophils are the most abundant (40% to 75%) type of granulocyte 
in mammals. They are formed from stem cells in the bone marrow. They are 
polymorphonuclear in nature and form an essential part of the innate immune system. 
Like macrophages they are also considered as a form of professional phagocyte. 
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Neutrophils are able to interact with other cellular components specifically monocytes, 
dendritic cells, T and B lymphocytes in a bidirectional, multi-faceted manner (Nathan 
2006).  
They migrate towards a locus of infection, attracted by cytokines released by activated 
endothelium, mast cells, macrophages and T-cells, with TNF-α, GM-CSF, IL-8 and IFN-γ 
respectively, the culprit cytokines. Neutrophils also recruit and activate monocytes, 
dendritic cells (DCs) and lymphocytes via the release of cytokines with a resultant 
amplification of inflammation (Ear and McDonald 2008, Wright, Moots et al. 2010). 
(b) Eosinophils. Similar to other granulocytes eosinophils undergo development and 
maturation in the bone marrow. They are found in low numbers constituting 1-4% of total 
peripheral blood (Shamri, Xenakis et al. 2011). They function as a bridge between the 
innate and adaptive immune system. Eosinophils secrete Th1 and Th2 cytokines (e.g. IL-4, 
IL-5, IL-9, IL-13, IL-12 and IFN-), acute proinflammatory cytokines (TNF-α, IL-1), and 
immune inhibitory cytokines (e.g., TGF- and IL-10). They also express complementary 
receptors for many of these cytokines (Lacy and Moqbel 2001, Spencer, Szela et al. 2009, 
Jacobsen, Helmers et al. 2012). 
Migration to sites of inflammation is mediated by certain chemokines and leukotrienes. 
At these sites, eosinophils are then activated by cytokines released from Th2 cells 
(Shamri, Xenakis et al. 2011). The induction of eosinophils leads to the expression of 
major histocompatibility complex II (MHC-II) complexes and co-stimulatory molecules 
which are required for the functional activation of T-lymphocytes. Thus, eosinophils 
primarily viewed from their perspective as effectors of allergic responses and parasite 
elimination, also function as antigen presenting cells (Shi 2004, Padigel, Lee et al. 2006).  
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(c) Basophils. These are the least numerous of the granulocytes, and account for less 
than 1% of all peripheral blood leukocytes occurring in the human body with a half-life of a 
few days. Basophils arise and mature in bone marrow and when activated, degranulate 
to release histamine, proteoglycans, and proteolytic enzymes. IL-3 is the most 
predominant cytokine which drives the activation of basophils. IL-5, GM-CSF, histamine-
releasing factor, and several chemokines are also able to prime basophils leading to 
enhanced IL-13 and IL-4 secretion, critical cytokines in the development of allergies and 
the production of IgE antibodies (Yamaguchi, Koketsu et al. 2009, Stone, Prussin et al. 
2010).  
(d) Dendritic cells (DCs). DCs are bone marrow derived cells which function as APCs 
and play a critical role in the regulation of the adaptive immune response. These cells 
exist as a complex, heterogeneous group of multifunctional APCs (Mohamadzadeh and 
Luftig 2004). DCs have been referred to as professional APCs because their primary role 
is the presentation of antigens, and the ability to induce a primary response in naïve T 
lymphocytes. To perform this function, DCs are capable of capturing antigens, processing 
them, and presenting them on the cell surface along with appropriate costimulatory 
molecules (Guermonprez, Valladeau et al. 2002). The role DCs have in the perpetuation of 
B cell function and recall responses has confirmed their importance in the initiation of 
immunological memory (Qin, Wu et al. 2000, El Shikh, El Sayed et al. 2010). 
They are generally identified by their cellular size and morphology, with all DCs 
possessing the ability to activate T lymphocytes while manifesting distinct functions 
within each subset. DCs can be broadly classified as two major subsets: the inflammatory 
or infection-derived DCs, which develop from monocytes in response to stimulation, and 
the steady-state DCs, which are present at all times (Moore and Anderson 2013). Recent 
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convention has stratified DCs to be either myeloid or plasmacytoid. Myeloid DCs (mDCs) 
typically express myeloid antigens, while plasmacytoid DCs (pDCs) typically lack myeloid 
antigens and are distinguished by expression of CD123, CD303 and CD304. CD14+ DCs 
which are situated in tissues and lymph nodes are a third subset originally described as 
‘interstitial DCs’ while the  Langerhans cells (LCs), and microglia are two specialized self-
renewing DC populations found in stratified squamous epithelium and parenchyma of 
the brain, respectively (Collin, McGovern et al. 2013).  
(e) Natural killer cells (NK cells).  NK cells are large granular lymphocytes that 
possess cytotoxic and effector functions. They make up 2% to 18% of total lymphocytes in 
human peripheral blood (Vivier, Tomasello et al. 2008). NK cells express several toll like 
receptors specifically, with studies showing the expression of TLR 1-8 and similar studies 
also show the expression of TLR 1-10 mRNA on purified human NK/NKT cells (Chalifour, 
Jeannin et al. 2004, Sivori, Falco et al. 2004, Lauzon, Mian et al. 2006). The magnitude 
and character of NK cell cytotoxic and cytokine responses is reliant on the cytokine milieu 
and on interactions with other cells of the immune system (Long 2007). IFN-, IL-12, IL-15, 
and IL-18 are all potent activators of NK cell function. Cells pre-activated with these 
cytokines in-vitro for 15 hours are detectable in high numbers 3 weeks after transfer into 
RAG-1−/− mice. The cells produce high levels of IFN-γ upon restimulation (Cooper, Elliott et 
al. 2009). 
In addition to their cytotoxic and effector functions NK cells may act as regulatory cells 
having an influence on various cell types. For example immature DC killing by NK cells in 
humans and mice has been shown to influence homeostasis (Hayakawa, Screpanti et al. 
2004, Vivier, Tomasello et al. 2008). Though little is known of the impact of NK cells in 
epithelia, a recent study employing a model of contact hypersensitivity has shown the 
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involvement of NK cells in memory type immune responses which are independent of T 
and B cells (O'Leary, Goodarzi et al. 2006). 
1.3.1.2 PAMPs, DAMPs, MAMPs and sterile inflammation 
 
Pathogen associated molecular patterns (PAMPs) and damage associated molecular 
patterns (DAMPs) are microbial and non-microbial signals respectively which are sensed 
by pattern recognition receptors (PRRs). The recognition of these signals leads to PRR 
activation and development of an acute inflammatory response.  A third signal defined as 
microorganism-associated molecular patterns (MAMPs) from pathogens and commensal 
bacteria has also been suggested. This has been used in some instances to replace 
PAMPs due to the presence of similar molecules such as lipopolysaccharide (LPS), 
lipoteichoic acid (LTA), peptidoglycans, lipoproteins and modulins which are recognized 
by PRRs and TLRs. A host of interactions have been observed to exist between these two 
groups which includes interaction manifested as binding between PAMPs and DAMPs 
exemplified by the binding of LPS from gram-negative bacteria (a PAMP) and several 
different DAMPs (Picard, Janela et al. 2010), the ability of DAMPs to act as PAMP 
transporters (Youn, Oh et al. 2008), occasional utilization of similar receptors such as the 
TLRs, and the PAMP induced release of DAMPs in infection (Baumann, Aspalter et al. 
2010, Mills 2011, Escamilla-Tilch, Filio-Rodriguez et al. 2013). 
The effector mechanisms underlying the inflammatory response ensures recruitment of 
leukocytes that are extremely effective at killing microbes but with a disadvantage of the 
production of highly reactive species which are also capable of destroying normal 
mammalian cells. DAMPs have been broadly characterized as self-molecules with the 
ability to activate inflammatory responses and mediate sterile inflammatory responses 
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(Matzinger 1994, Rubartelli, Lotze et al. 2013). Sterile inflammation refers to 
inflammation in the absence of microorganisms and as a result of trauma, ischaemia–
reperfusion injury or chemically induced injury. Specific hallmarks of this response include 
the release of DAMPS which activate PRRs resulting in a marked recruitment to the injury 
site of neutrophils and macrophages and the enhanced secretion of pro-inflammatory 
cytokines specifically tumour necrosis factor (TNF) and interleukin-1 (IL-1). Sterile 
responses have also been found to occur in situations where IL-1 was lacking (Chen and 
Nunez 2010, Rock, Latz et al. 2010, Kubes and Mehal 2012). 
 
 
 
 
 
Figure 1.5.  Inflammation as a result of PAMPs, DAMPs, and MAMPs.  Danger signals elicited by PAMPs due 
to infection, DAMPs due to tissue damage and by MAMPs in collaboration with DAMPs due to pathogenic 
and non-pathogenic organisms with tissue damage (Adapted from Mills, K.H.; 2011).  
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Inflammation and the attendant fibrosis which arises due to sterile particle stimulation is 
associated with diseases such as gout, pseudogout, dementia due to Alzheimer’s disease, 
and atherosclerosis (Akiba, Kehren et al. 2002, Liote 2003, Nuki and Simkin 2006, Beck, 
Morbach et al. 2009). 
1.3.2 Adaptive immunity 
The adaptive immune system, also referred to as the acquired immune system is a highly 
specific system composed of specialised cells and processes concerned with the 
protection of a host organism from pathogens.   
Primarily mediated by antibodies secreted by B lymphocytes, and by T lymphocytes, the 
consequence of activation of the adaptive immune system is usually a direct effect on 
the pathogen. This may lead to bacteriolysis, opsonophagocytosis and killing, and viral 
neutralization by T lymphocytes (Robbins, Schneerson et al. 1996). Studies have shown 
innate immune system regulation via modification of the adaptive system. Examples 
include the interplay between NK and CD8+ T cells in mouse cytomegalovirus (MCMV) 
infection, and also in non-infectious uveitis (Mitrovic, Arapovic et al. 2012, Willermain, 
Rosenbaum et al. 2012) 
A crucial feature of the adaptive immune system is the acquisition of an immunological 
memory which is specific to, and arises after an initial response to a given antigen. The 
memory acquired is long lived and ensures that in subsequent encounters with a similar 
pathogen the immune response is enhanced. The adaptive system includes both cell-
mediated and humoral immunity components. 
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1.3.2.1 Cell-mediated immunity 
 
(i) T Lymphocytes 
T lymphocytes play a crucial role in cell-mediated immunity. They originate from 
pluripotent hematopoietic stem cells (HSC) located in the bone marrow, especially in the 
pelvis and iliac crest (Dzierzak and Speck 2008), and are so named due to their 
maturation in the thymus. The recognition of processed antigenic materials in the form 
of unique antigenic peptides presented by MHC on APCs occurs via the T cell receptor 
(TCR), thus conferring antigen specificity on T cells, though some receptors are able to 
ensure direct T cell recognition of the antigen without the recognised requirements for 
antigen processing and presentation (Bukowski, Morita et al. 1995, Morita, Beckman et 
al. 1995, Davis, Boniface et al. 1998, Bukowski, Morita et al. 1999, Wu, Groh et al. 2002).  
The main subsets of T cells are the helpers, which express the CD4 co-receptor, and the 
cytotoxic T-cells, expressing the CD8 molecule (Mosmann, Cherwinski et al. 1986). A third 
subset, the regulatory T-cells (Tregs) has been identified. These cells express CD25 and 
FOXp3 markers (Sakaguchi, Sakaguchi et al. 1995, Fontenot, Gavin et al. 2003). 
(a) CD4+ Helper T-cells: CD4+ lymphocytes, or helper T-cells, are a vital component 
of the acquired immune response. Their involvement in B-cell antibody production, 
enhancement of CD8 T-cell function and macrophage activation ensures their central role 
in maintaining the effectiveness of the acquired immune response (Bell and Westermann 
2008, Zhu, Yamane et al. 2010). Furthermore they play an important role in the regulation 
of autoimmunity via immune suppression and the development of immunological 
memory. CD4+ antigen recognition occurs via presentation of antigenic peptides on MHC 
class II molecules by professional APCs. This is a precursor for the release of cytokines, 
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which don’t possess any cytotoxic or phagocytic activity. T helper cells are essentially 
divided into two functional classes Th1 and Th2, and their corresponding activation 
ultimately determines the nature of pathogen clearance (Zhu and Paul 2008, Zhu, 
Yamane et al. 2010). 
The Th1 cytokines of which IFN-γ is predominant, produce proinflammatory responses 
associated with the killing of intracellular parasites and perpetuation of autoimmune 
responses (Berger 2000). 
The Th2 response is characterized by the production of various Th2 cytokines including IL-
4, IL-5, IL-9, IL-10, and IL-13. Their functions include the activation of B cells to make 
neutralizing non-cytolytic antibodies, regulation of B cell class switching to IgE through 
their production of IL-4, and the control of tissue damage due to excessive Th1 
proinflammatory responses (Berger 2000, Paul and Zhu 2010). After the resolution of the 
infection most of the CD4+ helper cells die off and a few remain as CD4+memory cells. 
Newer T cell populations have been defined which include Th17, Th22 and Th9 subsets. 
Th17 cells are important in clearance of pathogens during infection and induction of 
tissue inflammation in autoimmune disease. They produce IL-17, IL-17F, and IL-22. IL-21 
secretion by Th17 cells enhances their communication with the cells of the immune 
system (Korn, Bettelli et al. 2009). Th22 subset of human Th cells has been characterized 
by the secretion of IL-22 and TNF-α, but not IFN-γ, IL-4, or IL-17. These cells infiltrate the 
skin in individuals with inflammatory skin disorders and could be detrimental or 
protective in their action (Eyerich, Eyerich et al. 2009). The Th9 subset is the most 
recently described subset of T-helper cells. Characterized by their secretion of 
interleukin-9, which suggests their involvement in microbial immunity and immune 
mediated disease (Kaplan 2013). Th9 cells are found in the peripheral blood of allergic 
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patients, normal and inflamed skin and is released following specific antigen stimulation 
(Jones, Gregory et al. 2012, Purwar, Schlapbach et al. 2012, Cortelazzi, Campanini et al. 
2013). The specific function of Th9 cells has been difficult to elucidate experimentally, 
thus establishing immune responses that are completely reliant on Th9 cells has not been 
possible. 
(b) CD8+ cytotoxic T-lymphocytes:  Cytotoxic T cells also referred to as killer T cell or 
cytotoxic T-lymphocytes (CTL) are a sub-group of T cells that are important mediators of 
adaptive immunity. They induce the death of cells infected with viral, bacterial, and 
certain protozoan pathogens. Naïve cytotoxic T cell activation occurs when antigenic 
derived peptides (8-10 amino acids in length) bound to MHC I on antigen presenting cells 
are presented to CD8+ cell bearing TCR specific for that antigen. This leads to clonal 
expansion and migration of activated cytotoxic lymphocytes to different body 
compartments in search of the specific MHC class I peptide. Antigen presenting cells such 
as dendritic cells are also capable of inducing naïve T cell proliferation and differentiation 
in response to an antigen due to their expression of co stimulatory molecules (Germain 
1994, Banchereau and Steinman 1998, Harty, Tvinnereim et al. 2000).  Similar to what 
occurs with CD4+ helper T cells, upon the resolution of the infection most CD8+ cells die 
and a few are retained as long-lived memory cells. 
(c) Regulatory T Cells (Tregs). Tregs are a sub-group of T cells that are actively engaged 
in the maintenance of immunological self-tolerance and immune homeostasis by the 
suppression of effector T cells and other immune responses (Sakaguchi 2004). Treg 
suppressive effects also extends to immune responses involving B cells, NK cells, NK T 
cells , monocytes as well as dendritic cells (DCs) and various cancers (Schmidt, Oberle et 
al. 2012). CD25 and FoxP3 have been identified as phenotypic markers for suppressive 
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CD4+ T cells in naïve mice, but also humans within the CD4+CD25highFoxp3 T cell 
population (Sakaguchi, Sakaguchi et al. 1995, Baecher-Allan, Brown et al. 2001, Fontenot, 
Gavin et al. 2003, Yagi, Nomura et al. 2004, Schmidt, Oberle et al. 2012). A role for the co 
inhibitory molecule CTLA-4 expressed in human and murine Tregs, in the suppressive 
effects of Tregs has been mooted due to the fact that an inhibition or lack of in mice, 
leads to the development of spontaneous autoimmunity which is mitigated by the 
presence of Tregs (Bachmann, Kohler et al. 1999, Read, Malmstrom et al. 2000, 
Takahashi, Tagami et al. 2000). 
1.3.2.2 The humoral immune system 
Humoral immune responses are mediated via antibodies produced by B-lymphocytes. 
These antibodies are found in the fluid component of blood, or plasma and in 
extracellular fluids classically referred to as ‘’humors’’. Hence the birth of the term 
‘humoral immunity’. 
1.3.2.3 B-cell development and differentiation 
 
B lymphocytes develop in the bone marrow from hematopoietic precursor cells, in adult 
human subjects and in all mammals. Early development is characterized by the ordered 
rearrangement of the Ig H (heavy) and L (light) chain loci, occurring via the functional 
reconstruction of their respective immunoglobulin gene segments which are the V, D and 
J for the heavy chain, and V and J for the light chain. The diverse repertoire of functional 
VDJH and VJL generated encode the B-cell receptor (BCR), potentially conferring onto the 
BCR an ability to express antibodies capable of recognizing more than 5 x 1013 different 
antigens (Brack, Hirama et al. 1978, LeBien and Tedder 2008, Pieper, Grimbacher et al. 
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2013). These are the earliest forms of B cells and are referred to as pro-B cells. At this 
stage which is the earliest in B cell development they are thought to express 
CD34+CD10+CD19− common lymphoid progenitors (CLP) before they mature via 
CD34+CD19+CD10+pro-B. Similar populations have been defined as CD34+CD38+CD10+CD19− 
but also with the expression of CD117 (LeBien 2000, Blom and Spits 2006, Hystad, 
Myklebust et al. 2007).  
Pre-B cells arise from pro-B cells and are formed by the pairing of surrogate L chains 
(SLC) with the resultant cytoplasmic expression of  H chain (LeBien and Tedder 2008). 
These cells with a functional   are referred to as immature B cells and express cell 
surface IgD, IgM as well as CD21 and CD22 (Cuss, Avery et al. 2006, Cariappa, Chase et al. 
2007, Alomar 2014). It should also be noted that this developmental process is loaded 
with checkpoints, which serve to censor autoreactive cells, employing various 
mechanisms such as clonal deletion, BCR editing or by putting implicated cells in a state 
of anergy (Hartley, Crosbie et al. 1991, Gay, Saunders et al. 1993). Studies suggest that 
this selection against self-reactive B cells is exclusive to the pro/pre-B cell stages and very 
unlikely at the latter stages of B cell development (Tussiwand, Bosco et al. 2009). 
Following positive selection, the migration of immature B cells to the spleen occurs 
where they are referred to as transitional B cells which express CD93 and CD19 clusters 
(Tussiwand, Bosco et al. 2009). Transitional B cells develop further into a heterogeneous 
population of mature B cells, which include re-circulating cells in the B-lymphoid follicles 
in the spleen and lymph nodes and non-circulating cells which sequester in the marginal 
zone (MZ) of the spleen (Martin and Kearney 2002). Signalling via the BCR, Notch-2, the 
BAFF receptor and other signals including that from the NF-κB pathway, all play roles in 
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determining the post transitional B cell fate into either follicular or marginal zone B-cells 
(Pillai and Cariappa 2009). 
 
 
Figure 1.6.     B cell development from haematopoietic stem cells (HSC). 
 
B lymphocytes may serve either as antigen presenting cells (APCs) or produce antibodies 
to prevent infection.  As an APC, their activation due to the binding of a ligand to the BCR 
leads to a cascade of intracellular signalling which results in the internalization, and 
processing of the antigen and subsequent presentation of antigenic peptides on MHC 
class II to T cells (Lanzavecchia 1985, Treanor 2012). 
The close proximity of the T cell zones to the follicles also allows for the interaction 
between activated B- and T- cells. Thus, the migration to T cell zones of secondary 
lymphoid tissues allows for the recruitment of T cell help from affiliated T cells that have 
been previously activated. Hence follicular B cells are the ideal candidates for T cell-
 36 
 
dependent immune responses to protein antigens, but are also able to respond in a T 
cell-independent manner to blood borne pathogens (Cariappa, Mazo et al. 2005, 
Cariappa, Chase et al. 2007, Pillai and Cariappa 2009).  
The interaction between B cells and T cells, leads to differentiation along either follicular 
or extrafollicular pathways. In the extrafollicular pathway short-lived plasmablasts only 
are formed by B cells. These plasmablasts though short-lived are able to provide critical 
functions, such as antibodies that protect against infection, even though the antibodies 
express only low affinity for the antigen (Luther, Maillard et al. 1997, MacLennan, 
Toellner et al. 2003, Lee, Rigby et al. 2011). The follicular pathway sees the formation of 
the germinal center by activated B cells. Here, B-cells undergo certain cellular events 
which include clonal expansion characterized by proliferation and amplification of the B 
cell; mutation of the heavy and light chain genes leading to an enhanced diversity in the 
antibody pool, by a process termed somatic hypermutation; and selection.  
The resulting B cells consequently leave as high affinity long-lived plasma cells or memory 
B-cells (MacLennan 1994). Antigen driven production of high affinity antibodies (affinity 
maturation) follows a similar pattern and starts with the light and heavy chains (VL and VH 
genes) selected in the primary response. Following the somatic hypermutation of the V 
genes, clonal selection of B cells that produce antibodies of the highest affinity are then 
selected. This has been confirmed by recent advances in phage-display technology which 
has been able to mimic this process in-vitro (Fujii 2004). 
Isotype or class switching is a biological process occurring after activation of the B cell, 
which allows the cell to produce different classes of antibody (IgA, IgE, or IgG) (Market 
and Papavasiliou 2003). The different classes of antibody, and thus effector functions, 
are defined by the constant (C) regions of the immunoglobulin heavy chain. 
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Figure 1.7.  B cell proliferation in response to antigens and T cell help. Figure adapted from Sridhar Rao 
P.N, 2014.   
 
1.3.2.4 Immunoglobulin secretion 
 
The discovery in 1890 by Von Behring and Kitasato (von Behring and Kitasato 1991) of a 
substance in serum from rabbits immunized with tetanus toxin that had the ability to 
neutralise the ‘poison of tetanus’ when transferred to healthy rabbits, was the first of 
many studies showing the presence of immunoglobulins also referred to as antibodies in 
animals and humans (Schroeder and Cavacini 2010, Novaretti and Dinardo 2011). 
Secreted by plasma cells immunoglobulins can be expressed either as a membrane 
bound form which is attached to the B cell surface and hereafter referred to as the B-cell 
receptor (BCR) or secreted as a soluble antibody which is released into the blood tissues 
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to combat invading microorganisms (Parker 1993, Borghesi and Milcarek 2006).  They are 
heterodimeric proteins which are made up of two identical light chains and 2 identical 
heavy chains which are composed of two functional units created by series of gene 
arrangements; a variable domain for antigen binding and a constant domain for specific 
effector functions (Schroeder and Cavacini 2010). 
The antibody is composed of the Fab (Fragment antigen-binding) region which is 
responsible for the recognition of specific foreign objects. This region is made up of one 
variable and one constant domain from each of the heavy and light chains. The Fc 
(Fragment crystallizable) region is responsible for the modulation of the effector 
mechanisms of the antibody.  
 
                                       
Figure 1.8.  Basic structure of the antibody. 
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Depending on the class of the antibody the 2 heavy chains which make up the Fc region 
can contribute constant domains. This ensures that the antibody is able to generate the 
appropriate immune response for antigens by binding to a specific class of Fc receptors, 
and complement proteins. This leads to the regulation of effects such as recognition of 
opsonized particles and a host of other physiological effects (Woof and Burton 2004). 
1.3.2.5 Immunoglobulin classes 
 
Antibodies are generally classified in mammals into IgA, IgD, IgE, IgG and IgM, and are 
referred to as isotypes or classes. These isotypes have diverse biological functions, 
locations and ability to deal with distinct antigens.  
Out of all the immunoglobulins and IgG subclasses, special attention has been paid to the 
role of IgG4 in the pathogenesis of disease which has assumed a new dimension. A 
plethora of diseases termed IgG4-related diseases (IgG4-RD) are identified and have been 
described as systemic immune mediated diseases. These diseases could involve any 
organ, their common denominator being the obvious IgG4 involvement (Brito-Zeron, 
Ramos-Casals et al. 2014). IgG4-RD have been identified and include sclerosing 
pancreatis, sclerosing cholangitis suggesting biliary tree involvement, thyroiditis, IgG4 
related pulmonary disease, Mikulicz’s disease and neurologic disease amongst others 
(Hamano, Kawa et al. 2001, Kamisawa, Nakajima et al. 2006, Inoue, Zen et al. 2009, 
Takahashi, Yamamoto et al. 2012, Flanagan, Chowdhary et al. 2014, Poplawska-Kita, 
Kosciuszko-Zdrodowska et al. 2015) 
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Table 1.2.  Table of IgG classes. The table shows their structures, anatomical locations and functions. 
 
 
Class 
 
Subclass 
 
 
Structure 
 
Anatomical location and function 
 
IgA 
 
IgA1, IgA2 
 
Dimeric 
Produced locally at mucosal sites, such as the gut, 
respiratory tract and urogenital tract. Found in colostrum 
(Woof and Kerr 2004, Woof and Russell 2011). 
 
 
IgD 
 
 
1 
 
 
Monomeric 
IgD is expressed on the surface of the majority of mature B 
cells before antigenic stimulation. IgD is also secreted 
(Finkelman, van Boxel et al. 1976, Finkelman, Woods et al. 
1979, Chen and Cerutti 2011). Functions as an antigen 
receptor on B cells prior to antigen exposure (Roes and 
Rajewsky 1993, Geisberger, Lamers et al. 2006). 
 
IgE 
 
1 
 
Monomeric 
Binds to allergens and triggers histamine release from mast 
cells and basophils, and is involved in allergy (Schroeder, 
MacGlashan et al. 2001). Also protects against parasitic 
worms (Bell 1996, Fitzsimmons, Falcone et al. 2014). 
 
 
IgG 
 
IgG1,IgG2, 
 
  IgG3, IgG4 
 
 
Monomeric 
Most abundant antibody in the blood. Functions include 
opsonization, activation of the classical pathway of the 
complement system, the neutralization of toxins. Antibody-
dependent cell-mediated cytotoxicity and intracellular 
antibody-mediated proteolysis (Janeway, Travers et al. 
2001). 
 
IgM 
 
1 
 
Pentameric 
Produced in the spleen and expressed on the surface of B 
cells and in a secreted form. Possesses very high avidity and 
effective at complement activation. 
 
1.4  Cystic fibrosis (CF) 
 
CF is a lethal genetic autosomal recessive condition that leads to abnormal airway 
epithelial ion transport (Whitaker, Meng et al. 2011). The majority of the incidents of 
morbidity and mortality in patients have been attributed to pulmonary disease, with 
respiratory failure accounting for deaths in 85% of patients (Flume, O'Sullivan et al. 2007). 
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CF is distinct in its racial, ethnic and geographic distribution. The prevalence of CF has 
been found to be 1/1800 to 1/5000 Caucasians in Europe, United States and Canada, 
1/14000 in Afro-Americans, 1/4000 in Finland and 1/7,000 in Brazil. CF exists in all known 
ethnic groups though rare in Africans and Asians (Brice, Jarrett et al. 2007, Haack, Aragao 
et al. 2013).  
1.4.1 Genetic determinants and management of CF 
The CFTR gene which is associated with CF is responsible for encoding the CF 
Transmembrane Conductance Regulator (CFTR) which works as a channel for the 
transport of chloride ions across the apical membranes of epithelial cells. Even though 
many mutations of this gene have been discovered, with about 2000 variations being 
shown to exist (US Cystic Fibrosis Foundation), very few have actually shown the 
tendency to cause CF. Previous studies have shown that on average, 10 mutations 
account for 79.7% of alleles in patients with CF but about 70% of European patients 
exhibit a similar defect, the F508del which leads to the deletion of 3 bases and eventual 
loss of phenylalanine. Two other common mutations in the European population are the 
G542X and N1303K (Estivill, Bancells et al. 1997, Bobadilla, Macek et al. 2002, Grossman 
and Grossman 2005, Castellani, Cuppens et al. 2008).  
A defect in the CF gene leads to the abnormal chloride conductance across the apical 
membrane of the epithelial cell. The resultant airway surface liquid depletion promotes 
ciliary collapse and inhibition of mucociliary transportation thus providing a suitable 
medium for the microbial colonisation with infection and inflammation as the end result 
(Ratjen 2009).  A fallout of this process is the development of increased numbers of 
membrane asialoGM1 molecules, which are thought to promote the increased binding of 
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Pseudomonas aeruginosa and Staphylococcus aureus (Saiman and Prince 1993), 
microorganisms which have been identified to predominate in cases of respiratory 
infections in these patients. However, a more recent elucidation of the crystal structure 
of Pseudomonas aeruginosa has found this proposed view to be inconsistent with the 
steric realities. This is due to the fact that the C-terminal, which is the proposed binding 
site of P. aeruginosa, is poorly positioned (Hazes, Sastry et al. 2000, Schroeder, Zaidi et al. 
2001). 
Due to the presentation of symptoms which are specific to patients with CF such as the 
development of polyps which have the potential to activate sinus infection, patients 
usually require a longer and more intensive antibiotic treatment, than with patients who 
present solely with pneumonia (Frederiksen, Koch et al. 1997). ß-Lactam antibiotics are 
the corner stone for the management for patients with CF. They are generally employed 
to prevent, eradicate or control infections which arise due to bacterial colonisation in the 
upper respiratory tract. Commonly used beta lactams include intravenous aztreonam, 
ceftazidime, flucloxacillin, meropenem, piperacillin-tazobactam, and Ticarcillin-clavulanic 
acid (CF trust 2009).  
Unfortunately their use is restricted due to the occurrence of severe hypersensitivity 
reactions, which are delayed in nature. Several studies involving patients with CF have 
reported a high incidence of reactions due to certain ß-lactam antibiotics, with frequent 
manifestations of drug-induced fever (DIF) being reported most commonly with 
piperacillin. Typically, the incidence of DIF in patients with CF (2.6 to 32%) is greater than 
that reported in non-CF patients (generally < 5%) (Pleasants, Walker et al. 1994). This 
trend corresponds with the incidence of -lactam hypersensitivity in the general 
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population of about 1-8% (Parmar and Nasser 2005) and 30-50% in patients with CF (Lin 
1992). 
1.5  Immune mechanisms of drug-induced allergy 
 
It is important to note that the immune mechanisms that are highlighted in this section 
are primarily concerned with allergic reactions mediated by T cells. The recognition of 
conventional antigens by T cells is made possible due to specialized antigen presenting 
cells (APCs), such as dendritic cells, macrophages, and B lymphocytes, which capture 
extracellular protein antigens, internalize and process them, then display the processed 
antigen on the surface of major histocompatibility complex (MHC) molecules. CD4+ 
helper T lymphocytes are thought to recognize antigens in association with MHC class II 
molecules (MHC class II restricted recognition), and CD8+ cytotoxic lymphocytes (CTLs) 
recognize antigens in association with class I molecules (MHC class I restricted 
recognition). Dendritic cells are the most efficient APCs for initiating primary responses 
by activating naive T-cells. Macrophages and B lymphocytes present antigens to 
differentiated helper T-cells in the effector phase of cell-mediated immunity and in 
humoral immune responses, respectively.  
The mechanisms by which a chemical or drug acts as an antigen and elicits immune 
activation has not been fully elucidated (Schnyder and Pichler 2009). Most 
pharmaceutical agents cannot bind directly to MHC molecules due to their low molecular 
weight and therefore cannot be directly presented to T cells by APCs (Hausmann, 
Schnyder et al. 2012), but drug-specific T-cells do exist. The hapten and pro-hapten 
concept, P-I concept, and the altered self-peptide repertoire are theories that have been 
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proposed to try and explain how drugs can act as antigens for T cells (Adam, Pichler et al. 
2011). 
1.5.1 Hapten concept/Pro-hapten concept  
Haptens are low molecular weight compounds (MW < 1000 Daltons), that may only elicit 
an immune response when complexed covalently to a large carrier such as a protein. 
“Hapten” is a term coined by Landsteiner and Jacobs to explain both humoral and 
cellular immune responses to low molecular weight chemicals observed in their research 
(Landsteiner and Jacobs 1935, Chipinda, Hettick et al. 2011, Pichler, Naisbitt et al. 2011). 
Most drugs being of low molecular weight were thought to be unable to stimulate 
immune responses due to their size, and thus undergo haptenation (Naisbitt, Hough et 
al. 1999, Naisbitt, Gordon et al. 2001, Naisbitt, Farrell et al. 2002) by binding to 
endogenous/self-proteins. This leads to modification of the proteins, and confers on 
them a form of immune recognition.  Chemical haptens or drugs also have the tendency 
to bind covalently to particular amino acid residues with some β-lactams and their 
derivatives as examples, binding covalently to lysine residues of human serum albumin 
(Whitaker, Meng et al. 2011, El-Ghaiesh, Monshi et al. 2012). The pro-hapten concept 
would require bio-activation/metabolism of drugs or chemical agents to intermediates 
that can react with endogenous constituents to initiate a chain of chemical and 
biochemical events which could lead to cellular damage. Nitroso sulfamethoxazole (SMX-
NO), the protein reactive metabolite of sulfamethoxazole (SMX) has been found to 
selectively modify cysteine residues on proteins. The abiotic activation of drugs and 
chemical agents without the requirement of a particular enzymatic system is also 
possible. Following exposure to air, various non-reactive molecules such as abietic acid (a 
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colophony resin), terpenes and p-phenylenediamine (PPD) are rapidly transformed into 
hapten reactive derivatives. Thus, in addition to the hapten and pro-hapten mechanisms 
of activation a further extension of the nomenclature was proposed. The term ‘pre-
hapten’ was therefore coined to include nonreactive sensitizing chemicals that undergo 
activation as described above (Matura, Skold et al. 2005, Lepoittevin 2006). 
Previous studies have also established a relationship between the nature and magnitude 
of the T-cell response and the degree of covalent hapten binding to proteins. In that 
study dinitrochlorobenzene (DNCB) and dinitrofluorobenzene (DNFB), chemicals that 
exhibited a Type 1 cytokine secretory profile were shown to bind selectively to cellular 
proteins while trimellitic anhydride (TMA), fluorescein isothiocyanate (FITC) and 
dinitrobenzenesulfonyl chloride (DNBSCI) that exhibited type 2 secretory profiles bound 
to serum. Notably, the reactions were not associated with the chemical structures or 
known amino acid specificity (Hopkins, Naisbitt et al. 2005). 
1.5.2 The P-i concept   
The direct pharmacological interaction of drugs with the immune receptors referred to 
as the P-i concept proposes that some drugs may bind non-covalently to some of the 
variable antigen specific T cell receptors (TCR’s) and MHC molecules (Gerber and Pichler 
2004). This concept tries to explain the induction of a primary immune response without 
the initial sensitization from previous exposure by the drug allergen. Though the exact 
mechanism of this TCR dependent T-cell activation by drugs has not been elucidated. 
Three ideal properties which a T cell must possess for activation to take place have been 
defined which include the expression of a TCR that may bind the drug, a low threshold of 
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activation and an additional interaction of the TCR with the MHC on the APC which must 
occur to enhance the response of the drug. (Schnyder and Pichler 2009). 
1.5.3 Altered Self-peptide repertoire:  
MHC molecules are highly polymorphic proteins encoded by Human leukocyte antigens 
(HLAs) that initiate immunity by presenting pathogen-derived peptides to T cells. 
Abacavir and carbamazepine are two drugs that mediate significant immune 
hypersensitivity reactions that are strongly associated with the HLA alleles B*57:01 and 
B*15:02 respectively (Illing, Vivian et al. 2012, Ostrov, Grant et al. 2012). These reactions 
are not explained simply by either the hapten and pro-hapten or the P-i concepts of drug 
binding. What we now know is that abacavir and carbamazepine (to a lesser extent) are 
able to bind specifically to the HLA alleles, altering the shape and chemistry of the 
antigen-binding cleft, and are thus able to influence a change in the pool of presented 
self-peptides capable of binding the HLA alleles B*57:01 and B*15:02 (Illing, Vivian et al. 
2012). It is this guided alteration of endogenous peptides that is assumed to be 
responsible for the significant incidence of hypersensitivity reactions in patients bearing 
the HLA risk alleles. More recently a similar association has been reported with acyclovir 
and HLA-B*57:01 but without the induction of hypersensitivity (Metushi, Wriston et al. 
2015). 
1.6  Functions of B-cells in disease states 
 
The involvement of the immune system in the pathogenesis of many human diseases, for 
example auto- and acquired immune diseases such as systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), hypersensitivity reactions, HIV-AIDS have been studied 
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in detail. In trying to decipher the mechanisms and functional roles played by the 
different components underlying the immune response seen in these conditions, the 
emphasis has been skewed in favour of the role T lymphocytes play. This was due to the 
popularly held view that T cells comprise the fundamental pathological component of 
autoimmune diseases, and the autoantibodies identified therein considered as 
accessories secondary to the loss of T cell tolerance. More recent studies have led to the 
development of B cell directed therapy. This has generated substantial interest in the 
potential modulatory role B cells may play in the management of such conditions (Lopes-
Carvalho and Kearney 2005, Browning 2006). 
Some conditions may involve interplay between the B cells and other immune 
components such as in RA, where alongside rheumatoid factors (RF) and anticitrullated 
antibodies generated by B cells which promote immune complex formation and 
complement activation, there is also the reactivation of autoreactive T cells by the B cells 
acting as APCs (Dorner and Burmester 2003, Silverman and Carson 2003).  Other 
autoimmune disorders such as SLE are derived from the generation of pathogenic 
autoantibodies. Immunodeficiency manifested as chronic inflammation has been found 
to involve B cells (Pelton and Denman 1982, Nashi, Wang et al. 2010). The efficacy of B cell 
depletion therapy in RA patients employing Rituximab an anti-CD20 chimeric monoclonal 
antibody is a perfect illustration of the relevance of B cells in autoimmune disease. A 
significant reduction in autoantibody levels, and significant improvement in clinical 
symptoms, being clear indicators (Edwards, Leandro et al. 2004, Edwards, Szczepanski et 
al. 2004, Lim, Beers et al. 2010). It should be noted though that responses obtained with 
SLE patients were highly variable, but in general this class of agents shows a lot of 
promise (Pescovitz 2006, Mandik-Nayak, Ridge et al. 2008). Studies have shown CD19 B 
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cells to play important roles in the elicitation of contact hypersensitivity (CHS), a 
cutaneous immune reaction mediated mainly by antigen specific effector T-cells. The 
mechanism of their action is probably via the antigen-specific IgM dependent 
recruitment of effector T cells, function of  regulatory B-cells (Bregs), and also the 
manifestation of defective CHS responses elicited by B cell deficient mice (Tsuji, 
Szczepanik et al. 2002, Watanabe, Fujimoto et al. 2007). 
Though the immunoglobulin subclasses are all closely related, they have different heavy 
chain structures and effector functions. The Fc portion of the IgG molecule (see figure 
1.8) contains binding sites for complement (C1q), IgG-Fc receptors (FcR) on effector cells 
and neonatal Fc receptor (FcRn). The subclasses of IgG which include IgG1, IgG2, IgG3 and 
IgG4 share a 90% homology but still possess unique profiles with respect to effector 
function. The individuality in effector function exists mainly due to the structural 
variations in the hinge regions (Hamilton 1987) and amino acid differences found in the 
N-terminal CH2 domain though other factors have been postulated  (Hovenden, Hubbard 
et al. 2013, Theo and Gestur 2014). These variations give rise to the differential binding of 
IgG subclasses to the C1q and FcR sites which in turn also determines the elicitation of a 
number of effector functions. 
The regulatory function of IgG4 has been observed in the control of IgE-mediated 
reactivity. Tolerance has been observed in human filariasis where antigen specific IgG4 
acts as a blocking antibody with an increase in circulating levels associated with tolerance 
(Hussain, Poindexter et al. 1992). Elevated levels of specific IgG4 was also observed in 
immunotherapy with bee venom (Wyss, Scheitlin et al. 1993) and in the maintenance of 
tolerance to cow milk in atopic individuals (Ruiter, Knol et al. 2007). The role of IgG4 in 
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the regulation of tolerance in cellular immune mediated hypersensitivity reactions 
beyond already elucidated mechanisms of microbial opsonization prior to processing and 
presentation still remains unclear. 
1.7  Evidence of humoral involvement in hypersensitivity reactions 
 
Historically the immune system has been found to be involved in the development of 
ADRs, with effects ranging from those due to immunosuppression (Salvadori and Bertoni 
2003, Stucker and Ackermann 2011) to severe hypersensitive reactions discussed earlier in 
this text.  
The characterisation of drug-specific CD4+ T-cell clones coupled with the identification of 
secreted cytokine products from these cells highlights their role in the elicitation of 
certain forms hypersensitivity reactions (Akiba, Kehren et al. 2002, Naisbitt, Farrell et al. 
2003, Heimann, Janda et al. 2011, El-Ghaiesh, Monshi et al. 2012). The identification of anti-
drug antibodies (Coleman, Yeung et al. 1986, Bougie, Wilker et al. 2006), immunoglobulin 
subclasses (Eric et.al, 2009), their secretions indicates that the humoral immune system 
contributes to the effector and regulatory immune process in the disease pathogenesis 
(Lund 2008, den Reijer, Lemmens-den Toom et al. 2013). 
Antidrug antibodies have been identified previously with studies from the 50’s and 60’s 
to the present day focussing on the detection and characterization, their hypersensitivity 
mechanisms, clinical implications and the development of improved detection 
techniques. Several studies are listed in table 1.3. 
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Table 1.3. Detection of antidrug antibodies (studies from 1961 – 2015). Emphasis is on the detection and 
characterization, mechanisms, clinical implications and experimental detection of antidrug antibodies. 
 
 
Study focus 
 
1. 
 
Detection and 
characterization 
 
(de Haan, Boorsma et al. 1979, Christie, Coleman et al. 
1988, Christie, Breckenridge et al. 1989) 
 
2. 
 
Mechanisms of 
hypersensitivity 
 
(Levine and Ovary 1961, Chandra, Joglekar et al. 1980) 
 
3. 
 
Clinical implications 
 
(Okuno and Crockatt 1976, Mok, van der Kleij et al. 
2013, Lundkvist Ryner, Farrell et al. 2014) 
 
4. 
Assay development 
for antidrug 
antibody detection 
 
(Van Cleave 2003, Bourdage, Cook et al. 2007, Macy, 
Goldberg et al. 2010, Bloem, van Leeuwen et al. 2015) 
 
 
 
Although a rise in the numbers of B and T-cells coincides with the protection against re-
infection with blood borne pathogens, it is also dependent to a large extent on pre-
existing titres of neutralizing antibodies. It has been hypothesized that antigen 
dependence via various cellular mechanisms, and the repetitive stimulation of B cells 
which may occur via a chronic low-grade infection or repeated exposure to external 
virus, bacteria or toxins is required for the differentiation of memory B cells to short-lived 
plasma cells with the ability to maintain high antibody titres (Ochsenbein, Pinschewer et 
al. 2000).      
1.8  Covalent binding in drug-specific B-cell activation 
 
The covalent binding of drugs to proteins leads to modifications that result in the 
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production of major and minor antigenic determinants. Major determinants include 
penicilloyl and nitroso metabolites from penicillin, and sulfamethoxazole respectively, of 
which multiple experimental data exists to show their interactions with the cellular 
adaptive system (Green, Rosenblum et al. 1977, Spath, Huber et al. 1979, Naisbitt, Hough 
et al. 1999, Naisbitt, Gordon et al. 2001). The minor antigenic determinants on the other 
hand may contribute to the induction of IgE mediated allergic responses (Weltzien and 
Padovan 1998). Mass spectrometry has significantly aided the qualitative and 
quantitative analysis of these peptides, proteins, reactive metabolites and conjugates. 
Initially developed in the early 20th century to measure masses of atoms by physicists, the 
application has evolved to natural products identification by scientists to their primary 
application under the purview of analytical chemistry in the latter part of the 20th 
century. The development of plasma desorption, fast atom bombardment (FAB), and 
thermospray ionisation were steps in the identification of proteins but were faced with 
the disadvantages of using high concentrations of small proteins and the fact they didn’t 
work well with larger proteins (Macfarlane and Torgerson 1976, Barber, Bordoli et al. 
1981, Morris, Panico et al. 1981, Liberato, Fenselau et al. 1983, Vestal and Blakely 1983, 
Griffiths 2008). Later development of matrix assisted laser desorption ionisation (MALDI) 
and electrospray ionisation (ESI) techniques with enhanced utility were the keys required 
to unlock the doors enabling the full characterization of these proteins and peptides 
(Karas and Hillenkamp 1988, Tanaka, Waki et al. 1988, Fenn, Mann et al. 1989). Thus it 
was suggested that these methods possess the capability to define the role of covalent 
binding of drugs and other low molecular weight chemical compounds to proteins in 
immunogenicity (Weltzien and Padovan 1998). Current applications involve the use of 
Multidimensional liquid chromatography with ESI (MudPIT) to characterize cisplatin 
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binding sites (Will, Wolters et al. 2008), liquid chromatography-mass spectrometry (LC-
MS) analysis to identify 2,4-dinitro-1-chlorobenzene covalent adducts in the skin and LC-
MS/MS to detect the presence of acyl glucuronide metabolites in diclofenac patients 
(Aleksic, Pease et al. 2008, Hammond, Meng et al. 2014). Other applications involved 
defining protein haptenation mechanisms in contact and delayed-type drug 
hypersensitivity (Aleksic, Pease et al. 2007, Meng, Jenkins et al. 2011, Jenkins, Yaseen et 
al. 2013).  
1.9  Immune response in β-lactam hypersensitivity 
 
Utilizing basic immunological principles, researchers have developed various methods 
which have been employed in the detection of the immune response in drug 
hypersensitivity. Hence the fact an infection gives rise to a significant increase in the 
number of lymphocytes specific for the target pathogen (Datta and Sarvetnick 2009), has 
led to the use of proliferation assays specifically the lymphocyte transformation test 
(which we shall discuss further in a later chapter) for the confirmation of hypersensitivity 
to chemical agent/drugs molecules/haptens. The generation of T-cell clones (Naisbitt, 
Farrell et al. 2003, Naisbitt, Farrell et al. 2005, Castrejon, Berry et al. 2010), the use of flow 
cytometry (Quah and Parish 2012) and the application of the ELISpot and enzyme linked 
assays have all contributed to enhance our understanding of the molecular processes 
which underlie drug hypersensitivity (Pichler and Tilch 2004, El-Ghaiesh, Monshi et al. 
2012). 
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1.10 Aims and objectives 
 
Having recently described the cellular immunological processes that underlie drug-
specific responses in hypersensitive patients: I would like to analyse in depth, the 
involvement of the humoral immune system which has been left somewhat ignored. I 
have specifically focussed on piperacillin hypersensitive patients with CF to begin to 
describe the different molecular events and components of the drug-specific humoral 
immune response.  
Thus, the main objectives of this thesis were to: 
1. Modify existing and develop new methods to detect drug-specific B-cell antibody 
secretion in piperacillin tolerant and hypersensitive patients with CF. 
2. Generate and characterize drug-protein adducts and detect anti-drug antibodies 
in piperacillin hypersensitive patients with CF. 
3. Define the role(s) of these anti-drug antibodies on T cell proliferation during 
immune reactions in piperacillin hypersensitive patients. 
4.  Develop methods for long term culture of B-cell lines and generation of anti-drug 
antibodies. 
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2.0 Introduction 
 
This chapter aims to showcase the various methods employed in the search for the 
underlying mechanisms explaining the role of B-cells in the pathogenesis of drug 
hypersensitivity disorders specifically those due to β-lactam antibiotics. This chapter 
has been divided into three general sections to enhance the clarity of the methods 
used. These are broadly the cell culture methods which includes cell isolation and 
culture, functional assays which covers the detection of secretory products from cells 
which helps to define to a certain extent their form and function, and lastly the 
proteomic studies which includes the identification of drug-protein interactions.  
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Figure 2.1 Figure showing the general assays employed. Some assays were multifunctional in the sense 
that they helped link two aspects of the study. 
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2.1 Cell culture methods 
 
The cell culture methods used form the basic foundation of this thesis and were based  
on methods that had been previously tested in various research groups and others 
modified to suit the aims of this thesis. 
2.1.1 Media for cell culture, cell separation and flow cytometry analysis 
The ingredients used in the preparation of the various culture media, and preparations 
for cell separation and flow cytometry analysis are represented in the table below. 
Other materials employed in this thesis are listed in appendices I – III. 
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Table 2.1 Media for cell culture, cell separation and flow cytometry analysis. Table showing the different 
preparations used in the culture, separation and phenotypic analysis of cells. The constituents of these 
media and sources are also listed. 
 
 
 
 
 
 
 
 
Preparation 
 
Contents/source 
 
 
 
F1 
1. RPMI 1640 (Sigma R0883) 
2. 10% pooled FBS (Gibco 10270) 
3. HEPES buffer 25mM (Sigma H0887) 
4. L-glutamine 2mM (Sigma G7513) 
5. Streptomycin 100 mg/ml 
6. Penicillin 100 U/ml (Sigma P0781)  
 
 
 
R9 
1. RPMI 1640 (Sigma R0883)  
2. 10% pooled human blood type AB serum (Innovative 
Research HP1022)  
3. HEPES buffer 25mM (Sigma H0887)  
4. L-glutamine 2mM (Sigma G7513)  
5. Transferring 25 mg/ml (Sigma T0665)  
6. Streptomycin 100 mg/ml 
7. Penicillin 100 U/ml (Sigma P0781) 
 
 
 
 
R10 
1. RPMI 1640 (Sigma R0883) 
2. 10% pooled FBS (Gibco 10270) 
3. HEPES buffer 25mM (Sigma H0887) 
4. L-glutamine 2mM (Sigma G7513) 
5. Streptomycin 100 mg/ml 
6. Penicillin 100 U/ml (Sigma P0781) 
7. 2-mercaptoethanol (Concentrated 2 - ME was diluted 
to 50 mM in PBS and added to media to attain a final 
concentration of 50 μm)  
 
FACS buffer 
1. Hanks balanced salt solution (HBSS) (500mL) 
2. Fetal bovine serum (50L) 
3. Sodium azide (100mg)  
 
10x 
MACS buffer 
 
1. Hanks balanced salt solution (HBSS) (47.5 ml) 
2. Ethylenediaminetetraacetic acid (EDTA) (2 ml) 
3. Bovine serum albumin (2.5 g) 
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2.1.2 Peripheral blood mononuclear cells (PBMC) isolation from blood 
using density centrifugation 
Twenty millilitres (20 ml) of lymphoprep was introduced into a 50 ml tube, and an 
equal volume of fresh venous heparinised blood collected from healthy volunteers or 
cystic fibrosis patients was layered onto the lymphoprep to form two distinct layers. 
The tubes were then centrifuged at 2000 rpm, for 25 minutes, with the absence of 
brake (brake = 0). After the spin cycle the tubes showed three distinct phases, with a 
thin layer of cells nestling between the top two layers (plasma and lymphoprep). 
Using a pasteur pipette the thin layer of cells was carefully removed from the tube and 
transferred into a sterile 50 ml tube. The tubes were filled up with hanks balanced salt 
solution (HBSS) and centrifuged at 1800 rpm, for 15 minutes, brake = 3. This was 
performed to facilitate washing of the cells. After the spin cycle the supernatant was 
discarded and the cells re-suspended in a small quantity of HBSS. At this point it was 
beneficial to contain all the cells in as few tubes as possible, thus necessitating pooling 
together cell pellets from the same donor. The tube containing the pooled cells was 
then filled with HBSS and centrifuged at 1500 rpm, for 10 minutes and brake = 3. After 
this spin the supernatant was discarded and the cells resuspended in a fixed volume of 
HBSS or culture medium. Trypan blue was added to an aliquot of cells prior to 
counting using a haemocytometer. Cells were then seeded in culture plates or froze 
by cryopreservation in foetal bovine serum + 10% DMSO at -150oc.  
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2.1.3 Lymphocyte transformation test 
PBMCs were isolated and counted as described earlier. The PBMCs were then cultured 
in triplicate using 96-well U-bottom plates at a cell density of 1.5 x 105 cells/well in 200 
l per culture condition (culture medium, titrated drug, and tetanus toxoid 5 g/ml; 
positive control). The plates were then labelled, wrapped in foil and stored at 370C, 5% 
CO2, for five days. 0.5 Ci of thymidine [3H] was added to each well for the final 16 hr 
of incubation. At the end of the incubation period the plates were harvested on filter 
mats using a microplate harvester (TOMTEC harvester 96 MACH III M), and the extent 
of thymidine incorporation measured as counts per minute (cpm) using a beta counter 
(Perkin ELMER microbeta Trilux). Analysis of cell proliferation was denoted by the 
stimulation index (SI), of which any SI value  2 was accepted as a positive result 
(Nyfeler and Pichler 1997, Pichler and Tilch 2004). 
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Figure 2.2. Schematic representation of the PBMC isolation and their various downstream applications. 
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2.1.4 PBMC culture and B-cell culture and activation studies 
Isolated PBMCs were re-suspended at 1 x 106 PBMC/ml in 1ml R10 (see constituents in 
section 2.2).  Various culture conditions were prepared including 1.5 μg/ml Cpg DNA 
mitogen stimulation medium and a 2 mM solution of piperacillin stimulation medium, 
in R10 medium sufficient for 1 well (1 ml/well) per treatment condition. Using sterile 
techniques, 1 x 106 PBMCs were added to each well containing R10 culture medium 
alone, 2 mM piperacillin, and Cpg-DNA in a 24-well plate. These plates were then 
placed in 5% CO2 at 37C for 5 days.  On the fifth day, plates were harvested with 
PBMCs and cell supernatants collected for ELISA and ELISpot analysis (Fig 2.2). 
 
 
Figure 2.3  Figure showing schematic diagram of PBMC culture and B cell activation as a starting point for the 
functional assessment of lymphocytes. 
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2.1.5 CD19 positive PBMC separation 
Isolated PBMCs were centrifuged and re-suspended in 80 μl MACS buffer per 107 cells, 
to which 20 μl of vortexed CD19 micro beads were added per 107 cells. Mixing was 
facilitated by gentle agitation and the mixture incubated for 15 minutes at 40C.  Note 
that for samples with less than 107 cells 80 μl/20 μl volume ratios of Macs buffer and 
CD19 micro beads was used. After incubation Macs buffer was added per 107 cells and 
tubes were centrifuged at 1500 rpm for 8 minutes at 40C. The supernatant was 
pipetted off completely and cells re-suspended at 108 cells per 500 μl Macs buffer. An 
MS column (Miltenyi Biotech GmbH Germany) was placed on a magnet and washed 
with 500 μl Macs buffer. Cells were then added to the column in 500 μl aliquots. The 
tube was rinsed once with 500 μl Macs buffer. The column was then washed three 
times with 500 μl Macs buffer, the buffer being added separately once the reservoir 
was empty. The flow through containing negative cells was collected in 5 ml bijou 
tubes. The column was removed from the magnet and placed over a collection tube. 1 
ml Macs buffer was added to the column and selected cells harvested by immediately 
applying the plunger firmly to the column. The number of CD19 positive B cells was 
counted using trypan blue exclusion with the aid of a haemocytometer.  
2.1.6 Generation of IgG secreting B-cell lines 
Long lived IgG secreting B cells were generated using methods modified from that 
employed by Lanzavecchia et al. (Lanzavecchia, Corti et al. 2007). Isolated PBMCs 
from patients bearing the CD19 phenotype were utilised for this assay. They were 
obtained using previously described CD19 positive separation techniques. Thirty to a 
hundred  (30 – 100) CD19+ B cells per well were cultured in U-bottomed 96-well plates 
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in the presence of  1 x 105 irradiated PBMCs per well which are employed as feeder 
cells. 1 μg/ml CpG-dna, 30% w/v Epstein barr virus (EBV), and 1 mM piperacillin were 
also added. This culture was kept at 370C, and 5% CO2 for 14 days. Care was taken to 
feed B cells with F1 medium supplemented with 0.01 mM sodium pyruvate twice 
weekly. After two weeks the volume of each well was reduced to 100 μl and 1 μg/ml 
Cpg-dna and 50 U/ml IL-2 added to give a total volume of 200 μl/well. Cells were kept 
under earlier prescribed culture conditions. Growing wells were then transferred to 
48-well culture plates to enhance cell proliferation and expansion. After an additional 
two weeks, culture supernatants were tested for IgG secretion using a total IgG 
enzyme linked immunosorbent assay (ELISA) and cells harvested to test for IgG 
secretion using an enzyme linked immunospot (ELISpot) assay (see figure 2.3). IgG 
secreting lines were then assayed for the presence of anti-drug specific IgG. 
 
 
 
Figure 2.4. TLR9 activation and viral induced immortalization of B cells for the generation of IgG secreting 
B cell lines. 
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2.1.7 Generation of drug-specific T- Cell clones 
2.1.7.1 Drug Dilutions 
 
Piperacillin was dissolved in R9 medium to create a stock solution of 4 mM.  PBMCs were 
counted and diluted to 3 x 106 cells/ml. 330 µl cells and 330 µl piperacillin were seeded 
onto a 48 well plate to give a final drug concentration of 2 mM with 2 wells per 
concentration. Cells were cultured for 14 days under prescribed culture conditions and 
were referred to as ‘bulk cultures’. On the 6th and 9th days in culture 330µl IL-2 in R9 
medium was added. 
2.1.7.2 Serial dilution 
 
On day 14 all 4 wells were mixed, cells counted, and the total bulk culture diluted serially. 
The cells were diluted to a stock solution of 1 x 104 cells/ml. Three cell concentrations 
were then prepared each utilising 9 µl, 30 µl, and 90 µl of the 1 x 104 stock in a 35 ml serial 
dilution cocktail. The serial dilution cocktail consisted of irradiated PBMC from an 
allogenic donor [5 x 104 PBMC/well, irradiated for 15 minutes], PHA [5 µg/ml], IL-2 [2.5 
µl/ml of the 105 stock solutions] was added and the required amount of 1 x 104/ml stock 
cells for each condition into 35 ml R9 medium. 96 well U-bottomed culture plates were 
used and the final T-cell number was 0.3 cells/well, 1 cell/well and 3 cells/well after 
seeding with 100 µl of the individual cocktails. Cells were cultured for 14 days. Medium 
was supplemented on day 5 and then every 2 days with 25 µl IL-2 in R9 medium (from a 
2.5 µl/ml solution of the 105 unit stock solution). 
On the 14th day the volume of the wells was reduced to 80 µl and a ‘re-stimulation’ 
cocktail which consisted of irradiated cells from an allogenic donor (5 x 104 PBMCs/well, 
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irradiated for 15 minutes), PHA (10 µg/ml), IL-2 (7 µl/ml of the 105 stock solution) was 
added. Feeding was carried out every 2 days with the addition of 25 µl IL-2 in R9 medium 
(from a 2.5 µl/ml solution of the 105 stock solution). Well growing wells distinguished by 
the formation of a solid pellet and a colour change of the cell culture medium from pink 
to yellow, were transferred and plated out in 2 wells in a new 96 U bottom well plate. 
Wells were split from 2 to 4 when further change of the 2 wells to yellow was observed 
and feeding was continued every 2 days. 
2.1.7.3 Testing for T-cell clone drug specificity 
 
Testing for drug specificity was carried out on clones that had proliferated sufficiently to 
be expanded to at least 4 wells on 96 well U-bottomed plates. The volume in each well of 
the 96 U bottomed plates was reduced to 100µl. Cells from 2 wells were then mixed and 
transferred to 4 wells (50 µl/well)  in a new 96 well U-bottomed plate. 1 x 104 autologous 
irradiated EBV transformed B cells (20 minutes in the presence of 123 [Cs]) were added in 
50 µl R9 medium. 100 µl of piperacillin (4 mM) was added to 2 of the 4 wells and R9 
medium alone to the other 2 wells. Plates were incubated for 48 hr, 370c, 5% CO2 and 0.5 
µCi/well 3H thymidine added for the last 16 hr. The proliferative response was analysed 
using a beta counter and clones that achieved S I values   2 when compared to R9 were 
considered as drug specific. Clones which did not exhibit drug specificity were discarded. 
2.1.7.4 Re-stimulation of drug-responsive T-cells 
 
Re-stimulation cocktail was prepared by mixing irradiated cells from any donor (5 x 105 
cells/well, irradiated for 15 minutes), PHA (10 l/ml), and IL-2 (7 l/ml of 105 stock). The 
two remaining 96U wells of each drug specific clone were mixed and transferred into 
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sterile FACS tubes. Each tube was then made up to 1 ml with R9 and centrifuged at 1500 
rpm for 5 minutes. Clones were then re-suspended in 330 l R9, plated onto a 48 well 
plate and 330 l of the re-stimulation cocktail was then added to each well. The following 
day and every 2 days thereafter 330 l R9 with IL-2 (2.5 l/ml) was added.  
2.1.8 Epstein Barr virus (EBV) induced immortalisation of B – Cells 
 
B95-8 cells are an extensively used cell line obtained from the marmoset monkey which 
secretes the B95-8 strain of Epstein-Barr virus (EBV). The B95-8 cell line was initially 
immortalized by infection with virus from the 883L cell line, which was acquired through 
the culture of lymphocytes from an elderly person with transfusion-induced infectious 
mononucleosis (Miller, Shope et al. 1972, Skare, Edson et al. 1982).  
B95-8 cells were centrifuged and 8 ml of supernatant was removed. 5 ml of the 
supernatant was filtered (using a 0.2 µm filter) onto 5 x 106 PBMCs followed by the 
addition of 1 µg/ml cyclosporin A (CSA). Cells were incubated at 370c, 5% CO2. Post 
incubation the cells were centrifuged at 1500 rpm for 5 minutes and the supernatant 
discarded. PBMCs were then re-suspended in 2 ml F1 medium + CSA (1 µg/ml) from which 
1 ml, 0.5 ml, and 2 x 0.25 ml volumes respectively were plated into 4 wells on a 24 well 
plate. F1 medium was then added to create a total volume of 1 ml in each well. The cells 
were then fed with F1 + CSA twice a week for 3 weeks. From this point forward CSA was 
removed from the culture medium. Splitting was performed when the medium in the 
wells started to turn yellow. Feeding was continued twice a week with F1 medium and 
cells transferred into 25 ml flasks and later into 60 ml flasks. Some cells were frozen at -
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1500C or in liquid nitrogen for long term storage using methods described in section 2.1. 
Lines were maintained at 37oC, 5% CO2 using a twice weekly feeding cycle.  
2.1.9 T- Cell proliferation assay 
 
Drug-specific T-cell clones (50 X 104 cells/well; 100 µl) were seeded in duplicate in a U-
bottomed 96 well plate, with varying drug concentrations in medium appropriate for the 
culture of T cells. To these wells 123Cs irradiated autologous EBV transformed B cells (1.0 x 
104 EBVs/well) were added, to achieve a total well volume of 200 l after which the plates 
were incubated at 370C, 5% CO2 for 48 hr. Cells were pulsed with [3H] thymidine for the 
last 16 hr of culture, and plates were subsequently harvested and incorporated 
radioactivity counted with a beta counter. Proliferation was calculated as the SI as 
described previously, and SI values  2 were considered positive. 
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Figure 2.5 Schematic diagram of the generation of autologous B cell lines, T cell clones and analysis of 
antigen-specific T cell responses. 
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2.2   Functional assays 
 
This section covers assays carried out to define the forms and function of cells and their 
secretory products and endogenous marker expression. 
2.2.1 Enzyme linked immunospot (ELISpot) assay 
The in-vitro cell culture of PBMCs or cell lines following incubation with antigens or 
mitogens leads to the production of antibodies and cytokines, and the number of cells 
expressing these molecules may be detected using an enzyme linked immunospot 
(ELISpot) assay which has been documented previously (Czerkinsky, Nilsson et al. 1983, 
Crotty, Aubert et al. 2004, Cao, Gordic et al. 2010). The ELISpot assay is presumed by 
some to be the gold standard for the enumeration of antigen-specific B-cells (Bonsignori 
and Moody 2012, Jahnmatz, Kesa et al. 2013). ELISpots were conducted using drug 
stimulated PBMCs and B-cell lines to detect the secretion of immunoglobulin G (IgG), but 
also PBMCs and drug-specific lines and clones to detect the secretion of interleukin-5 (IL-
5), interleukin-13 (IL-13), interferon gamma (IFN-γ), and granzyme B (GB) and interleukin-
22 (IL-22).  
2.2.1.1 Sterile Preparation of ELISpot plate 
 
This procedure was carried out in a class II microbiological safety cabinet. The coating 
antibodies with specificity for IgG or various cytokines were diluted to their required 
concentration in sterile PBS, pH 7.4. The polyvinyl difluoride (PVDF) membrane was pre-
wet by the addition of 100 l of 35% ethanol per well for 1 minute, after which the 
membranes were washed 5 times with sterile Hanks balanced salt solution (HBSS), using 
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200 μl/well each time.  100 μl/well of the required coating antibody solution was added 
and the plate incubated overnight at 4°C.  
2.2.1.2 Incubation of PBMCs for detection of IgG antibody secreting B 
lymphocytes 
 
PBMCs harvested from the 5 day PBMC culture described in section 2.3 were suspended 
in 1 ml of R10 medium and cell numbers for each treatment group determined using a 
haemocytometer. Excess antibody was removed from the ELISpot plate via washing as 
described above. 200 μl/well of R10 medium, the same as that used for the cell 
suspensions, was then added onto the plate and incubated for 30 minutes at room 
temperature. After this incubation, the medium was removed and 5 x 104 cells from 
PBMCS earlier pulsed with drug, Cpg-dna or medium control were added into separate 
wells (3 per treatment group) with each well containing a maximum volume of 200 l. 
The plate was then wrapped in foil and kept at 37°C, 5% CO2 for 24 hr. 
2.2.1.3 Incubation of PBMCs for detection of cytokine secreting T-
lymphocytes 
 
The excess antibody was removed and the plate washed as described above.  200 μl/well 
of R9 medium, the same as that used for the cell suspensions was then added onto the 
plate and incubated for 30 minutes at room temperature. The medium was then 
removed and 100 l/well of the stimuli which in this case was piperacillin (2 mM) and PHA 
(5 g/ml) was added followed by 100 l/well of the cell suspension containing 5 x 105 
PBMCs. The ELISpot plate was incubated at 37°C, 5% CO2 and incubated for 24 hr. Care 
was taken not to move the plate during this time and the plate was also wrapped in foil 
to prevent evaporation.  
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2.2.1.4 Incubation of drug-specific T-cell clones for detection of T-cell 
cytokines  
 
The excess antibody was removed and the plate washed as described above.  200 μl/well 
of R9 medium, the same as that used for the cell suspensions was then added to the 
plate and incubated for 30 minutes at room temperature. The medium was then 
removed, and 100 l/well of the stimuli added to achieve a final drug concentration of 
piperacillin 2 mM, PHA (5 g/ml) and medium control. This was followed by the addition 
of 50 l/well of the cell suspension containing 1.5 x 105 T-cell clones PBMCs, and 50 l/well 
of a cell suspension containing 5 x 104 autologous EBV-transformed B cells.  The ELISpot 
plate was incubated at 37°C, 5% CO2 and incubated for 48 hr. Care was taken not to move 
the plate during this time and the plate was also wrapped in foil to prevent evaporation.  
2.2.1.5 ELISpot membrane development and spot detection 
 
The cells were removed from the plate and wells washed 5 times with 200 μl/well HBSS. 
Detection antibodies for the respective IgG and T-cell cytokines were diluted to their 
preferred concentrations in PBS containing 0.5% fetal calf serum (PBS-0.5% FCS) and 100 
μl added to each well. The plates were then incubated for 2 hr at room temperature. 
After incubation the plates were washed 5 times as previously described and 100 μl 
Streptavidin-ALP (1:1000) in PBS-0.5% FCS added to each well. After incubation for 1 hr at 
room temperature the plates were washed and 100 μl/well of BCIP/NBT substrate 
solution was added and the plate observed until distinct spots emerged. Colour 
development was stopped by washing extensively under flowing tap water. Plates were 
then left to dry, after which the spots were counted on an ELISpot plate reader (ELISpot 
reader ELR06;AID Advanced Imaging Devices, GmbH Germany).  
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2.2.2 Flow cytometry 
2.2.2.1 CD3, CD19 and CD27 phenotype expression in activated PBMCS 
 
Phenotypical identification of CD3, CD19, and CD27 expressing lymphocytes was carried 
out using flow cytometry. Cells taken from PBMC antigen or mitogen cultures as 
described in section 2.11.2 were split between fluorescent activated cell sorting (FACS) 
tubes. Two conditions one stained with appropriate antibody and the other stained with 
isotype control were then set up for each treatment group. PBMCs were then washed by 
centrifuging the FACS tubes at 1500rpm, 5minutes, and brake = 3 after which the 
supernatant was discarded carefully. 200µl of FACS buffer was then added to each tube.  
Approximately 3 µl of each of CD3, CD19 and CD27 fluorochrome antibodies, depending 
on the phenotype to be determined was added in the dark to only the stained sample 
tubes. The samples in both tubes were then incubated in the fridge for 20 minutes at 40C, 
and covered in foil. After 20 minutes, 1 ml FACS buffer was added and the cells were 
washed. The samples were then either re-suspended in 200 µl of FACS buffer for same 
day analysis, or 200 µl 4% paraformaldehyde for next day analysis. The fixing process has 
been shown to be suitable for up to 30 hr storage at 4oC. The samples in FACS buffer can 
be stored at 4oC for a few hr covered with foil until required. 
2.2.2.2 CD4, CD8 phenotypical characterization of drug-specific T-cell 
clones 
 
 The phenotype expressed by drug specific T cell clones was also carried out using flow 
cytometry. T cell clones from expanded 48 well plates and confirmed to be drug specific 
were transferred into two FACS tubes per clone, ensuring that there was a maximum of 5 
x 105 PBMCs in each tube. Two conditions, one stained and the other unstained were 
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then set up for each treatment group. T cell clones were then washed as described above 
and suspended in 200µl of FACS buffer was then added to each tube.  3 µl of CD4 and 
CD8 fluorochrome antibodies, were added in the dark to stained sample tubes alone. The 
samples were incubated in the fridge for 20 minutes at 40C covered in foil. After 20 
minutes, 1 ml FACS buffer was added and a wash centrifuge cycle performed. The 
supernatant was then discarded. The samples were then either re-suspended in 200µl of 
FACS buffer for same day analysis, or 200µl 4% paraformaldehyde (PFA) for next day 
analysis.  
2.2.3 Enzyme Linked Immunosorbent Assay (ELISA) 
 
The identification of drug-specific antibodies was attempted using a modified protein for 
antigen (drug molecule). This is made possible by employing the use of drug-protein 
adducts prepared by the incubation of the drug with a model protein and then 
precipitation with an appropriate alcoholic precipitant (Ariza, Garzon et al. 2012) ; See 
section 2.3.1 for the precipitation of adducts. Flat-bottomed 96 well microplates were 
pre-coated with modified and unmodified protein-drug adducts, and the difference in the 
levels of antibodies detected between both conditions after plasma sample addition 
referred to as the amount of anti-drug antibody specific to the particular drug of interest.  
This may be confirmed by the pre-incubation of the plasma samples with known 
quantities of an inhibitor before addition to the microplate to see if the expression of 
circulating anti-drug antibodies will be nullified (Coleman, Yeung et al. 1986, Christie, 
Coleman et al. 1988, Clarke, Neftel et al. 1991, Zhang, Wang et al. 1996). 
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2.2.3.1 ELISA for the detection of total IgG levels in volunteer and patient 
plasma samples 
 
The method employed was the same as described using the commercial IgG detection kit 
(Mabtech). Microtitre plates were coated overnight at 4°C  with 100 l of a 1:100 solution 
of anti-IgG coating antibody (0.05 M phosphate buffer, pH7.2; 100 l/well). After 
overnight incubation the plates were washed 3 times with 200 l/well 0.15 M PBS 
containing 0.05% Tween 20 (PBS-Tween, pH 7.2) and tapped dry. Plates were blocked 
with 100 l of a non-specific protein (BSA) for 30 minutes, washed as previously 
described and then incubated with 100 μl of volunteer or patient serum serially diluted 
ten-fold and then incubated for 1 hr at room temperature. Goat anti-human IgG was 
diluted to 1/2000 in PBS/tween and 100 l was added to the plates. They were then left to 
incubate at room temperature for one hr. Plates were washed three times and 100μI of 
horseradish peroxidase-labeled rabbit anti-goat IgG (1/5000 in PBS-Tween) was added to 
each well. After a 1 hr incubation at room temperature 100 μl of TMB substrate was 
added to each well and the plates left for 20 minutes in the dark. The enzyme-substrate 
reaction was then terminated by addition of 100 μl of 0.18 M sulphuric acid. Absorbance 
values were read at 490 nm using dual wavelength automated plate reader (Dynatech 
MR600) with the reference wavelength set at 630 nm. 
2.2.3.2 ELISA for the detection of antidrug antibody levels in tolerant and  
hypersensitive patient plasma samples 
 
Microtitre plates were coated overnight at 4°C with 100 l of a 20 μg/ml concentrated 
solution of drug adducts (modified and unmodified HSA or BSA conjugates in 0.05 M 
phosphate buffer, pH7.2; 100 l/well). After overnight incubation the plates were washed 
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three times with 200 l/well of a 0.15 M PBS containing 0.05% Tween 20 (PBS-Tween, pH 
7.2) and tapped dry. Plates were blocked with 100 l of a non-specific protein for 30 
minutes, washed as previously described and then incubated with 100 μl of volunteer or 
patient serum serially diluted ten-fold and incubated at room temperature for 1 hr. Goat 
anti-human IgG was diluted to 1/2000 in PBS/tween and 100 l was added to the plates. 
They were then left to incubate at room temperature for one hr. Plates were washed 
three times and 100μI of horse radish peroxidase-labelled rabbit anti-goat IgG (1/5000 in 
PBS-Tween) was added to each well. After a 1 hr incubation at room temperature 100 μl 
of TMB substrate was added to each well and the plates left for 20 minutes in the dark. 
The enzyme-substrate reaction was then terminated by addition of 100 μl of 0.18 M 
sulphuric acid. Absorbance values were read at 490 nm using dual wavelength 
automated plate reader (Dynatech MR600) with the reference wavelength set at 630 
nm.  
2.2.3.3 ELISA for the detection and quantification of IgG subclasses and 
drug specific antibody subclasses in tolerant and hypersensitive 
patient plasma samples 
 
Microtitre plates were coated overnight at 4°C  with 100 l of a 1:100 concentrated 
solution of anti-IgG coating antibody (0.05 M phosphate buffer, pH7.2; 100 l/well). After 
the overnight incubation the plates were washed three times with 200 l/well 0.15 M PBS 
saline containing 0.05% Tween 20 (PBS-Tween, pH 7.2) and tapped dry. Plates were 
blocked with 100 l of a non-specific protein (BSA) for 30 minutes, washed as previously 
described and then incubated with 100 μl of volunteer or patient serum serially diluted 
ten-fold and then incubated for 1 hr at room temperature.  Horse radish peroxidase-
labelled mouse anti human IgG1, IgG2, IgG3 and IgG4 (Invitrogen) and NOR-01 human 
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serum standard for IgG sub-classes (Nordic immunology) were diluted to their 
appropriate concentrations (IgG1- 1:1000; IgG2-1:10,000;IgG3-1:10,000 and IgG4-1:10,000)  
in PBS (pH 7.4) and 100 l was added to the plates. They were then incubated at room 
temperature for one hr. Plates were washed 3 times and 100 μl of streptavidin diluted 
1:1000 for IgG1 and 1:10,000 for IgG2, IgG3 and IgG4 were added to each well and left to 
incubate for 1 hr at room temperature. 100 μl of TMB substrate was added to each well 
and left for 20 minutes in the dark. The enzyme-substrate reaction was terminated by 
addition of 100 μl of 0.18 M sulphuric acid. Absorbance values were read at 490 nm by 
dual wave length automated plate reader (Dynatech MR600) with the reference 
wavelength set at 630 nm. IgG antibody titers were calculated as previously described. 
 
 
Figure 2.6 Diagram of the enzyme linked immunosorbent assay (ELISA). The ELISA was employed in the 
detection of circulating antibodies in hypersensitive patient plasma and cell culture supernatants. 
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2.2.3.4 ELISA for the detection of total IgG levels in patient PBMC culture 
supernatants 
 
The method employed was the same as described using the commercial IgG detection kit 
(Mabtech). Microtitre plates were coated overnight at 4°C  with 100 l of a 1:100 solution 
of anti-IgG coating antibody (0.05 M phosphate buffer, pH7.2; 100 l/well). After 
overnight incubation the plates were washed 3 times with 200 l/well 0.15 M PBS 
containing 0.05% Tween 20 (PBS-Tween, pH 7.2) and tapped dry. Plates were blocked 
with 100 l of an non-specific protein (BSA) for 30 minutes, washed as previously 
described and then incubated with 100 μl of volunteer or patient 5 day pbmc culture 
(culture medium, CpG-dna and piperacillin 2 mM) supernatants serially diluted ten-fold 
and then incubated for 1 hr at room temperature. Goat anti-human IgG was diluted to 
1/2000 in PBS/tween and 100 l was added to the plates. They were then left to incubate 
at room temperature for one hr. Plates were washed three times and 100μI of 
horseradish peroxidase-labeled rabbit anti-goat IgG (1/5000 in PBS-Tween) was added to 
each well. After a 1 hr incubation at room temperature 100 μl of TMB substrate was 
added to each well and the plates left for 20 minutes in the dark. The enzyme-substrate 
reaction was then terminated by addition of 100 μl of 0.18 M sulphuric acid. Absorbance 
values were read at 490 nm using dual wavelength automated plate reader (Dynatech 
MR600) with the reference wavelength set at 630 nm. 
2.3    Protein analysis 
 
In this section we illustrate the methods employed in the preparation and 
characterization of synthetic β-lactam conjugates generated in the laboratory.  
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2.3.1 Preparation of drug adducts 
Drug modified protein adducts were generated and employed in functional assays and 
LC-MS characterization. 
2.3.1.1 Methanol precipitation of -lactam – protein adducts 
 
i. Drug-protein incubations. To prepare drug adducts amoxicillin, flucloxacillin, penicillin 
V and piperacillin -lactams were incubated with HSA and BSA at different protein-drug 
molar ratios. A 1 Molar (66 mg/ml) stock of HSA and BSA was prepared and used in all 
experiments. Drugs and proteins were prepared in PBS. Twenty four tubes were 
prepared for each condition. Protein and drugs were combined in the ratio HSA control 
(unmodified), drug-protein 20:1, drug-protein 50:1, and drug-protein 100:1 each with a 
total volume of 200 μl and incubated at 37°C for 24 - 96 hr. 
ii. Methanol precipitation. 1800 µl of ice-cold methanol was added to the 200 µl sample 
and the tubes were maintained on ice. One microlitre of 10% trifluoroacetic acid (TFA) 
was added to samples that did not precipitate. The samples were then centrifuged at 
17000g/14000rpm, 4°C for 15 minutes. Care was taken to pipette the methanol from the 
eppendorf tubes. 100 µl of the phosphate buffer was then added to each tube, which 
were vortexed and mixed with a pipette. The tubes were then made up to 1 ml with 900 
µl methanol to initiate a second precipitation step. The sample was centrifuged as 
previously described. 50 µl of protein free Roswell park memorial institute (RPMI-1640) 
medium at pH 8 was added to each tube to dissolve the pellet. The eppendorf tubes 
were then centrifuged at 13,000 rpm for 2 minutes and the supernatants from all the 
tubes pooled. A Bradford assay was conducted to quantify the total protein content of 
each adduct. 
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2.3.1.2 Spin column collection of -lactam – protein adducts 
 
Drug conjugates of different hapten densities of 1:1, 5:1, 10:1, 20:1, 50:1, and 100:1 were 
prepared using this method which was necessary to eliminate the presence of ethanolic 
solvents in the final adduct, to limit potential toxicity following their use in cell cultures. A 
132 mg/ml solution of BSA in phosphate buffer was prepared by dissolving 594 mg of BSA 
in 4.5 ml of phosphate buffer. 500 mM and 250 mM solutions of piperacillin were 
prepared in phosphate buffer, but only 500 mM of other  - lactam antibiotics were 
prepared. The protein and drug solutions were combined at the prescribed ratios and 
incubated in 24 well plates for 96 hr. The mixture was then transferred from the wells 
into Millipore amicon ultra-4 centrifuges spin columns equipped with a 10,000 KDa filter. 
3 ml of phosphate buffer was added into each column to make the volume up to 4 ml. 
The tubes were centrifuged at 4oc, 14,000rpm/4,000g, for 30 minutes. After the 
centrifugation step, 500 μl of the flow through from each sample was collected and 
stored at -80oc for future LC-MS analysis. Additional flow through was discarded. 
Addition of 3 ml phosphate buffer to the protein pellet, centrifugation and collection of 
the flow through were repeated four more times. After the fifth spin a 100 μl pipette was 
used to extract and transfer the filter contents into an eppendorf tube.  A Bradford assay 
was performed to quantify the protein in each conjugate formed and western blotting 
carried out to confirm adduct formation.  Once adduct formation was confirmed they 
were then applied to functional assays and LC-MS analysis was conducted to characterise 
and measure the extent of modification and specific amino acid residues modified.  
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2.3.2 Gel electrophoresis for confirmation of adduct formation 
2.3.2.1 Western blot analysis 
The western blot analysis is an important technique which is commonly employed for the 
separation and consequent identification of proteins based on their differing molecular 
weights (Liu, Mahmood et al. 2014). 
i. Sample preparation. 5 g/ml of the sample was prepared in HBSS. The sample was then 
mixed in a 4:1 ratio with Laemmli buffer (20 l sample + 5 l of Laemmli buffer).  Laemmli 
buffer consisted of a tracking dye (bromophenol blue), glycerol to increase the density 
hence allowing the samples to sink into the grooves and 2-mercaptoethanol which 
reduces disulphide bonds and disrupts protein cross-links.  
Samples were then placed in a heating block for 10 minutes at 1000c to denature the 
ordered structure thus ensuring movement in an electric field. After heating, the samples 
were ready for addition to the gel.  
ii. Sample separation. All instruments were sprayed and cleaned with 70% ethanol before 
coupling the casting block to ensure that there was no hardened acrylamide on the 
surfaces. A 10 % resolving gel (Protogel, Protogel resolving buffer, Water, 
tetramethylenediamine (TEMED), 10 % ammonium persulfate (APS) ;0.1 g in 1 ml) was 
made up and added into the gel compartments 1 ml at a time to just below the comb line. 
1 ml H2O was added to the top and the gel was left to set for 20-30 minutes. The stacking 
gel (Protogel, Protogel stacking buffer, Water, TEMED and 10 % APS (0.1 g in 1 ml) was 
then made up with TEMED and APS added right at the end. Water was then poured off 
and combs inserted. The stacking gel was then added 1 ml at a time and left to set for 20-
30 minutes. Electrophoresis buffer was used to flush out the wells then 4 µl of the see 
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blue marker was added to the first lane. Sufficient amounts of the sample (with a 10 well 
comb 12 µl of sample was added to each well, while for a 15 well comb 10 µl was used) 
was then added to the other wells as required. The gel was run at 300v, 30 mA per gel, 
for 1 hr at 40C to prevent the generation of heat.  
iii. Transfer: Following separation the gels were removed and proteins transferred onto 
8.5 cm x 6.5 cm nitrocellulose paper. A transfer cassette was placed into a tray with the 
white side at the bottom, the black side lifted and then components added in a specified 
order; sponge, filter paper (8.5 cm x 6.5 cm), nitrocellulose membrane (8.5 cm x 6.5 cm), 
gel, filter paper (8.5 cm x 6.5 cm), sponge and transfer buffer. Bubbles were smoothened 
out by rolling a pipette over the cassette. Transfer buffer was then poured into a transfer 
tank, and attached to a 40C cooler. The cassette was closed and put into the transfer tank 
with the black side to the black probe. The top was put on and transfer carried out at 
300v, 250 mA for 1 hr.  
iv. Ponceau stain and addition of the secondary antibody. After the protein transfer 
distilled water was placed in two glass dishes and the nitrocellulose membrane rinsed. 
The ponceau stain was then added for 1 - 4 minutes after which it was washed off the 
membrane with distilled water to visualise the protein. After visualization the membrane 
was washed in TST to remove the stain (TST: 8.76 g NaCl, 1.21 g Tris, 1 ml Tween in 1 litre 
of water). The nitrocellulose membrane was then kept in a plastic petri dish and 
approximately 20 ml of blocking buffer was added to the petri dish and rocked slowly at 
room temperature for 2 hr. The blot was then immersed in mouse anti-penicillin antibody 
(Sigma) diluted to 1:20,000 in 2.5 % blocking buffer (2.5 g milk in 100ml TST) or rabbit anti-
flucloxacillin antibody diluted to 1:2000 in 2.5% blocking buffer and left to rock overnight 
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at 40C.  The thiazolidine ring has been hypothesized as the site of antibody detection in 
our formed -lactam conjugates (figure 3.7a) apart from flucloxacillin conjugates where 
the masking of the thiazolidine ring by the side chain (figure 3.7b) suggests that the 
flucloxacillin-specific antibody is side chain specific.  
v. Membrane development. Excess primary antibody was washed off the membrane 
with four 5 minute washes using TST. The membrane was transferred into goat anti-
mouse antibody diluted to 1:10,000 in 2.5 % blocking buffer (2.5 g milk in 100ml TST) and 
left to incubate while rocking slowly for 1 hr at room temperature. After incubation, 
excess secondary antibody was washed off with four 5 minute washes with TST. Equal 
amounts of the brown and white developer (ECL) were combined and a total of 2 ml was 
used per blot. The blot was removed from the secondary antibody and dabbed to 
remove excess TST and laid facing up on a square of cling film. ECL was added in a 
manner that ensured it covered the whole blot and was left on for 1 minute. The excess 
ECL was dabbed off and wrapped by the cling film. With more than one blot wrapping 
was performed individually, while ensuring there were no air bubbles. The wraps were 
then secured in a cassette and taken into the dark room for exposure, taking care not to 
expose the film to any light beforehand. In the dark room the blots were exposed to the 
film(s) for varying durations after which the film was immersed in the developer (brown) 
for one minute, and fixer (yellow) for another minute then washed thoroughly with 
water to prevent the film from fogging.  The film was then left to dry following which 
scanning was performed. 
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Figure 2.7 Schematic diagram of conjugate analysis and application. Figure shows the generation of 
protein conjugates, confirmation of adduction and their downstream applications. 
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2.3.2.2 Coomassie stain 
Following the electrophoretic separation of proteins onto the gel, the gel was 
transferred into a dish containing gel fix solution (40 % methanol, 7 % acetic acid) and 
kept rocking for 1 hr. After fixing the gel fix solution was discarded and coomassie 
brilliant stain mixed with ethanol at a ratio 4:1 was added to the dish. After rocking for 1 – 
2 hr when one could visualize the bands, the coomassie blue solution was discarded and 
the gel washed for one minute with a solution of 25 % ethanol and 7 % acetic acid to de-
stain the gel. After washing, the gel was kept in 25 % ethanol overnight. The gel was 
scanned for use as a loading control or the bands detected were excised for LC-MS 
analysis. 
2.3.3 Mass spectrometric analysis 
2.3.3.1 Tryptic digests for mass spectrometric analysis 
 
i. Tryptic digest: 100 mM of dithiothreitol (DTT) and 550 mM iodoacetamide (IODO) were 
prepared (0.0154 g DTT in 1 ml PO4, 0.102 g IODO in 1 ml phosphate buffer). 10 µl of DTT 
was added to 100 µl of the samples. This mixture was vortexed and left at room 
temperature for 15 minutes. 1 ml of phosphate buffer was added to the already weighed 
out IODO from which 10 µl was removed and added to the sample. This mixture was 
vortexed again and left at room temperature for 15 minutes. 900 µl of methanol was 
added to the 100 µl sample and this mixture was centrifuged at 14000 x g for 15 minutes 
at 4°C. The methanol was discarded and 50 µl phosphate buffer added. Protein content 
was assessed using a simple Bradford assay and samples reconstituted to 5 mg/ml in 50 
µl using 50 mM ammonium bicarbonate buffer. Trypsin at 1/20th to 1/100th of the sample 
volume was added. In this case 18 µl phosphate buffer was added to the vial, from which 
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5 µl was used for each of the three samples. This mixture was left at 370C in a dry 
incubator overnight. 
ii. Zip Tip: Two 10 µl aliquots of the samples were transferred into new eppendorf tubes.  
1 µl of 1 % trifluoroacetic (TFA) acid was added to acidify the sample. This sample was then 
vortexed and C18 Zip Tips (Millipore, Watford, U.K) wetted with 10 µl of 100 % acetonitrile 
(ACN) by pipetting up and down the tube 2 - 3 times. The tip was then made aqueous by 
washing 5 times with 0.1 % TFA, taking care to dispense into a waste bottle each time. The 
tips were then taken into the acid sample and pushed ten times up and down in the tube 
after which they were washed five times as previously described with 0.1% TFA. 10 µl of 75 
% ACN + TFA was introduced into a new tube and labeled zip tipped. This 10 µl of 75 % ACN 
+ TFA was drawn up with the Zip Tip, then taken into the sample and drawn up and down 
seven times up to the white line. On the last pipette all the sample was ejected into the 
tube labeled zip-tipped. The elution was now ready for MALDI analysis. The samples are 
also dried for 15 minutes in a speed vac with the lids open after which they were ready 
for LC-MS analysis. 
2.3.3.2 Matrix assisted laser desorption ionisation (MALDI) 
 
MATRIX and sample were prepared and each vortexed before use. 0.8 µl of the 
trypsinized and desalted sample was placed on a MALDI plate spot. 0.8 µl of the MATRIX 
was then transferred onto the sample. Calibration was achieved by the addition of 0.8l 
of the calibration control which already contains matrix. This was placed in between the 
sample numbers The MALDI plate was then allowed to dry before being loaded into the 
mass spectrophotometer. When the desired number of hits and traces had been 
accumulated the data were collected using voyager control panel software. 
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2.3.3.3 Multiple Reaction Monitoring (MRM) characterization of β-lactam albumin 
binding    
 
Samples were reconstituted in 2% acetonitrile (ACN)/0.1% formic acid (v/v), and aliquots of 
2.4 – 5 pmol were delivered into a QTRAP 5500 hybrid quadrupole-linear ion trap mass 
spectrometer (ABSciex) by automated in-line LC (U3000 HPLC System, 5 mm C18 nano-
precolumn and 75 μm × 15 cm C18 PepMap column; Dionex) via a 10-μm inner diameter 
PicoTip (New Objective). A gradient from 2% ACN/0.1% formic acid (v/v) to 50% ACN/0.1% 
formic acid (v/v) in 70 min was applied at a flow rate of 300 nl/min. The ionspray potential 
was set to 2200–3500 V, the nebulizer gas to 18, and the interface heater to 150°C. 
Multiple reaction monitoring (MRM) transitions specific for drug-modified peptides were 
selected as follows: the mass/charge ratio (m/z) values were calculated for all possible 
peptides with a missed cleavage at a lysine residue; to these were added the mass of the 
appropriate hapten (cyclised Piperacillin, 517 atomic mass units [amu]; hydrolysed 
Piperacillin, 535 amu; Amoxicillin, 365 amu; Amoxicillin with loss of NH2, 349 amu; Benzyl 
Penicillin, 334 amu; Flucloxacillin, 453 amu; Penicillin V, 350 amu ); the parent ion masses 
were then paired with a fragment mass of 160 ([M+H]+ of cleaved thiazolidine ring 
present in all of the haptens) and/or a fragment mass of 106 ([M+H]+ of cleaved 
benzylamine group of a Piperacillin haptens). See figure 4.2c for schematic showing the 
mechanism of adduct (primary and desethyl) generation with cyclised and hydrolysed 
products.  
MRM transitions were acquired at unit resolution in both the Q1 and Q3 quadrupoles to 
maximize specificity, they were optimized for collision energy and collision cell exit 
potential, and the dwell time was 20 ms. MRM survey scans were used to trigger 
enhanced product ion MS/MS scans of drug-modified peptides, with Q1 set to unit 
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resolution, dynamic fill selected, and dynamic exclusion for 20 s. Total ion counts were 
determined from a second aliquot of each sample analysed by conventional LC tandem 
MS and were used to normalize sample loading on column. MRM peak areas were 
determined by MultiQuant 1.2 software (ABSciex).  
A semi-quantitative analysis of covalent modification at multiple sites within BSA was 
performed. This led to the construction of epitope profiles for the comparison of 
individual modified peptides across treatments (eg different drug concentrations) but 
did not allow the abundance of one modified peptide to be compared to another 
modified peptide because of the difference in basal ionisation efficiency.  
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Figure 2.8 Schematic for sample preparation for mass spectrometric analysis. 
 
2.4   Prospective study of piperacillin hypersensitive patients with CF 
 
 Piperacillin allergic and tolerant patients were recruited from the adult cystic fibrosis unit 
in Leeds. Blood samples were collected from these patients at 4 different time points; 
prior to piperacillin administration, midway into the treatment course, at the end of the 
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course and a prospective sample after a few months. 60 ml of blood at the beginning of 
the course and 12 ml for follow-up samples was collected into 10 ml tubes and isolated 
according to the method in section 2.1.2. PBMC and plasma were collected from each 
patient sample. A LTT was performed on each sample to assess the hypersensitivity 
status according to the method used in section 2.1.3. Plasma samples were used to 
perform total IgG ELISAs according to the method used in section 2.2.3.1, and ELISA for 
the detection of piperacillin-specific antibody according to the method used in section 
2.2.3.2. 
 
Figure 2.9  Schematic diagram for piperacillin tolerant and hypersensitive patient sample collection, 
isolation and analysis. 
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2.5    Statistical analysis 
 
Experiments were performed in triplicate and replicated on several occasions. Data are 
presented as mean ± standard deviation of the mean (SD) unless otherwise stated. 
Normality of data was assessed with the Shapiro Wilkes test. The unpaired Student’s t 
test at 95% confidence interval (CI), the Mann-Whitney or the Wilcoxon signed rank test 
were used to assess the significance of any differences in the data compared to 
appropriate controls. A two-sided P value of ≤ 0.05 was considered to be statistically 
significant. 
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3.0 Introduction 
 
B-cell activation and differentiation brought about by protein or non-protein antigens, 
lipids, sugars or DNA occurs in secondary lymphoid tissues. Protein responses normally 
require the participation of T helper (Th) cells specific for the antigen. T-cell dependent B-
cell responses are initiated at the edges of the follicles where B cells present the antigen 
to T-cells (Engel, Gomez-Puerta et al. 2011). The mainstay of the humoral immune 
response is anchored not only on the support rendered by the Th cells, but also on 
molecular events. The origin of mature B cells in the germinal centre can be traced to 
events such as cell differentiation, affinity maturation and class switch recombination 
(Han, Wang et al. 2014), which are controlled by molecules including lipopolysaccharide 
(LPS), cytosine phosphate guanosine-deoxyribonucleic acid (Cpg-DNA), or Polyinosinic 
acid:polycytidylic acid (poly(I:C)), a chemical agonist of TLR-3. All of these molecules elicit 
polyclonal B cell activation via toll-like receptors (Hoffmann, Galanos et al. 1977, Bauer, 
Heeg et al. 1999, Marshall-Clarke, Downes et al. 2007). 
B-cells are immunoglobulin producing cells. This property of B cells, though indicative of 
the protective role they play in the event of infection, also features prominently in the 
development and sustenance of inflammatory responses in certain disease conditions 
and hypersensitivity responses to drugs and environmental allergens. This is thought to 
contribute significantly to the subsequent presentation of clinical symptoms (Smits 2012), 
confirmed earlier via the assessment of antibody levels and specific antibodies to 
particular antigens which arise as a consequence of antigen induced cell activation an 
important part in the diagnosis of various diseases (Greenwald, Burstein et al. 2006, 
Niewold, Harrison et al. 2007). However, in some instances further diagnostic tests are 
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required to reach a more definite conclusion as illustrated by HCV-specific IgG and IgM 
detection in acute and chronic hepatitis which was possible in vivo but only inducible in a 
minority of patients’ in vitro (Quinti, Hassan et al. 1995). Furthermore, elevated levels of 
IgG and IgA, but not IgE, have been detected with three polymeric variants of 
diisocyanate hexamethylene diisocyanate (HDI), methylene diphenyl diisocyanate (MDI), 
and toluene diisocyanate (HDI, MDI, and TDI). These are chemical agents regularly 
employed in industry, but are capable of causing isocyanate-induced hypersensitivity 
pneumonitis, an acute inflammatory response which has an onset that ranges from 2 - 9 
hrs after exposure. Additionally IgG has been implicated in type II and III allergy 
according to Gell and Coombs but has not lent itself to a single test to enable easy 
diagnosis (Dixon 2000). Nonetheless, data generated using the ELISA and ELISpot assays 
have shown serum antibody responses which were mainly of the IgG type, generated in 
DNA vaccinated mice that developed antigen-specific delayed type hypersensitivity 
(Zhang, Yang et al. 1999) and also in nude mice grafted with thymic epithelium (Jordan, 
Chapman et al. 1990).  
In addition to their exclusivity with regard to the production of immunoglobulins, B cells 
are also known to express specific surface markers which have been introduced in 
chapter 1. Of primary importance is the pan B cell marker CD19 that promotes the survival 
and proliferation of mature B cells but plays a less understood role in immature B cells 
(Otero and Rickert 2003). This property serves to project CD19 as a suitable marker for B 
cell growth and proliferation. CD20 is also expressed on B-cells during all stages of 
development. Originally its expression was thought to be restricted to B-cells; however 
low levels of expression has recently been observed in a small population of CD3+CD20dim 
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T cells. Though earlier disputed in some quarters the presence of this subset is no longer 
in doubt (Hultin, Hausner et al. 1993, Palanichamy, Jahn et al. 2014). The development of 
memory B-cells with the ability to generate immunoglobulins rapidly in the secondary 
immune response has been defined by the enhanced expression of a CD19+CD27+ 
population (Agematsu 2000, Agematsu, Hokibara et al. 2000). This makes CD27+ an 
attractive marker to measure by flow cytometry to characterise the activation of B-cells. 
The ability to activate B-cells isolated from human peripheral blood leading to their 
proliferation via induction by T cell derived mitogens (CD40 ligands) + IL-4, and Cpg-dna 
has been described previously (Bauer, Heeg et al. 1999, Huggins, Pellegrin et al. 2007, 
Carpenter, Mick et al. 2009). Epstein-Barr virus has been employed in the immortalisation 
of B lymphocytes (Wall, Henkel et al. 1995). This confers upon the normal lymphocytes 
the ability to proliferate indefinitely as has been originally reported (Miller 1982). EBV-
immortalized lymphocytes still possess properties similar to normal B cells and they are 
thought to secrete IgG in certain circumstances (Kataoka, Tahara et al. 1997, Sugimoto, 
Furuichi et al. 1999). Novel methods have been established for the immortalization of 
antigen-specific human B cells for the generation of human monoclonal antibodies. 
Methods used by some researchers have involved EBV immortalisation and TLR9 
stimulation, leading to the isolation of antibodies from B cell clones from a patient 
recovering from severe acute respiratory syndrome coronavirus (SARS-cov), which were 
specific for viral proteins. Others have utilised a different approach employing STAT5 
overexpression for this purpose (Steinitz, Klein et al. 1977, Traggiai, Becker et al. 2004, 
Scheeren, van Geelen et al. 2011).  
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The mechanism of activation of T-cells by -lactams in hypersensitive patients with cystic 
fibrosis has previously been reported and the cellular processes that underlie the 
structural specificity of -lactam protein binding has also been described (El-Ghaiesh, 
Monshi et al. 2012). However the role of humoral processes specifically the mechanism of 
B cell activation and the roles of the B cell immunoglobulins in the disease state and drug 
hypersensitivity have not been defined. Thus, the main aims of this chapter were to; 
 Develop cell culture methods for the detection of the B cell response in 
hypersensitive patients. 
 Analyse IgG subclasses in hypersensitive patients. 
 Develop antibody producing B cell lines.  
 
3.1  Methods 
 
 The cell culture methods employed in this chapter include PBMC isolations (section 
2.1.2), lymphocyte transformation tests (section 2.1.3), PBMC culture assays (section 
21.4), B-cell separation and immortalization (sections 2.1.5 – 2.1.6), phenotypical 
characterization of PBMC populations using flow cytometry (section 2.2.2.1). Functional 
characterization of B cells (section 2.12), plasma and supernatants (sections 2.2.3.1–
2.2.3.4). Other methods employed involved the preparation of β-lactam adducts (section 
2.3.1), western blot analysis of formed adducts (section 2.3.2.1) and mass spectrometric 
analysis (2.3.3). 
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3.2   Results 
 
3.2.1 Patient and volunteer characteristics 
PBMC were isolated from 3 hypersensitive patients for the mechanistic studies described 
in this chapter. Table 3.2 describes the clinical characteristics of the patients and the 
nature of the reactions. For comparison, 3 patients with CF exposed to multiple 
piperacillin courses and 4 naïve healthy donors were used. 
 
Table 3.1 Patient and volunteer characteristics. The table above shows the age and gender of 
hypersensitive and tolerant patients, the drugs they were treated with, the type of hypersensitive reaction, 
the time to onset of physical manifestations of hypersensitivity from the start of treatment and magnitude 
of the response to the lymphocyte transformation test.  
 
 
 
++ Highly positive LTT    
+ Weakly positive LTT  
— Negative LTT 
N.A Not available. 
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3.2.2 Lymphocyte transformation tests (LTT)  
Preliminary assays were carried out to confirm the suspected hypersensitivity status of 
patients using blood samples obtained from the regional adult CF unit in Leeds. The 
lymphocyte transformation test was carried out using PBMC from naïve volunteers, 
hypersensitive and tolerant patient samples. A stimulation index (S.I) greater than 2 was 
taken as a positive result for hypersensitivity to piperacillin. Following isolation from 
blood, PBMC were exposed to piperacillin 0.125-8 mM, and maximal proliferation was 
seen at 1 mM for patients 1 and 2, and at 2 mM for patient 3. Hypersensitivity was 
regarded as the production of a SI > 2. The response observed with piperacillin 1 mM was 
significantly stronger and more consistent across all the samples than those of other 
concentrations; thus, this dose was selected for all subsequent cell culture assays. PBMCs 
from piperacillin naïve volunteers and tolerant patients were not activated in response to 
piperacillin treatment (d-i). 
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Figure 3.1 LTT from naïve volunteers, piperacillin hypersensitive and tolerant patients. PBMCs (1.5 × 105 
cells in 100 μL) from hypersensitive patients (a - c) tolerant patients (d - f) and drug naïve volunteers (g-i) 
were incubated with graded concentrations of piperacillin (0.125-8 mM in 100 μL) in 96-well U-bottom 
plates. Plates were incubated at 37°C under an atmosphere of 5% CO2 for five days. [3H]-thymidine (0.5 
μCi/well) was added for the final 16 hours of incubation and T-cell proliferation measured using scintillation 
counting in a Beta counter. The data were analysed by Students T-test with p < 0.05 considered significant 
(* denotes p <  0.05 ** denotes p < 0.01; *** denotes p < 0.001). 
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3.2.3 Phenotype of B-cells (CD19+CD27+) following mitogen and piperacillin 
stimulation 
PBMCs isolated from piperacillin naïve volunteers, and piperacillin tolerant and 
hypersensitive patients with CF were cultured with mitogen or piperacillin (2 mM) for five 
days after which the resultant phenotype was assessed. Compared to the untreated (29.2 
± 2.9%) and positive (46.9 ± 14.1%) controls, the piperacillin treated groups (24.9 ± 4.2%) in 
the naïve volunteers [figure 3.2] did not show an expansion in the memory B cell 
(CD19+CD27+) population [figure 3.2]. A similar result was obtained with PBMC from 
tolerant patients with no difference observed between the drug-treated and untreated 
control (untreated control = 8.5 ± 0.2%; Piperacillin = 11.6 ± 6.3%;  and Cpg-dna = 15.6 ± 3.8% 
; p > o.o5). In contrast, a  significant increase in the expression of memory B cells was 
observed with the piperacillin-treated PBMC from hypersensitive patients when the drug 
treated and untreated control cells were compared (p ≤ 0.05). The number of cells 
staining positive for CD19CD27 increased from 18.3 ± 5.7% to 28.5 ± 1.27% following drug 
treatment. 30.0 ± 6.35% cells stained positive for CD19CD27 after exposure to the 
mitogen control.  
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Figure 3.2.a B-cell phenotyping for CD19+CD27+ cell surface expression from piperacillin naïve volunteers 
and piperacillin tolerant and hypersensitive patients. PBMCs were incubated in medium or stimulated with 
CpG- DNA or piperacillin for 5 days.  PBMC suspensions (200 μL) were incubated with CD3-FITC, CD19-APC 
and CD27-PE immunoflourescent antibodies for 20 minutes at 4°C. Cells were washed and surface staining 
by the fluorescent markers was measured by flow cytometry. Data were expressed as dot plots to obtain 
percentage of cells in each quadrant (with n=3) for each treatment condition. 
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Figure 3.2.b B-cell phenotyping for CD19+CD27+ cell surface expression from piperacillin naïve volunteers 
and piperacillin tolerant and hypersensitive patients. Graphical representation of the data in Figure 3.2a 
showing CD19CD27 expression on from naïve volunteers, tolerant and hypersensitive patients. The data 
were analysed by Students T test with p < 0.05 considered significant (* denotes p < 0.05  ;** denotes p < 
0.01). 
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3.2.4 Optimization of an ELISpot assay for determination of IgG antibody 
secretion as a marker for antigen-specific B cell activation 
Using PBMC from piperacillin naïve volunteers, preliminary experiments were carried out 
to determine the optimum conditions under which in vitro secretion of IgG from isolated 
B-cells could be pursued.  
The ELISpot plates were pre-coated with anti-human IgG according to the manufacturer’s 
instructions and incubated overnight at 4oC. PBMCs were harvested from 24 well plates 
after 120 hour incubation, transferred to each well of the ELISpot plate and incubated at 
37oC, 5% CO2. After 48 hours the ELISpot plates were developed according to the 
manufacturer’s instructions, and the wells left out to air dry. Spots were visualised using 
an AID ELISpot reader. 
Figure 3.3A-B and E show results of IgG ELISpots conducted with PBMC from different 
drug naïve healthy donors cultured at different cell numbers of 4 x 103, 10 x 103, 20 x 103 
and 50 x 103 PBMC.   Figure 3.3 C-D show separate experiments where 5 x 103, 10 x 103, 
and 20 x 103 PBMCS were used. An increase in the number of IgG secreting cells was 
observed at each cell number when the mitogen-treated cells were compared to the 
negative control. As expected piperacillin did not increase IgG secretion. Experiments 
conducted with 20 x 103 PBMCS produced the most consistent results (both in the 
magnitude of spots and consistency across all the samples) and as such, this cell number 
was used in all subsequent experiments using PBMC from piperacillin naïve, tolerant and 
allergic patients. 
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Figure 3.3 Optimization of the cell concentration needed for the detection of total IgG secretion by 
PBMCs from naïve volunteers. 1 x 106 PBMCs were cultured in 24 well plates with piperacillin and cpg-dna 
for 5 days. ELISpot plates were pre-coated with anti-human IgG according to the manufacturer’s 
instructions and incubated overnight at 4oC. After washing PBMC’s were harvested and 5 x 103, 10 x 103, 20 
x 103 transferred to each well and incubated for 48 hours. ELISpot plates were developed according to the 
manufacturer’s instructions, and the wells left to air dry. Spots were counted using an AID ELISpot reader. 
Results from 4 naïve volunteers (a) - (d) graphical representation of spot counts, (e) pictures of ELISpot 
wells. 
(a) 
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Following the determination of optimum cell numbers required for the ELISpot assay, 
ELISpot plates were pre-coated with anti-human IgG according to the manufacturer’s 
instructions and incubated overnight at 4oC. PBMCs (20 x 103) from the three patient 
groups were harvested from 24 well plates after 120 hour incubation, were transferred 
onto each well of the ELISpot plate and incubated for 48 hours. After washing ELISpot 
plates were developed according to the manufacturer’s instructions, and the wells left 
out to air dry. Spots were visualised using an AID ELISpot reader. 
Figure 3.4 A - I show results of IgG ELISpots conducted with PBMC from piperacillin naïve 
volunteers with tolerant and hypersensitive patients cultured at cell numbers of 20 x 103.   
A single measurement was taken for each sample for the various treatment groups. An 
increase in the number of IgG secreting cells was observed with all groups when 
mitogen-treated cells were compared to the negative control. Piperacillin treated 
hypersensitive patients PBMC also showed an increase in IgG secretion.  
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Figure 3.4.1 Total IgG secretion from naïve volunteers, piperacillin hypersensitive and tolerant patients. 1 
x 106 PBMCs were cultured in 24 well plates with piperacillin (1 mM) and cpg-dna (1.5µg/ml) for 5 days. The 
ELISpot plates were pre-coated with anti-human IgG according to the manufacturer’s instructions and 
incubated overnight at 4oC. PBMCs were harvested and 5 x 104 transferred to each well and incubated for 
48 hours. ELISpot plates were developed according to the manufacturer’s instructions, and the wells left to 
air dry. Data were analysed using an AID ELISpot machine. 
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Figure 3.4.2 Total IgG secretion from naïve volunteers, piperacillin hypersensitive and tolerant patients.  
Spots were visualised using an AID ELISpot reader. Representative images from an ELISpot plate of naïve 
volunteer, tolerant and hypersensitive patient.  
 
 
3.2.5 ELISA for total IgG secretion from piperacillin and mitogen-treated 
PBMC 
High binding 96 well plates were pre-coated with anti-human IgG according to the 
manufacturer’s instructions and incubated overnight at 4oC. Samples were added in a 1:10 
dilution and the ELISA carried out as described in chapter 2. 
 Mitogen-treatment of PBMC was associated with a significant increase in total IgG 
secretion in all but one patient from all treatment groups. An increase in IgG levels was 
not detected with supernatants from one naïve volunteer (figure 3.5). In contrast IgG 
secretion from piperacillin-treated PBMC was much more restricted. Small but significant 
increases in IgG were only observed with PBMC from 1 out of 3 hypersensitive patients 
with p = 0.027 (figure 3.5) 
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Figure 3.5 Total IgG secretion in naïve volunteers, tolerant and hypersensitive patient supernatants. 1 x 
106 PBMCs from naïve volunteers, tolerant and allergic patients were cultured with piperacillin (1 mM) and 
cpg-dna (1.5 µg/ml) in 24 well plates for 5 days. Flat bottomed high binding 96 well plates were pre-coated 
with anti-human IgG according to the manufacturers’ instructions and incubated overnight at 4oC. After 
washing 100 µl cell culture supernatants diluted at a ratio of 1:10 (Supernatant:diluent) was added to each 
well and incubated for 1 hr. The presence of drug specific antibodies was detected by anti-IgG HRP 
conjugated antibody and TMB substrate. The reaction was stopped with 0.18M H2SO4 and absorbance 
measured at 470nm using a spectrophotometer. The data was analysed by Students T test with p<0.05 
considered significant (* denotes p < 0.05;** denotes p < 0.01). 
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3.2.6 In vitro generation of HSA:Piperacillin adducts and characterisation 
by mass   spectrometry 
The presence of antidrug antibodies in certain penicillin hypersensitive patients has been 
described previously using piperacillin-modified HSA as an antigen (Christie, Coleman et 
al. 1988). To assess the quantity of piperacillin-specific IgG in plasma of volunteer and 
patient groups, the initial step required the generation of protein conjugated to the drug 
molecule at sufficient levels for antibody binding, but generated via a method that did 
not result in significant non-specific binding. 
Initially, SDS-PAGE western blot analysis was carried out to confirm the binding of 
piperacillin to HSA, at HSA:Piperacillin binding ratio of 1:50 after 96 hours incubation 
(figure 3.6). Adduct formation was confirmed at this point. Notwithstanding the cleavage 
of the β-lactam rings, the monoclonal antibodies (MABs) raised against the 
benzylpenicilloyl group have been found to recognize at least three separate epitopes. 
Specific sites identified include the side chain, the new antigenic determinant and the 
thiazolidine ring of penicillin dependent on the nature of the MAB antibody raised (de 
Haan, de Jonge et al. 1985). Similar to benzylpenicillin the piperacillin hapten adopts an 
adduct structure with the thiazolidine ring exposed when bound covalently to lysine 
groups on protein(figure 3.7b). Thus, the MAB that recognises the thiazolidine ring was 
used to visualize the piperacillin protein binding by western blotting. In contrast, the 
thiazolidine ring of flucloxacillin is masked when bound covalently to protein. Thus, an 
antibody raised in rabbit by Van Pelt (Carey and van Pelt 2005) through immunisation 
with a flucloxacillin-rabbit serum albumin conjugate was used to study flucloxacillin 
protein binding 
5-OH-Flu adduct 
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This adduct was assessed for the nature of amino acid modification post conjugation by 
mass spectrometry, analysis of which showed that covalent binding occurred to specific 
lysine residues in the protein. This occurs via the spontaneous opening of the β-lactam 
ring leading to the formation of penicilloyl conjugates. Fifteen penicilloylated lysine 
residues were detected at a drug-protein molar ratio of 50:1 (Table 3.2). The piperacillin 
adducts undergo fragmentation into cyclised and hydrolysed forms (figure 3.7 a). These 
forms are represented in the MS/MS spectra of one of the tryptic peptides 
182LDELRDEGK*ASSAK195 as an example. This peptide bears a covalent modification of 
Lys190 with a penicilloyl hapten (Figure 3.7 c). Confirmatory evidence to back up the 
modification stems from the presence of the characteristic fragment ions at m/z 160 and 
143, which are indicative of a cleavage of the thiazolidine ring and anticipated 
fragmentation of the piperacillin hapten. 
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Figure 3.6.  SDS-PAGE confirmation of HSA:Piperacillin binding. Protein and drug were mixed at a molar 
ratio of 1:50 then incubated for 96 hours at 37oC (ref). Adducts were then precipitated with methanol, dried 
and dissolved in RPMI 1640. Samples (5 µg/ml) were run on SDS-PAGE and blotted onto a nitrocellulose 
membrane.  The membrane was blocked with 2.5 % milk in TST and incubated overnight at 4oC with a 
monoclonal mouse anti-penicillin antibody. After washing, the membrane was incubated with goat anti-
mouse HRP-conjugated secondary antibody prior to ECL development with photographic film. 
 
Table 3.2 Penicilloylated lysine residues due to HSA:piperacillin adduction. The binding of piperacillin to 
HSA leads to the modification of lysine residues in HSA. Mass spectrophotometric characterization of the 
formed adduct was carried out to determine the extent of residue modification. Adducts were denatured 
and treated enzymatically with trypsin. Desalting and enrichment of peptides was carried out prior to mass 
spectrophotometric analysis.  
 
 LYSINE PEPTIDE 
1. 212 AFK*AWAVAR 
2. 195 ASSAK*QR 
3. 541 ATK*EQLK 
4. 4 DAHK*SEVAHR 
5. 545 EQLK*AVMDDFAAFVEK 
6. 159 HPYFYAPELLFFAK*R 
7. 525 K*QTALVELVK 
8. 137 K*YLYEIAR 
9. 12 FK*DLGEENFK 
10 351 LAK*TYETTLEK 
11. 190 LDELRDEGK*ASSAK 
12. 199 LK*CASLQK 
13. 432 NLGK*VGSK 
14. 436 VGSK*CCK 
15. 162 YK*AAFTECCQAADK 
*  Indicates site of modification 
(a) 
 
 
66 Kda 
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Figure 3.7 Chemical structures of cyclised and hydrolysed forms of the modified piperacillin hapten 
bound covalently to a tryptic peptide derived from HSA. (a) Chemical structure of cyclised and hydrolysed 
forms of HSA:Piperacillin conjugates and (b) Crystal structure models of cyclised and hydrolysed piperacillin 
and flucloxacillin adducts showing the conformational change that leads to the masking of the thiazolidine 
ring by the side chain. 
 
 
Cyclised Hydrolysed 
(a) 
Thiazolidine ring 
Cyclised flucloxacillin 
adduct 
Cyclised piperacillin 
adduct 
Hydrolysed piperacillin 
adduct 
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(b) 
Masked thiazolidine ring 
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Figure 3.7c Chemical structures and MRM spectral images of cyclised and hydrolysed forms of the 
modified piperacillin hapten bound covalently to a tryptic peptide derived from HSA. Spectral images of 
MRM MS spectrometry analysis of cyclised and hydrolysed modification on LYS190 showing the presence 
of characteristic fragment ions at m/z 160 and 143 and 106.1 and 333.0.  
 
 
 
 
 
 
 
 Cyclised 
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(c) 
peptide2+ 
peptide2+ 
peptide2+ 
peptide2+ 
peptide2+ 
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3.2.7 Optimization of hapten inhibition ELISA to detect drug-specific IgG in 
hypersensitive patient plasma 
The low level of IgG secretion exhibited by tolerant and hypersensitive patient PBMC 
culture supernatants suggested that it was unsuitable for the characterisation of drug-
specific antibodies. Thus protein-drug adducts were prepared (figure 3.6) and plasma 
was used in an alternative approach to detect these antibodies. To optimize the assay 
different piperacillin-HSA adduct concentrations bound to plates was used for the 
detection of drug-specific IgG. Furthermore different dilutions of known hypersensitive 
patient plasma were applied to optimize the assay conditions (figure 3.8). Anti-
piperacillin antibody was discernible; however, experiments were constantly hindered by 
the high levels of non-specific binding associated with adducts prepared using HSA 
(figure 3.8). This necessitated the preparation of adducts using alternative proteins in the 
generation of piperacillin antigens. These adducts were then compared with HSA 
adducts in the detection of IgG (figure 3.9) to assess their relative or not of non-specific 
binding. 
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Figure 3.8. Optimization of the detection of anti-drug antibodies by ELISA. Three concentrations of 
unmodified BSA and piperacillin-modified HSA were used to coat flat bottomed high binding 96 well plates. 
After washing, 100 µl plasma from 3 different hypersensitive patients was added at 3 different dilutions and 
incubated for 1 hr. The presence of drug-specific antibodies was detected by anti-IgG HRP conjugated 
antibody and TMB substrate. The reaction was stopped with 0.18M H2SO4. The data were analysed by 
Students T-test with p < 0.05 considered significant (* denotes p < 0.05;** denotes p < 0.01). 
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3.2.8 Formation of piperacillin adducts using human serum albumin (HSA), 
bovine serum albumin (BSA) and lysozyme (LYS) for the optimization 
of the IgG ELISA  
Protein:Piperacillin adducts were generated with three proteins bovine serum albumin 
(BSA), human serum albumin (HSA), and lysozyme (LYS) using methods previously 
described in section 2.16. SDS-PAGE Western blot analysis was carried out to confirm the 
protein:piperacillin binding after a 96 hour incubation for, at protein:drug binding ratio of 
1:50 (Figure 3.9). Piperacillin modification of all proteins was detected. 
Effects of the various unmodified and drug-modified proteins on different parameters of 
the ELISA assay including; diluents used, PBMC culture supernatants, and plasma were 
established. Unmodified BSA, HSA, and LYS all showed negligible absorbance levels 
[figure 3.10 (a)] with the sample diluent. Supernatants produced high backgrounds with 
HSA [figure 3.10 (b)]. Plasma elicited high backgrounds with both HSA and LYS with only 
BSA yielding low levels that might be suitable for the establishment of an assay to detect 
piperacillin-specific IgG [figure 3.10 (c) and (d)].  
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Figure 3.9. SDS-PAGE confirmation of Protein:piperacillin binding. Proteins and drug were mixed at a 
molar ratio of 1:50 then incubated for 96 hours at 37oC. Adducts were then precipitated with methanol, 
dried and dissolved in RPMI 1640. Samples (5 µg/ml) were run on SDS-PAGE and blotted onto a 
nitrocellulose membrane.  The membrane was blocked with 2.5% milk in TST and incubated overnight at 4oC 
with a monoclonal mouse anti-penicillin antibody. After washing, the membrane was incubated with goat 
anti-mouse HRP-conjugated secondary antibody prior to ECL development with photographic film.  
  
 
 
 
 
 
 
 
 
 
Figure 3.10.  ELISA to determine the non-specific binding capacity of various unmodified and drug 
modified proteins. 20 µg/ml of unmodified bovine serum albumin (BSA), human serum albumin (HSA) and 
lysozyme were used to were used to coat flat bottomed high binding 96 well plates. After washing 100 µl 
of sample diluent (a) culture supernatants, (b) or plasma (c and d) was added were added and incubated 
for 1 hr. The presence of binding was detected by anti-IgG HRP conjugated antibody and TMB substrate. 
The reaction was stopped with 0.18M H2SO4.  
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3.2.9 In vitro characterization of BSA:Piperacillin binding in adducts 
generated for the detection of anti-drug antibodies 
After the selection of the BSA:Piperacillin adduct for use after comparison of ELISA data, 
SDS-PAGE western blot analysis was carried out to confirm the time dependency of 
piperacillin adduct formation (figure 3.11). This was assessed using 5 g/ml of each 
conjugate prepared at a ratio of 1:50 (protein:drug). The results show that a significant 
increase in the binding was observed at 96 hours when incubations at 96 and 24 hours 
were compared (fig 3.11). Mass spectrophotometric analysis of the 96 hour conjugate 
was carried out. The MS/MS spectrum of BSA lysine residue modification showed the 
characteristic internal peptide fragment ions m/z 160 and 143 (Figure 3.12). Piperacillin 
haptens were detected on 8 of the 13 lysine residues modified in HSA. The relative level 
of modification of the LYS residues are shown in figures 3.13 a and 3.13 b.  
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Figure 3.11 SDS-PAGE characterization of BSA:piperacillin adduct time dependent formation. BSA and 
piperacillin were combined at a molar ratio of 1:50 then incubated for 24 hours and 96 hours respectively at 
37oC. Proteins and drug were mixed at a molar ratio of 1:50 then incubated for 96 hours at 37oC. Adducts 
were then precipitated with methanol, dried and dissolved in RPMI 1640. Samples (5 µg/ml) were run on 
SDS-PAGE and blotted onto a nitrocellulose membrane.  The membrane was blocked with 2.5 % milk in TST 
and incubated overnight at 4oC with a monoclonal mouse anti-penicillin antibody. After washing, the 
membrane was incubated with goat anti-mouse HRP-conjugated secondary antibody prior to ECL 
development with photographic film.  
 
 
                        
 
Figure 3.12 MRM spectral images of BSA lysine residue modification. Spectral images of MRM MS 
spectrometry analysis modification on LYS190 showing the presence of characteristic fragment ions at m/z 
160 and 143. 
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Table 3.3 Incubation of piperacillin with BSA leads to the modification of 8 specific lysine residues. The 
binding of piperacillin to BSA leads to the modification of lysine residues in BSA. Mass spectrophotometric 
characterization of the formed adduct was carried out to determine the extent of residue modification. 
Adducts were denatured and treated enzymatically with trypsin. Desalting and enrichment of peptides was 
carried out prior to mass spectrometric analysis.  
 
 
 
 
 
 LYSINE PEPTIDE 
1.  ADEK*K 
2. 211 ALK*AWSVAR 
3.           131 
20 
DLGEEHFKGLVLIAFSQYLQ 
QCPFDEHVK 
4. 4 DTHK*SEIAHR 
5. 12 FK*DLGEEHFK 
6. 136 FWGK*YLYEIAR 
7. 535 HK*PK 
8. 537 HKPK*ATEEQLK 
9. 132 K*FWGK 
10. 524 K*QTALVELLK 
11. 431 SLGK*VGTR 
12. 473 VTK*CCTESLVNR 
13. 221 LSQK*FPK 
*  Indicates site of modification 
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Figure 3.13  
Lysine residues modified with cyclised and 
hydrolysed forms of the piperacillin hapten. 
Graphs showing the semi-quantitative analysis 
of covalent modifications at multiple sites on 
cyclised and hydrolysed piperacillin, at 
BSA:piperacillin molar ratio of 1:100 to enhance 
the modifications expressed by the protein. The 
abundance of modified peptides cannot be 
compared against each other because of their 
difference in ionisation efficiency. Cyclised and 
hydrolysed forms also ionise differently. 
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3.2.10 Detection of piperacillin-specific antibodies in hypersensitive patient 
plasma using piperacillin modified BSA as a drug antigen 
Hapten inhibition assays were conducted using the plasma of piperacillin hypersensitive 
patient samples with CF. For the hapten inhibition plasma was pre-treated with an excess 
of the parent drug for 30 minutes. All hypersensitive patient samples contained anti-
piperacillin antibodies, but at different levels ranging from < 250 ng/ml to >2000 ng/ml 
(figure 3.14 a - e). In each case addition of piperacillin for hapten inhibition reduced 
absorbance values to almost control levels.  
To confirm the specificity of the antidrug antibodies p-phenylenediamine and isoniazid 
conjugates were prepared according to methods used by Jenkinson et al. and Meng et al. 
(Jenkinson, Jenkins et al. 2010, Meng, Maggs et al. 2014) respectively. Addition of patient 
plasma alone or with the addition of the anti-piperacillin antibody inhibitor did not 
produce an increase in absorbance values indicating the IgG did not bind to these 
alternative drug/chemical antigens. As expected, addition of piperacillin for hapten 
inhibition had no effect (figure 3.15 a - b).  
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Figure 3.14.  Anti-piperacillin-specific IgG ELISA with hypersensitive patient plasma. Flat bottomed 96 well 
plates were pre-coated with 20 µg BSA:piperacillin adduct employed as an antigen. After washing 100 µl of 
hypersensitive patient plasma with and without prior incubation with the hapten, was added to wells and 
an ELISA carried out. Absorbance was read with an automated plate reader (Dynatech MR600). Data were 
analysed by the Students T test to compare the difference between means.   p≤0.05 considered as 
significant. (* denotes p < 0.05; ** denotes p < 0.01).  
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Figure 3.15 Confirmation of the specificity of anti-drug antibodies to piperacillin haptens using p-
phenylenediamine (PPD) and isoniazid (INH) conjugates. Flat bottomed 96 well plates were pre-coated 
with 20 µg HSA:PPD and HSA:INH piperacillin adduct. After washing 100 µl of hypersensitive patient plasma 
with and without prior incubation with the hapten, was added to wells and an ELISA carried out. 
Absorbance was read with an automated plate reader (Dynatech MR600). Data were analysed by the 
Students T test. No significant differences (p≤0.05) were observed between the data. 
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3.2.11 Generation and characterisation of IgG secreting B-cell lines, from 
piperacillin hypersensitive patients 
B cells from piperacillin naïve, and hypersensitive patients were transformed with 
Epstein-Barr virus. The immortalization was carried out with and without the 
incorporation of cpg-dna according to the methods described in section 2.7(i) and section 
2.7 (ii). The different populations were initially analysed for total IgG secretion using an 
ELISpot assay. Immortalised B cell lines from naïve volunteers treated with piperacillin 
and cpg-dna did not produce any significant spots even when higher numbers of cells 
were used in the ELISpot assay. B-cell lines generated from hypersensitive patients and 
treated with piperacillin and cpg-dna produced spots indicative of IgG secretion with an 
increased frequency of IgG producing cells as the number of seeded cells per well was 
increased (figure 3.16 ). 
Results from flow cytometry analysis of immortalised B cells indicated the substantial 
expression of CD19+27+ surface marker expression on the majority of lines, with values 
ranging from 11.4% to 57.69% of the total visible population of cells. This expression varied 
widely from one line to the other (figure 3.17 a). In fact, some cell lines were only positive 
for CD19+ (figure 3.17 b). Furthermore several lines did not express either CD19+ or CD27+ 
(figure 3.17 c). 
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Figure 3.16 Analysis of immortalised cell lines for total IgG secretion using an ELISpot assay. The ELISpot 
plates were pre-coated with anti-human IgG according to the manufacturer’s instructions and incubated 
overnight at 4oC. Immortalised B cells were harvested and four cell concentrations were transferred to 
each well and incubated for 48 hours. ELISpot plates were developed according to the manufacturer’s 
instructions, and the wells left to air dry. Data were analysed and images captured using an AID ELISpot 
machine. (a) Spot counts (b) ELISpot pictures.  
 
Figure 3.17. CD19+27+ expression on B-cell lines. Twelve cell lines from a hypersensitive patient were 
stained with CD3-FITC, CD19-APC and CD27-PE fluorochrome antibodies and analysed by flow cytometry to 
determine the phenotype of the immortalized cells. Dot plots show (a) CD19+27+ phenotype (b) CD19+27- 
phenotype and (c) non-CD19 phenotype. 
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3.2.12 Detection of anti-drug antibodies in B-cell lines 
B cell lines were generated from the 3 piperacillin hypersensitive patients. After 
immortalization and TLR9 stimulation 48 B cell lines were produced from patient 1, 140 
lines from patient 2 and 160 lines from patient 3. From the total number of lines 
generated 8, 12 and 15 lines respectively were found to secrete IgG after testing using an 
IgG ELISA. Thus the percentage IgG secreting lines generated from each patient were 
16%, 8.5% and 9.3%, respectively (Table 3.4).  The introduction of Th cytokines to emulate a 
T cell dependent immortalization of EBVS saw an enhancement in the efficiency of IgG 
secreting B-cell line generation to 99%. 
Table 3.3. Immortalization of IgG secreting B-cell lines from hypersensitive patients.  Immortalized B-cell 
lines were generated from 3 hypersensitive patients utilizing T-cell independent and T-cell dependent 
methods incorporating specific Th cell cytokines. Supernatants from these cell lines were tested for IgG 
secretion by ELISA and the efficiency of generation calculated. Tests for anti-piperacillin-specific IgG in 
these cell lines proved negative. 
 
 
 
 
Total number of 
cell lines 
generated. 
Total number of 
cell lines 
secreting IgG 
Efficiency of 
generation (%) 
Number of cell 
lines secreting 
piperacillin-
specific antibody 
Hypersensitive 
patient 1 
48 8 16% Nil 
Hypersensitive 
patient 2 
140 12 8.5% Nil 
Hypersensitive 
patient 3 
160 15 9.3% Nil 
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Figure 3.19. Secretory profile of B-cell lines producing IgG. B cells from 3 hypersensitive patients were 
immortalised by Epstein-Barr virus transformation in a T-cell independent manner. Supernatants were 
collected and assessed for IgG secretion. Flat bottomed high binding 96 well plates were pre-coated with 
10 µl/ml anti-IgG overnight and 100 µl of plasma was added to the wells in duplicate. Colour development 
was performed with HRP and TMB substrate and stopped with 0.18M H2SO4.  
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Utilizing supernatants from the IgG producing lines and employing a hapten inhibition 
ELISA, lines were tested for the presence of antibodies specific for piperacillin. None of 
the lines generated from the patients were found to secrete IgG with specificity for 
piperacillin.  
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Figure 3.20 Anti-piperacillin antibody is not detectable in hypersensitive patient B-cell lines. Secretion of 
anti-piperacillin antibody by 6 B cell lines from piperacillin hypersensitive patient 1 and 8 B cell lines from 
hypersensitive patient 2 was assessed by ELISA. High binding U-bottom 96 well plates were pre-coated 
with 20 µg/ml BSA:piperacillin adducts and incubated overnight at 40C. After washing 100 µl Cell culture 
supernatants diluted at a ratio of 1:10 (Supernatant:diluent) was added per well and incubated for 1 hr. The 
presence of drug specific antibodies was detected by anti-IgG HRP conjugated antibody and TMB 
substrate. The reaction was stopped with 0.18M H2SO4 and absorbance measured at 470nm using a 
spectrophotometer. The data were analysed by Students T test with p<0.05 considered significant (* 
denotes p <0.05;** denotes p < 0.01). 
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3.2.13 IgG sub-class analysis in patient plasma and B-cell line supernatants 
IgG sub-classes were assessed in plasma of naïve volunteers and, plasma and B cell line 
supernatants from piperacillin hypersensitive patients. IgG subclass analysis of naïve 
volunteers (n=5) produced a subclass profile with antibody levels in the order of IgG1 > 
IgG2 > IgG3 > IgG4 (figure 3.21 a). This is in agreement with previously established IgG 
subclass values in human sera (Morell, Skvaril et al. 1971, Oxelius 1978, Madassery, Kwon 
et al. 1988, Schauer, Stemberg et al. 2003). 
The subclass profile of IgG antibodies secreted from B-cell lines was assessed to 
determine if there was any variation from the norm. IgG subclass expression from 
selected antibody secreting lines generated from piperacillin hypersensitive patient 1 
showed a profile similar to that observed in the plasma of control group of patients 
(Figure 3.21). 
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Figure 3.21 IgG sub-class secretory profiles of normal volunteers. (a) Plasma from 5 naïve volunteers was 
analysed and (b) 5 B cell lines form hypersensitive patient 3 were analysed. Flat bottom high binding 96 
well plates were pre-coated with 20 µg/ml anti-IgG antibody, and incubated overnight at 4oC. After washing 
100 µl plasma was added to each well and incubated for 1 hour. After washing subclass specific antibodies 
were added. Colour development by reaction of HRP and TMB substrate was stopped with 0.18M H2SO4. 
Absorbance was read with an automated plate reader (Dynatech MR600) with the reference wavelength 
set at 630 nm. The data were analysed by Students T test with p<0.05 considered significant (* denotes p < 
0.05;** denotes p < 0.01). 
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hypersensitive patients, mass values for subclass-specific anti-piperacillin IgG in 
hypersensitive patient plasma samples were designated.   Subclass-specific anti-
piperacillin IgG expression showed varied patterns of IgG1 and IgG2 antibody expression 
in the three patient samples. Patient 1 showed a profile consistent with that observed 
previously with naïve volunteers and tolerant patients in figure 3.21. Patient 2 expressed 
IgG1 and IgG2 at 19.58% and 27.8% of the total piperacillin-specific IgG, while patient 3 
expressed IgG1 and IgG2 at 23.4% and 20.4% of total piperacillin-specific IgG (fig 3.22). 
 
 
Figure 3.22 IgG sub-class specific responses to piperacillin stimulation. The amount of different IgG 
subclasses in the plasma from 3 piperacillin hypersensitive patients was analysed by ELISA. Wells of the 
high binding 96 well plates were pre-coated with 20 µg/ml BSA:piperacillin adduct and incubated overnight 
at 4oC. 100 µl of hypersensitive patient plasma was added to wells in duplicate. This was followed by the 
addition of IgG1, IgG2, IgG3, and IgG4 subclass specific antibodies. 100 μI of streptavidin (diluted 1:1000 for 
IgG1 and 1:10,000 for IgG2, IgG3 and IgG4) were added and the assay developed with TMB. The colour 
change was then read with automated plate reader (Dynatech MR600) with the reference wavelength set 
at 630 nm. The data were analysed by Students T test with p < 0.05 considered significant (* denotes p < 
0.05;** denotes p <  0.01; *** denotes p < 0.001). 
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3.3   Discussion 
 
The cellular and humoral components of the immune system have been described in 
great detail. Characterization of the humoral response to infectious organisms and in 
autoimmune disorders have been defined in mice (Teixeira, Marques et al. 2005, Yang, 
Rui et al. 2013) and humans (Wahlgren, Berzins et al. 1983, Grammer and Lipsky 2003, den 
Reijer, Lemmens-den Toom et al. 2013).  
B cells play a critical role in humoral responses. The protective function of IL-10 secreting 
B regulatory cells (Bregs) has been demonstrated in experimental models of arthritis 
(Yanaba, Bouaziz et al. 2008). In contrast the pathogenic role of B cells has been 
described in models of type 1 diabetes. Non-obese diabetic (NOD) mice have the partial 
or total loss of B cells, which correlates directly with the development of diabetes (Xiu, 
Wong et al. 2008, Marino, Villanueva et al. 2009), with a reduction in the number of 
circulating B cells leading to a reduction in the development of insulitis. Researchers have 
utilised the advances in B cell biology to enable the identification of specific 
immunoglobulins (Christie, Coleman et al. 1988), the development of methods for the 
identification of immunoglobulin subclasses (Lefevre, Carr et al. 2009), and the effector 
and regulatory roles they perform in the immune process (Lund 2008) to enable an 
understanding of the contribution of B-cells to self-recognition, specificity and 
immunologic memory.  
Characterization of the cellular immune response in delayed-type drug hypersensitivity 
has been thoroughly explored (Naisbitt, Farrell et al. 2003, Naisbitt, Farrell et al. 2005, 
Whitaker, Meng et al. 2011, El-Ghaiesh, Monshi et al. 2012), but the corresponding 
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humoral responses have been knowingly or otherwise neglected. Thus, in this chapter 
the objective was to evaluate whether existing methods could be modified or new cell 
culture methods developed to detect drug-specific B cell responses. Piperacillin 
hypersensitive patients with cystic fibrosis were selected as the study cohort for 3 
reasons. First hypersensitive, tolerant and drug-naïve patients were willing to participate; 
second, the nature of the cellular response to piperacillin has been fully defined; and 
third, the binding of piperacillin to protein in patients plasma has been characterized; 
hence methods are available to develop drug-protein adducts as antigens. The drug-
specific activation of B-cells, the development of antibody producing B cell lines and the 
characterization of the IgG antibodies generated by these cells, including their subclasses 
was determined. Further analysis was performed to detect piperacillin-specific antibodies 
in cell supernatants and plasma. 
In order to achieve these goals PBMCs were isolated from piperacillin naïve volunteers, 
piperacillin tolerant and hypersensitive patients with cystic fibrosis. The analysis of the 
proliferation of PBMCs to piperacillin was performed using the lymphocyte 
transformation test (LTT), which is a simple assay for diagnosis, to verify sensitization to 
the drug. T-lymphocytes from hypersensitive patients, but not tolerant controls or naïve 
donors were stimulated to proliferate in the presence of the drug. The peak 
concentration for T-cell activation was 1 mM. Proliferative responses started to taper off 
at 4 mM, in most cases. Thus, the same concentrations of piperacillin were used to detect 
B-cell proliferative responses in each patient group. The detection of B-cell responses and 
specific IgG secretion is important as antibodies play a pathogenic or regulatory role in 
the development of drug hypersensitivity. 
 137 
 
To detect the B cell responses to either piperacillin or cpg-dna, PBMC were cultured with 
antigen or mitogen for 5 days prior to the detection of specific B cell markers by flow 
cytometry and/or IgG secretory profiles by ELISpot. Cpg-dna was selected as a positive 
control because of its propensity to activate immature and mature B cells via TLR9 
stimulation (Azulay-Debby, Edry et al. 2007) leading to cell proliferation and antibody 
production (He, Qiao et al. 2004).  
Phenotypic assessment of the different treatment groups showed that while they all 
expressed CD19 indicative of B-cells, only the hypersensitive patients showed an increase 
in expression of the activation marker CD27+ in response to in vitro piperacillin 
stimulation. This increase in peripheral levels of memory B cells is indicative of an existing 
reservoir of piperacillin-specific B cells generated during prior piperacillin exposure, likely 
around the time of hypersensitivity reaction. This coincides with previous studies 
confirming the increase in frequencies of memory B cell subsets in a population of 
Schistosoma Haematobium infected patients (Labuda, Ateba-Ngoa et al. 2013). The 
tolerant patients B-cells did not display an increase in CD27 expression after exposure to 
the drug. Similarly B-cells from naïve donors were not activated with piperacillin.  
Stimulation of hypersensitive patient PBMC also led to an increase in the secretion of IgG, 
detection of which was performed using an IgG ELISpot assay, utilizing PBMCs harvested 
from a 5 day culture. In contrast no difference in IgG secretion was observed with PBMC 
of naïve volunteers and tolerant patients after drug treatment. Cpg-dna, which has the 
capacity to initiate the activation of naïve B cells and the release of immunoglobulins M 
and G (Huggins, Pellegrin et al. 2007) was used as a positive control. High levels of IgG 
secretion was consistently observed in each patient group. Collectively, these data 
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indicate that piperacillin-specific B-cells are present only in hypersensitive patients. Later 
chapters expand on these data by assessing a larger patient cohort, defining the 
specificity of the antibody response and the role of B-cells in regulating piperacillin-
specific T-cell responses. 
The detection of antibodies specific to penicillin in patient plasma was first described 
several decades ago (Rammelkamp and Keefer 1943, Kern and Wimberley 1953). Penicillin 
was also shown to bind proteins such as HSA (Tompsett, Shultz et al. 1947) and the 
pharmacological implication with respect to penicillin activity also explored (Ley, Harris 
et al. 1958). Nowadays research has been able to further confirm the presence of 
antibodies specific to β-lactams. The binding of these drug haptens to proteins, their 
subsequent peptide synthesis and presentation by MHC to T cells have now been 
identified as key precursors for the onset of reaction. However significant questions still 
remain unanswered concerning the role B-cells and their secretory products play in the 
inhibition and regulation of delayed hypersensitivity.  
The Enzyme Linked Immunosorbent Assay (ELISA) has proved useful in the 
detection/assessment of antibody responses in a variety of cellular compartments (Bishai 
and Galli 1978, McNeil, Simpson et al. 1990). An anti-IgG antibody was used for the 
detection of total IgG secretion in B-cell line supernatants and in piperacillin 
hypersensitive patient plasma. IgG ELISA analysis of supernatants from PBMC cultured 
with piperacillin showed low level detection of IgG secretion in response to piperacillin in 
each patient group. Thus, it seems likely that the number of memory B cells activated 
with piperacillin in the in vitro culture was insufficient to generate IgG levels required for 
detection by ELISA. This necessitated the generation of IgG secreting B cell lines from 
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hypersensitive patients and/or the use of plasma samples wherein we were able to 
assess the different subclasses and attempt to confirm the presence of IgG antibodies 
specific to piperacillin. 
Substantial levels of IgG antibody was detected in plasma suggesting that quantifiable 
amounts of IgG subclasses could possibly be detected. Piperacillin-HSA adducts were 
generated and employed as antigens in hapten-inhibition assay for unambiguous 
determination of antibody specific to the piperacillin hapten. Unmodified HSA produced 
a high background apparently binding IgG itself; hence its further use was discontinued. 
The fact that piperacillin binds specifically to Lys residues  (Whitaker, Meng et al. 2011) 
meant that an appropriate replacement would need to be rich in lysine. Thus, HSA was 
compared with BSA and lysozyme, two Lys rich proteins that have been used previously 
to form conjugates for the assessment of drug specific responses (Coleman, Yeung et al. 
1986, Haas, Moolenaar et al. 2002, Yeh, Lee et al. 2008, Haselberg, Harmsen et al. 2011, 
Nguyen, Bobst et al. 2013). Different parameters of the assay including diluents used, 
PBMC culture supernatants, and plasma were assessed.  
Piperacillin-protein adducts with modifications arising at multiple lysine residues was 
detected with all proteins. Low backgrounds in the ELISA was observed when BSA was 
compared to that of HSA and lysozyme suggesting that BSA is a suitable protein for the 
generation of piperacillin antigens to detect specific IgG.  
Previous studies aimed at establishing a pattern for the levels of specific IgG in tolerant 
and hypersensitive patients have produced diverse results ranging from no observable 
significant changes between the groups (Sletten, Halvorsen et al. 2006), to elevated IgG 
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levels in clinically reactive patients when compared to tolerant individuals (Lopes de 
Oliveira, Aderhold et al. 2013).  
Comparison of the IgG subclass profiles in plasma between naïve volunteers, and patient 
samples did not manifest any differences in expression.  The generally described ratios of 
IgG1>IgG2>IgG3>IgG4 was shown in hypersensitive patient and naive volunteer plasma as 
well as IgG secreting B-cell lines. Other investigators have previously identified an 
elevation in serum levels of IgG4 though it has been explained as a by-product of the 
general increase in total IgG and not a feature of any clinical condition (Shryock, Molle et 
al. 1986, Moss 1987, Hodson, Morris et al. 1988). Using the piperacillin BSA antigen, a 
hapten inhibition ELISA was used to detect the presence of antidrug antibodies specific 
to piperacillin in patient plasma samples. Antidrug antibodies specific to piperacillin were 
detected in plasma from hypersensitive patients. This expression was not limited to the 
reactive stage of drug treatment but in some instances was shown to be present several 
months or even years after the termination of therapy. This is not surprising considering 
the fact that most of the patients have been exposed to the drug previously, and would 
be expected to develop an immunologic memory with antibodies remaining quiescent 
until re-exposure. An attempt to ascribe the specificity to a specific IgG subclass using a 
modified ELISA shows substantial interindividual variability (figure 3.22) the sample size 
used (n =3) was small thus a larger sample size would have to be employed before a 
definite conclusion can be reached.  
The phenotypic characterization of B cell lines and analysis of their IgG secretory profiles 
was carried out primarily to assess their potential to produce anti-drug antibodies 
specific to piperacillin. However, if successful these lines would also be used in T-cell 
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assays as antigen presenting cells to assess whether piperacillin-specific IgG has the 
ability to regulate drug-specific T-cell responses.  
In vitro infection of B-cells with EBV under controlled conditions resulted in 
immortalization. The EBV induced proliferation and differentiation with eventual fixation 
in the lymphoblast stage are thought to be the pathways by which indefinite 
differentiation leading to immortalization occurs (Thorley-Lawson and Mann 1985). The 
virus binds to the C3d receptor (complement receptor) and cells subsequently express 
viral genes amongst which include the EBV nuclear antigens (EBNAs), latent membrane 
proteins (LMP) and RNA species called EBV-encoded RNA’s (EBERs) (Fingeroth, Weis et 
al. 1984). The EBNAs have been implicated in the reduced dependence on serum factor in 
mice, enhanced expression of CD23 (B-cell activation antigen) and CD21  and the 
development of lymphocytic lymphoma and leukaemia in transgenic mice B-cells 
(Dambaugh, Wang et al. 1986, Wang, Gregory et al. 1987, Wilson and Levine 1992).  
Long lived IgG secreting B cells were generated using methods modified from that 
employed by Lanzavecchia et al (Lanzavecchia, Corti et al. 2007). CD19 expressing cells 
were cultured in the presence of Epstein-Barr virus (EBV), irradiated PBMCs and CpG-dna 
which activates B-cell via TLR9 stimulation (see chapter 2, figure 2.3). IgG secreting 
immortalized B-cells from hypersensitive patients were identified by ELISA and ELISpot 
assays. They were shown to express a pure CD19+CD27+ phenotype consistent with the 
memory B cell phenotype exhibited by normal B cells. Though there was a sustainable 
production of IgG in many immortalized lines the inability to detect anti-drug antibodies 
in these lines should also be noted. The addition of IL-4 and IL-5 during the 
immortalization as exogenous sources of Th cytokines produced an increased efficiency 
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in the generation of IgG secreting B cells. However, these lines with the ability to produce 
antibodies still did not secrete piperacillin-specific IgG (Schultz and Coffman 1991, 
MacLennan 1994, Manis, Tian et al. 2002). 
Future experiments should be directed towards modification of methods utilized for the 
generation of B-cell lines for the purpose of producing antigen specific antibody. Efforts 
could also be made to assess isotype switching, somatic hypermutation, and class switch 
recombination to fully understand the way molecular processes are affected.  
Collectively these data show the availability of in vitro experimental methods to define B 
cell activation in disease states in general, and drug hypersensitivity in particular, and 
points us in a new direction in the characterization of the humoral response in 
hypersensitive patients.  
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CHAPTER 4 
CHARACTERIZATION OF ANTIDRUG ANTIBODIES IN PIPERACILLIN 
HYPERSENSITIVE PATIENTS, AND ASSESSMENT OF β-LACTAM CROSS-
REACTIVITY. 
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4.0 Introduction 
 
The -lactams are a group of drugs which include a -lactam ring as a major component 
of the structure. These drugs are either used alone or in combination with other chemical 
agents referred to as -lactamase inhibitors which serve to conserve activity and extend 
their spectrum (Lee, Yuen et al. 2001). Classically, -lactams inhibit bacterial cell growth 
leading to death and lysis. These results are directly linked to the inhibition of enzymes 
responsible for peptidoglycan synthesis responsible for the maintenance of bacterial cell 
wall integrity. -lactams bind covalently to multiple proteins located in the bacterial cell 
membrane collectively referred to as penicillin binding proteins (PBPs). Previously -
lactams were thought to bind through the formation of an ester; however it has now 
clearly been shown that the -lactam is attached via the penicilloyl moiety. (Waxman and 
Strominger 1983)  
        
Figure 4.1. β-lactam antibiotic structures. Structure of 4 -lactam antibiotics: (a) penicillin G (b) cefuroxime 
a cephalosporin (c) piperacillin and (d) amoxicillin showing the core β-lactam nucleus (encircled). 
-lactams have been implicated in the initiation of a plethora of adverse drug reactions 
which are for the most part cutaneous in nature. These reactions have been observed 
 146 
 
with structurally related drugs. Thus, there is concern of cross-reactivity with structurally 
similar and diverse drugs that contain the β-lactam ring, including amoxicillin, piperacillin 
and cephalosporins (Figure 4.1) (Crieco 1967, Tsuchiya, Shiho et al. 1979, James and Gurk-
Turner 2001, Arndt and Garratty 2002, Terico and Gallagher 2014). Clinical manifestations 
vary in severity ranging from maculopapular rashes to erythema multiforme, Drug 
reactions with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson 
syndrome and Toxic epidermal necrolysis (SJS-TEN). The mechanisms that lead to tissue 
injury generally involve activation of the host immune system. The basic concepts have 
been elaborated upon in chapter 1. 
Piperacillin is a -lactam antibiotic used to combat respiratory tract infections in patients 
with CF. Cutaneous hypersensitivity reactions occur at a higher frequency in patients with 
CF when compared to the general population (Whitaker, Naisbitt et al. 2012) with an 
incidence of up to 30 % reported in some studies. Thus, such reactions represent an ideal 
model to study the role of drug-specific T and B lymphocytes in the disease pathogenesis 
(Whitaker, Naisbitt et al. 2012). 
The role played by proteins in the initiation of -lactam hypersensitivity reactions is 
becoming clearer by the day. Substantial evidence now exists to show that the binding of 
a drug hapten to a protein as originally proposed by Landsteiner and Jacobs is a 
prominent mechanism for immunogenicity and hypersensitivity (Chipinda, Hettick et al. 
2011). A number of mechanisms for the immunogenicity of these haptenated proteins 
have been proposed. They include but are not restricted to their multivalent nature, 
differences in the affinities, avidities, and precursor frequencies of antigen-specific cells, 
and the likely contribution of protein denaturation due to haptenation (Elahi, Wright et 
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al. 2004). While the mechanism of immunogenicity of haptens remains ill defined, we 
know for a fact that modification of skin proteins influence the relative skin sensitisation 
by cinnamic compounds (Basketter 1992, Cheung, Hotchkiss et al. 2003). The formation 
of benzylpenicillin-protein conjugates, and further mass spectrometric characterization 
to reveal the diastereoisomeric nature of the benzypenicilloyl adducts has recently been 
described (Meng, Jenkins et al. 2011). Most recently, piperacillin has been shown to 
modify lysine residues present in human serum albumin in vitro and in drug-exposed 
patients (Whitaker, Meng et al. 2011, El-Ghaiesh, Monshi et al. 2012). Importantly four 
hapten structures are found; a primary cyclised and hydrolysed hapten structure and 
desethyl metabolites of both structures (see figure 4.2c).  A synthetic piperacillin-HSA 
adduct was found to activate T-cells isolated from hypersensitive patients (El-Ghaiesh, 
Monshi et al. 2012). However to date it is not known whether one or all adduct structures 
activate the immune response.  
Adducts have also been detected in patients exposed to other classes of drugs. For 
example diclofenac, abacavir and isoniazid all modify HSA cysteine, lysine, and/or 
histidine groups in exposed patients (Hammond, Meng et al. 2014, Meng, Lawrenson et 
al. 2014). In each of these examples adduct formation is dependent on drug metabolism 
and liberation of a chemically reactive intermediate. In contrast to piperacillin the 
immunogenicity of such adducts has not been studied. In addition, abacavir binds non-
covalently to the floor of the peptide binding groove of HLA-B*5701 thereby altering the 
repertoire of self-peptides that load on the molecule to be presented to the immune 
system as shown by Illing, Vivian et al. (as stated in chapter 1)  a mechanism suggested to 
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predispose individuals to abacavir hypersensitivity reactions. Thus the role of abacavir 
protein adducts in the hypersensitivity reaction has not been defined.  
Drugs and metabolites have previously been incubated with proteins or peptides to 
determine their reactivity, and also to detect the presence of circulating antibodies 
(Coleman, Yeung et al. 1986, Annunziata, Kohn et al. 2013). Efforts have been made to 
understand the role of hapten density on the intensity of the immune response, as 
shown in the study carried out by Hu and others (Hu, Huang et al. 2012), and also on the 
antibody repertoire/spectrum induced by conjugates at different densities (Li, Rodriguez 
et al. 2010). The main downside of these studies has been the failure to elucidate the role 
the various lysine residue modifications play in the detection of anti-drug antibodies and 
subsequent intensity of the immune response and also the possibility of functioning as 
reactive epitopes. 
The presence of IgE-mediated penicillin hypersensitivity generally predisposes an 
individual to similar reactions in response to exposure to other β-lactams. This cross 
reactivity, usually occurs between -lactams and -lactam classes (Preston, Briceland et 
al. 1994, James and Gurk-Turner 2001). However different rates/incidences of 
hypersensitivity are observed in different patient groups. For non-IgE mediated 
reactions, the side chain of the -lactam antibiotic is thought to be involved in antigen 
specificity; however our knowledge of IgG drug-protein conjugate binding is limited 
(Robinson, Hameed et al. 2002).   
Thus the aims of this chapter were to; 
I. Characterize piperacillin (Pip) covalent binding to protein. 
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II. Quantify the time and concentration dependency of piperacillin covalent binding 
to protein and the antidrug antibody response. 
III. Assess antibody cross reactivity across a spectrum of -lactams.  
 
4.1 Methods 
 
See material and method sections on Gel electrophoresis for confirmation of adduct 
formation (2.3.2), SDS-PAGE western blot (2.3.2.1), mass spectrometric analysis (2.3.3), 
trypsin digests for mass spectrometric analysis (2.3.3.1), matrix assisted laser desorption 
ionisation (MALDI) (2.3.3.2), multiple reaction monitoring characterization of β-lactam 
albumin binding (2.3.3.3). Modification of ELISA for the detection of anti-drug antibody 
levels in tolerant and hypersensitive patient plasma samples to assess hapten density 
assay cross reactivity is discussed in section 2.2.3.2. 
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4.2   Results 
4.2.1 Confirmation of drug-protein binding in Piperacillin-BSA conjugate 
Cell culture methods to detect the B-cell response in hypersensitive patients were 
developed in chapter 3.  Identification of piperacillin-specific IgG using Piperacillin-BSA 
adducts prepared as antigens was carried out. A piperacillin-BSA adduct was 
characterized using western blotting to confirm piperacillin-protein binding, and mass 
spectrophotometric analysis was performed to define the extent of lysine residue 
modification. Figure 4.2 provides a summary of piperacillin-BSA binding and 
characterization carried out in the previous chapter as a preamble to further studies 
carried out in this chapter. SDS-PAGE western blot was used to characterize the time-
dependent piperacillin-BSA binding at 24 and 96 hours. A higher degree of Piperacillin-
BSA adduction was observed at 96 h compared to 24 h (Figure 4.2a). The 96 h time point 
was picked for subsequent studies on adduct formation. The extent of lysine residue 
modifications by cyclised and hydrolysed piperacillin covalently bound to BSA at 1:100 
molar ratio of BSA-piperacillin was also described (Figure 4.2b). The identification of 
binding and detection of modified residues set the stage for further characterization of 
these adducts with respect to piperacillin-protein binding and the relationship with time, 
concentration and the antidrug antibody response. 
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Figure 4.2.  
Summary of piperacillin BSA binding discussed in 
detail in chapter 3. 
 (a) SDS-PAGE characterization of the time-
dependent formation of Piperacillin-BSA adduct. 
SDS-PAGE western blot was used to characterize the 
time dependent Piperacillin-BSA binding. BSA and 
piperacillin were combined at a molar ratio of 1:50 
then incubated for 24 hrs and 96 hrs respectively at 
37oC. The enhanced binding exhibited at the 96 h 
time point led to its characterization and use in the 
hapten inhibition assays using plasma and culture 
supernatants as discussed in chapter 3. This same 
conjugates were employed in this chapter. 
 
 
 
 
 
 
(b) Mass spectrometric characterization of cyclised 
and hydrolysed forms of piperacillin haptens bound 
covalently to BSA.  
Graphs showing the extent of lysine residue 
modifications by cyclised and hydrolysed piperacillin, 
at Piperacillin-BSA molar ratio of 100:1. Analysis was 
conducted after a 96 h incubation period. 
  
(a) 
(b) 
 152 
 
 
 
 
 
 
 
 
(c)  Chemical structures showing points of modification and insertion of functional groups (R) of (ii) 
cyclised and (iii) hydrolysed piperacillin-BSA adducts formed from the (iii) primary piperacillin structure 
(R=CH2CH3) and desethyl piperacillin (R=H) adducts. 
 
 
 
(ii) 
(i) 
(i) 
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4.2.2 Epitope profiling of piperacillin-BSA conjugate using mass 
spectrometry 
Piperacillin-BSA conjugates with varying hapten densities were synthesized as previously 
described in the materials and methods section (see chapter 2). SDS-PAGE analysis of the 
conjugates revealed bands at 66 kDa using 1:1, 1:5, 1:10, 1:20, 1:50 and 1:100 - of BSA to 
piperacillin. SDS-PAGE analysis exhibited increased intensity in the bands. The 
conjugation of piperacillin to BSA occurred in a dose-dependent fashion (Figure 4.3)  
A screen of the amino acid targets modified by piperacillin adduction were assessed 
using mass spectrometry analysis. The semi-quantitative analysis of individual lysine 
residue modification was then carried out. The comparison of individual lysine residue 
modifications across the different molar ratios was possible but comparison of separate 
modified lysine residues was not possible due to their differences in ionisation. Epitope 
profiles showing the individual lysine residues modified by piperacillin and the relative 
level of binding at each site derived from the mass spectrometric analysis of 96 hr 
BSA:Pip conjugates are shown in figure 4.4. The conjugates were prepared at various 
molar ratios ranging from 1:1 to 1:100. Lysine modifications were observed on 8 (eight) 
lysine residues, specifically residues at positions 4, 12, 132, 136, 211, 221, 431, and 524. The 
magnitude of individual modifications observed were found to increase as the BSA-
Piperacillin molar ratio increased i.e. from 1:1 to 100:1, with the peptide containing the 
Lys431 residue appearing to ionise better than other residues at all the molar ratios 
(Figure 4.4). Importantly an increase in the total number of sites modified was not 
observed as the drug:protein ratio increased. 
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Figure 4.3. SDS-PAGE confirmation of Piperacillin-BSA binding.  SDS-PAGE western blot was used to 
characterize the binding in various Piperacillin-BSA adducts at different molar ratios. Drug and BSA were 
combined at 1:1, 5:1, 10:1, 20:1, 50:1 and 100:1 Piperacillin-BSA molar ratios then incubated for 96 hours at 
37oC. Adducts were then precipitated with methanol, western blotting  performed and subsequently 
incubated overnight at 4oC in the presence of  anti-penicillin mouse monoclonal antibody then goat anti-
mouse secondary antibody prior to development and exposure in the dark room to confirm drug-protein 
adduction.  
                 
 
Figure 4.4 Epitope profiles at different BSA-Piperacillin hapten densities. The semi-quantitative 
comparison of individual lysine residues across different molar ratios was performed. BSA-Piperacillin 
adducts formed at molar ratios of 1:1 to 1:100 were digested with trypsin, denatured and desalted. The 
epitope profiles show a concentration dependent increase in individual lysine residue modification from 1:1 
to 1:100. 
 
 
          Western blot  
     Coomassie stain 
66 kDa 
66 kDa 
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4.2.3 In vitro concentration dependency of piperacillin-BSA binding 
The overall modification of BSA with piperacillin (1:1 to 1:100) in vitro shows a 
concentration dependency with the highest ratio of drug to protein showing the highest 
level of modification (Figure 4.5 a). This is consistent with the concentration dependent 
increase in adduct formation which is observed at each individual lysine group (figure 
4.5b).  
   
         
Figure 4.5 In vitro analysis of the modification of lysine residues in Piperacillin-BSA conjugate. (a) 
Piperacillin concentration-dependent modification of BSA (b) Total level of piperacillin-BSA modification at 
each ratio of drug:protein for individual lysine residues. Values were calculated by adding levels of binding 
detected at the 8 sites of drug modification. 
 
 
(b) 
(a) 
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4.2.4 Average molar quantification of Piperacillin-BSA conjugates 
MALDI-TOF analysis showed the corresponding masses of the various conjugates at their 
different molar ratios. The masses observed at the different molar ratios were 66528.98 
for the unmodified protein (Piperacillin-BSA 0:1), then 66740.73, 67029.0, 67499.0, 
67499.33 and 67430.38 for the modified conjugates, 1:1, 10:1, 20:1, 50:1, and 100:1 
respectively (Figure 4.6). 
The mass values obtained from the MALDI-TOF analysis were then used to determine the 
density of the hapten bound to the carrier protein molecule. Determination was carried 
out via comparison of the variations in molecular weight of the different conjugates (1:1 
to 100:1). The result obtained shows the hapten densities of the conjugates increasing 
with an increase in the piperacillin-BSA molar ratio, from 0.41 hapten molecules at 1:1 to 4 
molecules at a ratio of 100:1 (Table 1). These values are considered to represent an 
estimate of the average molar quantification of drug:protein binding in piperacillin-BSA 
conjugates.  
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Figure 4.6.  Spectral images of the molar quantification of piperacillin-BSA conjugates using matrix 
assisted laser desorption ionisation (MALDI). Undigested Piperacillin-BSA conjugates (0.8 µl) at molar 
ratios (1:1 to 1:100) was placed on a MALDI plate spot. (CHCA)  matrix (0.8 µl) was then placed onto the 
sample, ensuring proper mixture of the matrix and sample before use. Calibration was achieved by the 
addition of 0.8 µl of the calibration control which also contained matrix. This was placed in between the 
sample spots. The MALDI plate was then allowed to dry before being loaded into the MALDI. The desired 
number of hits and traces were accumulated using Voyager control panel software. 
  
 
(c) Molar ratio = 10:1     (d) Molar ratio = 20:1 
 (e) Molar ratio = 50:1     (f) Molar ratio = 100:1 
(a) Molar ratio = 0:1     (b) Molar ratio = 1:1 
Mass = 66528.98 Mass = 66740.73 
Mass = 67029.0 Mass = 67499.34 
Mass = 67743.98 Mass = 68430.38 
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Table 4.1 Average molar quantification of piperacillin-BSA conjugates. The observed molecular mass 
values from the MALDI - TOF was obtained, and these values were used to determine the mass variations 
detected from 0:1 to 100:1. The ratio of the variations to the molecular mass of piperacillin (∆M/Mh) 
produced the hapten density, which was found to increase as the Piperacillin-BSA ratio increased. This 
value is roughly indicative of the number of piperacillin molecules that bind each BSA molecule after 
conjugation. 
 
 
Molar ratio 
Piperacillin-BSA 
Observed molecular 
mass (Da) 
Mass variation 
(∆M) 
∆M/Mh  
(hapten density) 
 
0:1 
 
66,528.98 
 
0 
 
0 (0) 
 
1:1 
 
66,740.73 
 
211.75 
 
0.41 (0) 
 
10:1 
 
67,029.0 
 
500.20 
 
0.97 (1) 
 
20:1 
 
67,499.34 
 
970.36 
 
1.88 (2) 
 
50:1 
 
67,743.98 
 
1,215.0 
 
2.35 (2) 
 
100:1 
 
68,430.38 
 
1,901.40 
 
3.67 (4) 
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4.2.5 Assessment of the molar ratio-dependent binding of piperacillin-
specific antibody to protein conjugates 
The hapten inhibition assay was employed (see chapter 2) to assess the response of 
antidrug antibodies to different densities of piperacillin haptens bound covalently to 
BSA. 
Using plasma samples from piperacillin hypersensitive patients and patients from the 
cohort that express high levels of piperacillin-specific IgG, we employed these piperacillin 
conjugates of varying hapten densities (BSA-piperacillin- ratios of 1:1 to 1:100). The 
difference observed in IgG secretion between the piperacillin treated and hapten 
inhibited groups at each molar ratio was taken as the amount of piperacillin specific IgG. 
Results were obtained following a single treatment per molar ratio; hence standard 
deviations are not presented and formal statistical analyses were not performed on 
individual patients.The results suggested a direct correlation between the hapten density 
(degree of conjugation) and the subsequent antibody response. Immunogenic responses 
varied depending on the individual sample used. Responses were observable from 
1:5<1:10<1:20<1:50<1:100 molar ratios in (Figure 4.7 a, and 4.7 c) 
1:1<1:5<1:10<1:20<1:50<1:100 in (Figure 4.7 b) and 1:10<1:20<1:50<1:10 (Figure 4.7 c). The 
anti-drug antibody dependency on total hapten density also shows a molar ratio 
dependent increase in antibody-drug binding (Figure 4.7 e) which is consistent with the 
individual increases observed in figures 4.7 (a), (b), (c) and (d).  
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Figure 4.7 Molar ratio-dependent binding of antibody to β-lactam conjugates. Using plasma from 2 
patients from the cohort expressing high levels of piperacillin-specific IgG (a), (b) and 2 piperacillin 
hypersensitive patients (c and d) Piperacillin-BSA conjugates of varying hapten densities (Piperacillin-BSA 
ratios of 1:1 to 1:100) were  employed to assess the in vitro molar ratio-dependent antibody binding (e) 
Combined results of the three hypersensitive patients. Data were analysed by the Students T test to 
compare the difference between means with p≤0.05 considered as significant. * denotes p = 0.01 t0 0.04. 
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4.2.6 Epitope profile of amoxicillin (AMOX), benzyl penicillin (BP), 
flucloxacillin (FLU), penicillin V (PEN V) and aztreonam (AZT) BSA 
adducts 
BSA:drug (piperacillin, amoxicillin, benzyl penicillin, flucloxacillin, penicillin V and 
aztreonam) conjugates with varying hapten densities were synthesized as described 
previously in materials and methods (see chapter 2). SDS-PAGE analysis of the conjugates 
showed drug-protein binding - via the detection of visible bands at 66 kDa for all drugs 
tested. Epitope profiles derived from the mass spectrometric analysis of these 
conjugates show different levels of lysine (Lys) residue modification. Furthermore, drug-
dependent modification profiles of Lys residues were observed. Amoxicillin, benzyl 
penicillin and flucloxacillin were all found to modify Lys residues at positions 4, 12, 131, 211, 
431, 523, and 524, but in addition also lysine residues at positions 20, 473 and 537 were 
modified for amoxicillin and BP. Position 132 was common to Flu and BP and Lys535 was 
only modified with flucloxacillin.  Aztreonam and penicillin V showed the least number of 
modified lysine residues with Lys136, 211 and 524 bound by aztreonam and Lys 211, 431, 
and 524 bound by penicillin V. The Lys residue at position 211 was the only modification 
that was consistent in all adducts. Due to the low abundance of the FLU-BSA conjugate, 
the true extent of modification possible may have not been defined. (Figure 4.8 (a) to 
4.8(e)) 
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Figure 4.8.  Epitope profiles for β-lactam-BSA adducts. β-lactam-BSA adducts with molar ratios of 50:1 
were digested with trypsin, denatured and desalted then characterized by mass spectrometry.  
(a) 
(b) 
(c) (d) 
(e) 
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Figure 4.9 MS/MS spectral images of modified BSA:amoxicillin, BSA:benzylpenicillin, BSA:flucloxacillin 
and  BSA:penicillin V, adducts. Modification of LYS431 with different penicillins consistent with the 
presence of a characteristic fragment ions at m/z 160 and drug-specific fragment ions. 
peptide1+ 
peptide1+ 
peptide1+ 
peptide1+ 
peptide2+ 
peptide2+ 
peptide2+ 
peptide2+ 
peptide2+ 
peptide2+ 
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4.2.7 Determination of β-lactam cross-reactivity of antipiperacillin 
antibodies 
The hapten inhibition assay as described in materials and methods (chapter 2) was 
employed to determine the cross reactivity of anti-drug antibodies in hypersensitive 
patient plasma samples. Conjugates were prepared using five different -lactam 
antibiotics; amoxicillin (Amox), aztreonam (Azt), flucloxacillin (Flu), penicillin G (Pen V), 
and piperacillin (Pip). These conjugates were assessed for antidrug antibody detection 
using samples obtained from 4 (four) hypersensitive patients, earlier confirmed to have 
substantial amounts of circulating anti-piperacillin IgG antibodies (figure 4.10 a). The 
results obtained indicate substantial antibody binding to piperacillin-BSA conjugates in all 
patients and subsequent inhibition of the response following the addition of an excess of 
soluble piperacillin to block hapten binding. The antibody binding noted with piperacillin-
BSA was notably absent when amoxicillin, aztreonam, flucloxacillin and penicillin V - BSA 
conjugates were employed. A clear indication of the specificity of the antidrug antibodies 
and absence of any form of cross reactivity between these drug haptens and piperacillin. 
The cleavage of the -lactam ring and the presence of a thiazolidine ring are common to 
all adducts formed using the various -lactam antibiotics (See schematic in figure (3.7a-b) 
and 4.2c). Therefore, the ability of circulating antidrug antibodies to bind to piperacillin 
conjugates alone and also be inhibited by free piperacillin suggested that in contrast to 
other -lactams, antibody recognition of the piperacillin adduct was via the piperacillin 
side-chain. 
The detection of low levels of IgG binding to the flucloxacillin adduct likely represents 
non-specific binding as it was not blocked with the addition of soluble drug. 
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(d) 
(e) Figure 4.10.  
Hapten inhibition ELISA employing unmodified and β-
lactam modified BSA to assess cross-reactivity to other 
β-lactams. 
The presence of antidrug antibodies in plasma of four 
patients (a, b, c, and d) was measured by ELISA. Flat 
bottom high binding 96 well plates were pre-coated 
overnight with the BSA-drug adducts for aztreonam 
(Azt), amoxicillin (Amox), flucloxacillin (Flu), penicillin G 
(Pen G) and piperacillin (Pip) as an antigen. Plasma (100 
l)  was added, with 1 mM soluble drug employed as 
the inhibitor. Colour was developed by reaction of HRP 
and TMB substrate. The reaction was stopped with 
0.18M H2SO4.  Data was analysed by the Students T test 
(e) to compare the difference between means with 
p≤0.05 considered as significant. ** denotes p < 0.01; 
*** denotes p < 0.001). 
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4.3   Discussion 
 
Piperacillin-protein adducts with different levels of hapten binding were generated 
initially to enhance antigen binding in the ELISA. However, these adducts also permitted 
the characterization of the relationship between the extent of amino acid residue 
modification and the strength of antibody binding. HSA was initially used to prepare the 
piperacillin adducts but the high backgrounds led to the selection and use of BSA as the 
protein backbone. This choice was further justified by the similar masses and structure of 
adducts as determined by mass spec analysis, the detection of the same lysine targets 
that are modified with piperacillin in HSA (Whitaker, Meng et al. 2011, Jenkins, Yaseen et 
al. 2013) and the high backgrounds associated with the other alternative protein analyzed 
(see chapter 3).  
The ratio at which drugs and proteins are conjugated has previously been shown to influence 
the nature of the antibodies induced by the hapten, with an increase in the ratio usually 
bringing about an increase in the strength and specificity of the immune responses (Marco, 
1995). Western blot analysis using an established protocol (Whitaker, Meng et al. 2011) was 
employed to confirm adduct formation. The mass differences between conjugates compared 
to the molecular weight of BSA at 66 kDa, was too small to provide significant measureable 
migration distances using electrophoretic analysis. Nevertheless, the results show that the 
number of piperacillin molecules bound to BSA increased in a linear fashion with an increase in 
the ratio between piperacillin and BSA. Molar ratios ranging from 1:10 to 1:100 showed an 
increase in adduction based on data following quantification with MALDI-TOF with a 
corresponding increase in the ratio showing hapten densities of 1, 2, 2 and 4 (approximate 
values from table 4.1). BSA-modified ciprofloxacillin at a molar ratio of 1:800 has previously 
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shown binding of up to 30 ciprofloxacin molecules. Only 26 out of the 56 lysine residues exist 
on the BSA molecule surface, suggesting that ciprofloxacin is able to bind other amino acid 
residues apart from lysine (Rosenoer VM 1977, Hirayama, Akashi et al. 1990). An important 
point here is that protein targets of reactive electrophilic metabolites usually contain strong 
nucleophilic sites. Subsequently, in addition to lysine amines, these protein targets include 
cysteine thiol, histidine imidazoles, and protein N-terminal amines. The accessibility of these 
nucleophilic groups, protein localization within the cell, the nature of the reactive metabolite 
and post adduction chemistry may alter the nature of the final adduct (Labenski, Fisher et al. 
2009). This further affirms the possibility of adduction to specific lysine residues and other 
multiple nucleophilic sites by ciprofloxacin and most likely other drugs and chemicals.  
Herein, with piperacillin such high drug-protein adducts were not used by virtue of 
previous studies where plasma kinetics were studied  (Paton, Mander et al. 1982, Gath, 
Charles et al. 1995, Roder, Frimodt-Moller et al. 1995) and molar ratio of drug to HSA in 
plasma was determined to be 1:16, with adducts also detectable at a 1:10 molar ratio. 
Clinically however, patients are also administered multiple doses of the drug which leads 
to accumulation of the drug-protein conjugate despite the half-life of HSA (Anderson and 
Anderson 2002). Thus, drug to BSA molar ratios from 1:1-1:100 used in our study were 
thought to be reasonable relative to those obtainable in vivo.  
From our results we can see that an increase in the protein-hapten molar ratio led to an 
increase in the hapten density of conjugates, which has a great influence on the binding 
affinity of piperacillin-specific antibodies, whereby an optimum molar ratio of piperacillin-
BSA conjugates was able to induce significant piperacillin binding.  
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Western blot analysis showed that the incubation time of drug with protein had a direct 
effect on the level of adduct formation. A significant increase in piperacillin hapten 
binding was observed at the 96 hours compared to the 24 h incubation time (4.2.2).  
Following the concentration - and time-dependent characterization of the conjugates, 
protein modifications which arose due to adduction were assessed by LC-MS/MS. The 
mass spectrophotometric analysis of piperacillin-HSA conjugates formed in vitro has 
been previously carried out (Whitaker, Meng et al. 2011) and was further confirmed in our 
study with the predicted mass of 517 amu identified (MS/MS profile of piperacillin binding 
using BSA conjugates). Similarly, modification was seen at the 8 lysine residues in BSA at 
positions 4, 12, 131, 132, 136, 211, 431, 524, and 537. The relative level of modification at 
each lysine residue increased significantly with an increase in drug:protein molar ratio. 
Collectively, these data coincide with that seen previously with HSA binding, and though 
Lys 4 and Lys 12 appear to be the only similar residues that were modified in both HSA 
and BSA adducts, in actual fact 4 additional piperacillin modified residues namely Lys 136, 
Lys 211, Lys 431, and Lys 524 were identified which ended up with different residue 
numbers due to their different primary amino acid sequences in BSA and HSA. 
The hapten mechanism of drug hypersensitivity discussed in chapter 1 illustrates the 
significance of drugs/hapten-protein adduction in precipitating hypersensitivity reactions. 
Previously, the relationship between epitope density has been related to adduct 
disposition and immunogenicity using albumin-dinitrofluorobenzene (DNFB) conjugates. 
Low levels of modification were not detected by IgG antibodies, while the high levels of 
modification lead to protein degradation. Hence a bell-shaped curve was observed when 
epitope density was plotted against IgG binding (Park, Tingle et al. 1987).  Subsequently 
our study has shown that in addition to the hapten density, the increase in the extent of 
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lysine residue modification, with an increase in the molar ratio rather than only the 
numbers of modified lysine residues are factors that define the extent of antibody 
binding. How these factors affect immunogenicity though, still remains unresolved.   
Clinical cross-reactivity has been found to occur in hypersensitive patients with different 
classes of drugs including the β-lactam antibiotics. The cross-reactivity in drug 
hypersensitivity reactions between amoxicillin and cephadroxil, and to sulfasalazine and 
sulfamethoxazole both sulfonamides are clinically well documented examples (Sastre, 
Quijano et al. 1996, Zawodniak, Lochmatter et al. 2010). It is possible that the drug 
haptens bind to the same protein targets. This promiscuity could be due to the structural 
similarities which these molecules possess (Oldstone 1998), though unrelated ligands 
have also been implicated (James, Roversi et al. 2003) with data obtained from previous 
studies pointing to binding involving specific hydrogen bonds dependent upon the  
chemistry of the cross reactant and the availability of complementary antibody residues 
(James and Tawfik 2003). 
 
Previous studies employing piperacillin-specific T-cell clones have shown the selective 
proliferative capacity with piperacillin and not other -lactams which share the penicilloyl 
core structure or drugs that share similar side chains (El-Ghaiesh, Monshi et al. 2012).  To 
show the specificity of the anti-drug antibodies for piperacillin, adducts were generated 
using five different β-lactams. Mass spectrometric analysis and indirect competitive 
ELISA analysis were carried out to define antibody binding and relate the individual lysine 
residue modifications to the immune response. The total absence of responses with Azt, 
Amox, BP and Pen V or the significant reduction as seen with flucloxacillin of anti-
piperacillin IgG binding to drug–protein conjugates was indicative of the absence of cross 
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reactivity with piperacillin. Thus, piperacillin-specific antibodies are highly drug-specific 
and must recognize both the penicilloyl structure and specific side chain of piperacillin; 
thus, restricting interactions with similar drugs that bear different side chains.  
Epitope profiles showed similar lysine residues were modified in amoxicillin, 
benzylpenicillin and flucloxacillin conjugates though the extent of ionisation of the 
various modified peptides varied. The modifications identified were specific for each 
hapten and the subsequent effect on peptide ionisation; hence the various intensities 
could not be compared across the different drugs. Also the reactivity of flucloxacillin with 
its propensity to cause protein damage at high concentration leading to losses during 
sample processing could be regarded as a factor that may have led to the low abundance 
of the FLU-BSA conjugate. 
In this chapter drug conjugates have been used to characterize piperacillin protein 
binding and assess the variable effects of time and concentration on the drug-specific 
antibody binding. Collectively, the data begins to describe the cellular processes that 
determine the specificity of piperacillin antibody binding and enhances the 
understanding of the humoral response in piperacillin hypersensitive patients. 
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CHAPTER 5 
CHARACTERISATION OF PIPERACILLIN-SPECIFIC T-CELL RESPONSES AND 
IgG ANTIBODIES IN PATIENTS WITH CF. 
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5.0 Introduction 
 
In earlier chapters of this thesis I tried to enumerate the molecular mechanisms that 
underlie the development of drug hypersensitivity. I have also reviewed the obvious 
relationship which exists between the presence of an existing pathology, which in this 
case is cystic fibrosis (CF), and the increased expression of a form of these reactions due 
to β-lactam administration, specifically piperacillin. Literature to support these facts has 
been documented in chapters 1 and 2 of this thesis. 
In prospective cohort studies, the design, subject recruitment and data collection are 
usually the primary responsibility of the investigator(s). Data is also usually collected 
before any treatment or outcomes of interest have been developed by the subjects. 
These kinds of studies have important applications in epidemiology and in clinical studies 
(Bhandari and A. 2009, Bookwala, Hussain et al. 2011). After collection of the initial data 
these subjects are usually followed up longitudinally to the conclusion of the study.  
Previously, prospective studies have been conducted utilising cohorts of patients with CF 
to study certain disease parameters such as disease prevalence, patient mortality and 
survival, disease genetic correlation, and also effects on pregnancy and surgical 
interventions. A collection of these studies have been enumerated in the table below 
(Table 5.1). None of these 12 studies was tailored towards understanding the 
immunological basis of the adverse reactions observed in patients exposed to β-lactam 
antibiotics, a scenario we have tried to address in our study.  
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Table 5.1. Prospective studies utilising CF patient cohorts to study incidence, prevalence, survival and 
mortality, and genetic studies. 
 
Year 
 
Reference 
 
Nature of study 
 
Number of patients in 
the study 
 
1996 
1998 
2002 
2007 
 
(Kosorok, Wei et al.) 
(Hamosh, FitzSimmons et al.) 
(Scotet, Gillet et al.) 
(Bellis, Cazes et al.) 
 
 
Incidence of CF 
 
19,781 
17,755 
543 
4,104 
 
1982 
2003 
2007 
2008 
 
(Kollberg) 
(O'Connor, Quinton et al.) 
(Bellis, Cazes et al.) 
(Castellani, Cuppens et al.) 
 
Prevalence, 
survival and 
mortality studies 
 
116 
23,817 
4,104 
8,284 
 
1998 
2001 
2004 
2006 
 
(Feingold, Guilloud-Bataille et 
al.) 
(Koch, Cuppens et al.) 
(Badet, Bellis et al.) 
(McKone, Goss et al.) 
 
 
Genetic studies 
 
15,620 
8,963 
3,220 
16,651 
 
The above studies employed large cohorts, but the nature of the data generated is 
limited. Apart from the few genetic-based studies very little molecular information can 
be gleaned from the studies in relation to drug-related reactions and other clinical 
parameters. This form of analysis would require the assessment of select molecular 
characteristics of the CF cohort, enabling us to characterise the contributions or not of 
various cellular subsets and their secretions to the onset of the adverse events. 
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An improved understanding of drug hypersensitivity requires a multidisciplinary 
approach that relates immune responses to clinical outcome using samples obtained 
prior to a reaction, in the acute phase and longitudinally as the patient recovers. This 
form of investigation can only be conducted through establishment of a prospective 
clinical study in combination with specialized laboratory facilities to explore immune 
function. Piperacillin hypersensitivity in patients with CF represents one of the few 
reactions where sufficient samples can be collected prospectively from patients with a 
clinically relevant adverse drug reaction. The data presented in this chapter represents 
the first analysis of a four year study involving 80 patients. On recruitment an initial naïve 
or tolerant–blood sample was obtained; PBMC and plasma were isolated from whole 
blood and frozen at -150oC and -80oC respectively. Repeated blood samples were 
obtained on commencement of each piperacillin treatment course as well as on clinical 
diagnosis of a hypersensitivity reaction. Finally, a post-hypersensitivity sample was 
obtained after the resolution of clinical symptoms of hypersensitivity reactions. From 
each blood donation piperacillin-specific T-cell responses were assessed using the 
lymphocytes transformation test (LTT) and/or interferon-gamma (IFN-γ) ELISpot. Total 
and drug-specific IgG was measured by ELISA. The main objective of this chapter was to 
establish when piperacillin-specific T-cell and antibody responses are detectable in drug-
exposed patients and to establish their possible relevance in the onset of drug 
hypersensitivity. 
5.1 Methods   
 
Refer to chapter 2 sections 2.4. 
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5.2   Results 
 
5.2.1 Sample collection and presentation of data 
Eighty patients undergoing therapy with intravenous piperacillin were recruited for this 
study. Blood samples were collected at different time points of piperacillin 
administration; before the administration of piperacillin (pre), during piperacillin drug 
therapy (mid), at the end of therapy (end) or clinical diagnosis of a hypersensitivity 
reaction (reaction). Finally, a retrospective sample (retro) was obtained at least 1 month 
after allergy diagnosis. LTT results were positive for 32 patients (one or more samples) 
during the course of piperacillin administration; while the remaining 48 patient samples 
were negative. Forty-three patients had complete course samples taken. From this 
cohort the number of piperacillin courses per patient ranged from a single course to a 
maximum of 5 courses. Twelve patients produced positive LTTs within the duration of 
the first course, 3 patients by the second course and 3 by the third course (figure 5.1). 
Positive LTTs were observed from as early as the first day after administration to 14 days 
and also at the resumption of treatment up to 14 months after the first course of 
piperacillin was given. Positive LTTs were also observed up to 8 weeks post 
desensitisation. 
Since the clinical study is still ongoing it is not possible to access clinical details of 
patients. However a hypersensitivity reaction was diagnosed clinically following the 
discovery of one or more of the following, delayed onset maculopapular/urticarial rash, 
fever and arthralgia. Firstly we used the LTT to relate T-cell responsiveness to the 
allergy/tolerant phenotype. Patients that produced negative LTTs throughout were 
deemed negative hence tolerant. Patients that initially had positive LTTs from the pre 
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sample but subsequently had a negative end or reaction sample were classified as 
negative. Patients that produced positive LTTs throughout were deemed positive hence 
hypersensitive. Patients that initially had negative LTTs from the pre sample but 
subsequently had a positive end or reaction sample were classified as positive 
(irrespective of a clinical diagnosis of allergy).   
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Figure 5.1 Summary of total number of piperacillin courses administered to each patient. Blood samples 
were obtained during each course of piperacillin administration from CF patients at different time points. 
The figure shows the total number of courses administered to each patient, the number of courses leading 
to the detection of hypersensitivity and the point at which tolerance (black bars) and hypersensitivity to 
piperacillin was detected in-course (red bars). Retrospective samples (purple bars) are indicated for some 
of the patients. 
 
A total of 20 patients were clinically classified as allergic. From this group of patients 9 
produced positive LTT results from which 5 were specifically from the allergy/reaction 
 
 
 
Key: 
 Negative LTT  (tolerant samples) 
 Positive LTT (hypersensitive samples) 
 Retrospective samples 
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sample, while 11 patient samples produced negative LTTs (figure 5.2). Importantly of the 
11 negative LTTs with acute reaction samples, 65 patients are yet to donate a 
retrospective sample; hence, the specificity of the LTT cannot yet be assigned.   
 
Figure 5.2 Relationship between clinical diagnosis of hypersensitivity and drug-specific T-cell responses. 
Pie chart showing the total number of patients clinically diagnosed with hypersensitivity and their drug 
specific responses. 
 
The presence of clinically diagnosed hypersensitive patients without piperacillin-specific 
T-cell responses suggested that these patients may have been misdiagnosed or there 
could be a deficiency in the test used. Resolving these questions would require (i) the 
donation of the post reaction blood sample and (ii) the patients being rechallenged with 
a test dose of the drug. Individual courses were assessed to determine whether and how 
the detection of piperacillin-specific T–cells related to clinical outcome. The LTT results 
obtained from pre, mid, reaction and retrospective samples helped to define the stages 
during a course of piperacillin administration at which (i) tolerance was observed (ii) the 
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point when hypersensitivity was diagnosed and (iii) if these responses persisted 
retrospectively (figure 5.3 and 5.4). 
 
Figure 5.3 Assessment of piperacillin-specific T-cell responses from 3 hypersensitive patient’s individual 
courses. LTT positive blood samples collected at pre, mid, end and retro time points were individually 
assessed to determine the relationship to the clinical outcome.  Graphs show LTTs from three 
hypersensitive patients indicating the point at which tolerance ended and a hypersensitivity diagnosis was 
made via the LTT, and also if this status persisted retrospectively.                    
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Figure 5.4 Assessment of individual courses from tolerant patients. LTT negative blood samples collected 
at pre, mid, end and retro time points were individually assessed to determine the relationship to the 
clinical outcome. Graphs show LTTs from three tolerant patients indicating the absence of a 
hypersensitivity diagnosis and the retrospective status. 
 
A host of clinically diagnosed piperacillin tolerant patients presented consistent LTT 
profiles over multiple courses that reflected their non-responsive nature (figure 5.5). 
However a small number from this group of patients also developed positive piperacillin-
specific T cell responses. 
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Figure 5.5 Representative LTT profile from clinically diagnosed tolerant patients. Figure shows 
representative LTT graphs from a single tolerant patient of 3 piperacillin administration courses. Consistent 
LTT profiles were observed over multiple courses of piperacillin administration with SI < 2. 
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Figure 5.6 Clinically diagnosed patients with a positive LTT.  Figure shows representative LTT profiles from 
clinically diagnosed tolerant patients. Over a single course of piperacillin administration, patients exhibited 
a tolerant profile at earlier time points but a hypersensitivity diagnosis at the terminal sample collection 
point (SI > 2). 
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5.2.2 Assessment of patients LTT status, with total and piperacillin-specific 
IgG secretion 
Blood donations were divided according to the piperacillin-specific T-cell response and 
assayed for the expression of total and drug-specific IgG. There was no significant 
difference in total IgG between LTT positive and negative patients (Figure 5.7a) However, 
a significant difference (p <0.05) was observed in piperacillin-specific antibody between 
both groups with LTT positive samples expressing a higher average (Figure 5.7b). The 
kinetics of IgG detection was assessed in CF patients (Figure 5.8) and a cohort of patients 
that developed a clinically diagnosed reaction in the presence or absence of a drug-
specific T-cell response (Figure 5.9). Two time points (Pre, and reaction samples) were 
assessed for their total IgG levels but no significant differences were found in the IgG 
levels between groups (Figure 5.9). 
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Figure 5.7 Drug-specific T-cell responses and the expression of drug-specific IgG. Patient blood samples 
were divided into LTT positive and negative samples Patient plasma was collected and total IgG and hapten 
inhibition ELISAs performed (a) Plasma was assessed for total IgG [LTT negative (n=92) and positive 
(n=23)] production and (b) piperacillin-specific antibody [LTT negative (n=74); LTT positive (n=21)]. Data 
were analysed by the Students T-test with p ˂ 0.05 considered statistically significant (* denotes p ˂ 0.05)  
 
 
 
(a) 
(b) 
* 
LTT positive LTT negative
0
5000
10000
15000
Individual data points
Patient LTT status
Ig
G
 (
n
g
/m
l)
n.s
LTT positive LTT negative
0
1000
2000
3000 p < 0.05
Individual data points
Patient LTT status
P
ip
e
ra
ci
lli
n
-s
p
e
ci
fi
c 
Ig
G
 (
n
g
/m
l)
 186 
 
      
Pr
e
M
id
En
d
Re
ac
tio
n 
0
2000
4000
6000
8000
10000 Individual data points
   Time of sample collection
Ig
G
 (
n
g
/m
l)
 
 
 
     
Pr
e
M
id
En
d
Re
ac
tio
n
0
2000
4000
6000
8000
10000
   Time of sample collection
Ig
G
 (
n
g
/m
l)
 
Figure 5.8 Kinetics of IgG detection in CF patients. Dot (a) and whisker plots (b) showing the total IgG 
secretion in CF patients being administered piperacillin. Plasma samples were obtained at four different 
time points namely from pre-drug treatment (pre) [n=36], a sample at halfway (mid) [n=19], through to the 
end of the course (end) [n=38] or at the clinical diagnosis of hypersensitivity (reaction)[n=11].  
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 074 end 
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Figure 5.9 Kinetics of IgG detection in clinically diagnosed hypersensitive patients. Plasma samples from 
clinically diagnosed hypersensitive patients were assessed for IgG antibody using an ELISA. Individual data 
points were captured and the average concentration at each sample collection point determined. A 
students T-test was performed to determine the significance level (p ≤ 0.05 was considered as statistically 
significant). 
 
5.2.3 Characterisation of piperacillin-specific T-cell responses, total and 
piperacillin-specific IgG in patients undergoing desensitisation 
T-cell responses and drug-specific IgG was measured in a cohort of patients undergoing 
desensitisation. Blood samples were collected from patient’s pre-desensitisation (pre-
des) and at different time points during desensitisation. LTTs were performed on these 
samples to determine T-cell responsiveness during desensitisation. However due to the 
inconsistent time points employed with desensitisation blood samples during collection 
(table 2) the 1h, and 24h post-desensitisation times were used for data analysis.  
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Table 5.2. Representative sample of LTT analysis of PBMC from desensitisation patients. Samples were 
collected from patients undergoing desensitisation at 6 different time points and assessed for Piperacillin-
specific T-cell responses. Table shows some of the samples tested to present an overview of the time 
points used and the need to restrict analysis to only 1h and 24h. 
 
     — = Negative LTT result;  + = Positive LTT result;   NS = No sample received. 
 
Analysis of the total IgG level was performed on all patient desensitisation samples 
(figure 5.10), and with four specific patients that had a full complement of pre, 1h and 24h 
post desensitisation samples (figure 5.11). In both groups the total IgG was significantly 
higher pre-desensitisation than 24h post-desensitisation. This could possibly be 
attributed to two patients that possessed extremely high IgG levels which could be as a 
consequence of the drug, disease or interindividual variability. 
 
DESENSITISATION TIME POINT 
PATIENT ID Pre-Des 1hr 3hr 18hr 24hr 48hr 
019   NS   NS 
024  + NS NS + NS 
043 + + NS NS +  
044 + + + NS  NS 
050  NS NS NS NS  
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Figure 5.10 Analysis of total IgG level of all desensitisation samples. Total IgG ELISA whisker plots (a) and 
dot plots (b) showing total IgG levels in patients prior to desensitisation n = 12 , 1 hour (n = 4) and up to 24 
hours post desensitisation to piperacillin (n = 8). Data were analysed by the Students T-test to compare the 
difference between means with p≤0.05 considered as significant (* denotes p < 0.05). 
(a)
 
 074 end 
(b)
 
 074 end 
 190 
 
Pr
e 
1 h
r p
os
t 
24
 h
r p
os
t 
0
5000
10000
15000
p < 0.05
ns
Desensitisation time point
Ig
G
 (
n
g
/m
l)
 
Pr
e 
1 h
r p
os
t 
24
 h
r p
os
t 
0
5000
10000
15000
Individual data points
p < 0.05
ns
Desensitisation time point
Ig
G
 (n
g/
m
l)
*
 
Figure 5.11  Analysis of the total IgG level of four desensitisation patient samples.  Total IgG ELISA whisker 
plots (a) and dot plots (b) showing total IgG levels in patients (n = 4) prior to desensitisation and up to 24 
hours post desensitisation to piperacillin. Data were analysed by the Students T-test to compare the 
difference between means with p≤0.05 considered as significant (** denotes p = 0.001 to 0.009). 
  
All samples were assessed for their ability to produce antidrug antibodies at the different 
time points during the course of piperacillin administration. Box plots show there is no 
significant difference between the amounts of anti-piperacillin antibody produced at all 
(a)
 
 074 end 
(b)
 
 074 end 
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the time points. One patient showed an extremely high level of anti-piperacillin-specific 
antibody which resulted in the large standard error exhibited by that group (the reaction 
group), See figures 5.12a and 5.12b. 
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Figure 5.12  Kinetics of piperacillin-specific IgG detection in CF patients receiving piperacillin using ELISA. 
Whisker (a) and dot plot (b) of antipiperacillin antibody levels (ng/ml) in piperacillin treated patients with 
CF obtained at different stages of drug administration. 
(a)
 
 074 end 
(b)
 
 074 end 
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Further assessment was carried out on the kinetics of anti-piperacillin antibodies in four 
(4) hypersensitive patients pre- and 24h after the commencement of desensitisation. 
Plasma samples collected pre-desensitisation and 24 hours post-desensitisation were 
assessed for piperacillin-specific IgG using a hapten inhibition ELISA. The results indicated 
that at 24h post-desensitisation there was a significant reduction in the levels of 
circulating anti-piperacillin antibodies (figure 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Time-dependent secretion of antidrug antibodies during piperacillin desensitisation. Plasma 
samples were obtained from patients undergoing piperacillin desensitisation (n=4). Samples were obtained 
pre-desensitisation and 24h after the start of desensitisation. A hapten inhibition ELISA was performed. 
Data were analysed by the Students T test to compare the difference between means with p≤0.05 
considered as statistically significant. ** denotes p = 0.001 to 0.009.  
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5.3   Discussion 
 
T-cells have been shown to proliferate in response to stimulation by drug antigens using 
the established lymphocyte transformation test (Luque, Leyva et al. 2001, Pichler and 
Tilch 2004). As I have stated previously in chapters 2, 3, and 4, LTT positive patients were 
considered as hypersensitive. This test was employed to establish when piperacillin-
specific T-cells could be detected in the cohort of CF patients undergoing piperacillin 
therapy. A hypersensitivity screen of the individual patient drug courses (figure 5.1) and 
individual samples collected (figure 5.2) showed that the diagnosis of hypersensitivity 
was not restricted to a specific stage of drug treatment as positive LTT results were 
obtained from samples obtained prior to a specific course of piperacillin administration, 
during drug administration and at the onset of drug hypersensitivity when symptoms 
began to manifest (figure 5.2). Piperacillin-specific T-cell responses were also shown to 
persist retrospectively. Also hypersensitivity was detected in patients as early as their 
first course of treatment (n = 12) and second course (n = 5) as represented in figure 5.1. 
The detection of positive LTT is due to the fact that many patients have been exposed to 
prior courses of piperacillin. It also infers that there isn’t a strict paradigm with respect to 
the number of courses required to facilitate the onset of hypersensitivity.  
Two important points must be highlighted from this initial analysis of T-cell responses 
during the prospective study. First, these data identify positive LTT results in a small 
number of patients currently classified clinically as piperacillin tolerant. It will be 
interesting to see whether these patients develop a reaction when next exposed to 
piperacillin. Secondly, the negative LTT results obtained from certain acute allergy 
samples does not necessarily indicate an incorrect clinical diagnosis. A retrospective 
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sample still needs to be obtained from certain patients, whilst it is also possible that 
certain allergic patients present with a negative LTT. A significant difference in 
piperacillin-specific IgG was observed between LTT positive and negative samples (figure 
5.5). This is the first indication of a relationship between the humoral and cellular 
components in piperacillin hypersensitivity. Further studies will be required to determine 
the relationship of these parameters to the clinical outcome. 
The next approach involved assessment of the total IgG and piperacillin-specific IgG from 
baseline, pre, mid, end and reaction stages during piperacillin therapy. Studies have 
shown that the antibody type, and level detected during immune responses against 
infectious organisms is dependent on the organism and body/tissue compartment from 
which the samples analysed are collected. Differential expression of IgA, IgG and IgM 
antibodies has been observed in serum, bronchoalveolar lavage fluid, nasal secretions 
and saliva (Maiz, Cuevas et al. 2008, Aanaes, Johansen et al. 2013, Petrova, Strateva et al. 
2013). An increase in certain specific antibodies to Pseudomonas aeruginosa and 
Aspergillus fumigatus in CF has been attempted previously but no mention was made of 
the total IgG levels (Pressler, Pedersen et al. 1992, Skov, Pressler et al. 1999). Tailoring our 
expectations along those lines would not be ideal simply because the nature of 
inflammatory immune response initiation and perpetuation of the immune system by 
infectious and non-infectious agents are fundamentally different (Kaczmarek, 
Vandenabeele et al. 2013). Subsequently using patient plasma we observed that there 
was no significant difference in total IgG levels between the various time points (pre, 
mid, end and reaction) during the course of piperacillin therapy (figure 5.7). Antidrug 
antibody levels also remained constant (figure 5.11a and 5.11b). Nonetheless, the 
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investigation of these levels in other body compartments should not be discountenanced 
as this may reveal a differential expression of clinical significance.  
Drug desensitisation is routinely carried out in antibiotic hypersensitive patients with CF. 
The primary aim is to retain patients on preferred first line therapy, even in the presence 
of extreme disease conditions such as the severe decrease in lung function in CF patients. 
There are no formalised dosage regimens, but there have been a number of published 
reports recognising the validity of this process (Borish, Tamir et al. 1987, Cash, Caulder et 
al. 2013, Yusin, Klaustermeyer et al. 2013). The results obtained have been highly variable 
ranging from 24 % to 100 % success rates observed (Burrows, Toon et al. 2003, Turvey, 
Cronin et al. 2004, Legere, Palis et al. 2009, Whitaker, Naisbitt et al. 2012). Patients also 
require multiple desensitisations, prior to each course of the drug. In contrast to total IgG 
levels during piperacillin therapy, the desensitisation of hypersensitive patients showed a 
reduction of total IgG 1h after the start of desensitisation (see figure 5.9). This reduction 
was significant at 24h and with circulating piperacillin-specific antibodies 24 hours post-
desensitisation. This is an indication that during desensitisation there is also a reduction 
in the total amount of circulating antibodies. The immuno-molecular mechanisms of 
successful desensitization have yet remained unclear and further studies will have to be 
performed to unravel the relevance of this on the clinical outcome therein. 
In summary our initial screen of the first prospective study of drug hypersensitivity has 
established a few cardinal points:  
 The LTT proved its usefulness in the experimental diagnosis of piperacillin 
hypersensitivity. Confirmation from clinical data will be required as some patients 
clinically diagnosed as hypersensitive did not develop drug-specific T-cell 
 196 
 
responses. As stated earlier in this chapter, this may be due to misdiagnosis, a test 
deficiency or the absence of a retrospective sample and this can only be validated 
after a rechallenge with the drug.  
 A relationship exists between piperacillin-specific T-cell responses and piperacillin-
specific antibody levels during desensitisation. Further studies need to be carried 
out to explore the relevance of this relationship. Questions should also involve 
determining if this phenomenon is restricted to piperacillin hypersensitivity or 
applicable to drugs in general.  
 Due to the chronic management of these patients with relatively high doses of β-
lactams, most of the patients showed the presence of low levels of antidrug 
antibodies specific to piperacillin even in the absence of hypersensitivity. Thus, 
the presence of antidrug antibodies alone isn’t an indication of hypersensitivity 
occurring, even though a reduction in the amount of circulating piperacillin-
specific antibodies in hypersensitive patients is noted during desensitisation. 
 Finally, there are no set time points during which these reactions arise though the 
data suggests a preference for the first and second courses of piperacillin 
administration. 
Thus, with proper sample collection and patient recruitment the LTT has shown its 
potential relevance in the determination of the onset of piperacillin-specific T-cell 
responses as a precursor to the manifestation of clinical hypersensitivity. However, this 
conclusion is dependent on the reconciliation of patients’ experimental and clinical data 
in order to generate a clearer picture. 
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CHAPTER 6 
THE EFFECT OF IgG ANTIBODIES ON THE ACTIVATION OF DRUG-SPECIFIC T-
CELLS FROM PIPERACILLIN HYPERSENSITIVE PATIENTS WITH CYSTIC 
FIBROSIS. 
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6.0 Introduction 
 
The humoral immune pathway classically terminates with the secretion of antibodies 
derived from a culmination of activities primary of which are B and T cell activation. The 
activation of B cells, due to biological or chemical agents could be T cell independent or 
dependent. T cell dependent responses have also been shown to play a role in the 
generation of antidrug antibodies (Jawa, Cousens et al. 2013).  
While the role of T-cells in B-cell activation and differentiation leading to the 
development of the B cell response has been clearly elucidated, the same cannot be said 
of the role B cells and secreted antibodies play in the proliferation of T cells, and 
subsequent development of the T-cell response. Generally  B cells have an established 
capacity for antigen presentation (Rodriguez-Pinto 2005, Chen and Jensen 2008) even 
though they are less potent in this regard when compared to dendritic cells (Corinti, 
Medaglini et al. 2000). While earlier studies have suggested antibody regulation of 
immune expression via the enhancement of antigen presentation (Celis, Zurawski et al. 
1984), the potential of B cells and their secretions to have a pronounced effect on T cell 
function via other means should also not be disregarded. This is partly due to the 
presence of co-stimulatory molecules (Gimmi, Freeman et al. 1991, Grewal and Flavell 
1996) and the B cell capacity to also secrete factors with known regulatory (Taga and 
Tosato 1992, Pistoia 1997, Moore, de Waal Malefyt et al. 2001, Anderton and Fillatreau 
2008) and inflammatory functions (Locksley, Killeen et al. 2001, Ireland and Monson 
2011).  
Immunoglobulin G (IgG) is the most abundant immunoglobulin isotype present in human 
serum. The Fc portion of the IgG molecule (see figure 8, chapter 1) contains binding sites 
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for complement (C1q), IgG-Fc receptors (FcR) on effector cells and neonatal Fc receptor 
(FcRn). The subclasses of IgG which include IgG1, IgG2, IgG3 and IgG4 share a 90% 
homology but still possess unique profiles. The individuality of these subclasses with 
respect to effector function exists mainly due to structural variations in the hinge regions 
(Hamilton 1987) and amino acid differences found in the N-terminal CH2 domain though 
other factors have been postulated  (Hovenden, Hubbard et al. 2013, Theo and Gestur 
2014). These variations give rise to the differential binding of IgG subclasses to the C1q 
and FcR sites which in turn also determines the elicitation of a number of effector 
functions.  
Table 6.1 Properties of Human IgG subclasses. Adapted from (Vidarsson, Dekkers et al. 2014) 
 IgG1 IgG2 IgG3 IgG4 
Molecular mass 146 146 170 146 
Amino acids in hinge region 15 12 62a 12 
Inter-heavy chain disulphide bonds 2 4b 11a 2 
Susceptibility to proteolytic enzymes ++ +/- +++ + 
Mean adult serum level (g/l) 6.98 3.8 0.51 0.56 
Proportion of total IgG (%) 60 32 4 4 
Half-life (days) 21 21 7/~21a 21 
Placental response ++++ ++ ++ +++ 
Complement activation     
Notes:  a Depends on allotype          b For A2 isomer 
The effect of immunoglobulins on T-cell responses is exemplified through the use of 
purified intravenous immunoglobulin G (IVIG) in vitro with isolated PBMCs and CD3+ T 
cell populations (Lee, Koh et al. 2001, MacMillan, Lee et al. 2009). IVIG pooled from 
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multiple volunteers has been shown to impede immune cell effector functions, such as 
the activation and proliferation of T-cells and T-cell dependent polyclonal 
immunoglobulin production by B lymphocytes. The mechanisms underlying these effects 
are rather unclear with some groups suggesting an indirect mechanism via ancillary cells 
while others have suggested a direct T cell interference (Kondo, Ozawa et al. 1991, Bayry, 
Lacroix-Desmazes et al. 2003, Tha-In, Metselaar et al. 2007, Heidt, Roelen et al. 2009). 
Existing data shows that secreted immunoglobulins exert a certain amount of influence 
on the immune process. Thus, based on this current hypothesis we aimed in this chapter 
to characterize the regulatory activity of the antidrug antibodies on T cells from a 
piperacillin hypersensitive patient. Initially we attempted to generate B-cell lines 
secreting piperacillin-specific IgG (see chapter 3) to compare their antigen presenting 
capacity against IgG negative B cell lines and their influence on the nature of the induced 
T-cell response. Since the piperacillin-specific IgG secreting lines were not generated, an 
alternative strategy was adopted. Specifically piperacillin-responsive T-cell lines were 
cultured with drug and antigen presenting cells in the presence and absence of various 
plasma some of which contained piperacillin-specific IgG. 
 
6.1   Methods 
 
The methods employed include T cell proliferation assays, the ELISpot assay, and FACS 
analysis as illustrated in sections 2.1.9, 2.2.1, and 2.2.2.2 of the second chapter of this 
thesis. 
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6.2  Results  
 
6.2.1 Quantification of antidrug antibodies in piperacillin hypersensitive 
patient plasma 
The hapten inhibition assay (as previously described in chapter 2) was performed on 
plasma from two piperacillin hypersensitive patients. The amount of anti-piperacillin 
antibody which is the difference in antibody detection between the haptenated protein 
adduct (BSA:Pip) and the hapten inhibited (BSA:Pip + pip) samples was then quantified 
with antibody concentrations of 34.73 ng/ml and 28.80 ng/ml observed for patients 1 and 
2 respectively (Figure 6.1). 
 
 
 
 
 
 
 
Figure 6.1. Detection of piperacillin-specific antibodies in hypersensitive patients. Graphs showing hapten 
inhibition assays carried out on 2 hypersensitive patient samples. High binding flat bottomed 96 well plates 
were pre-coated with 20 µg BSA:piperacillin adduct employed as an antigen. After washing, 100 µl of 
hypersensitive patient plasma with and without prior incubation with the hapten was added to wells and 
an ELISA carried out. Absorbance was read with an automated plate reader (Dynatech MR600).  
 
 
 
 
Patient 1             Patient 2 
 B
SA
 B
SA
:P
ip
 B
SA
:P
ip
+P
ip
0
50
100
150
200
250
                Treatment conditions
Ig
G
 (
n
g
/m
l)
 B
SA
 B
SA
:P
ip
 B
SA
:P
ip
+P
ip
0
50
100
150
200
               Treatment conditions
Ig
G
 (
n
g
/m
l)
 203 
 
6.2.2 Proliferation assay to determine piperacillin-specificity of T-cell 
clones 
Nineteen T-cell clones were generated from hypersensitive patient 1 and eleven clones 
from patient 2, comprising twenty clones in total from both hypersensitive patients.  
T cell clones from hypersensitive patients 1 and 2 were seeded in duplicate at 
concentration of 50 x 104 cells/well (100 µl) in a u-bottomed 96 well plate, with varying 
drug concentrations in R9 medium. To each of these wells of 1.0 x 104 autologous 
irradiated EBV transformed B-cells were added as a source of antigen presenting cells. 
The plates were then incubated at 370C and 5% CO2 for 48 h. At the last 16 h of culture, 
cells were pulsed with [3H] thymidine and plates subsequently counted using a beta 
counter. Eight clones from patient 1 and 3 clones from patient 2 were identified as being 
drug specific (figure 6.2a and 6.2b). The maximal proliferative responses seen over a 
range of doses for the different drug specific clones was assessed and graphs plotted 
(Figure 6.3a and 6.3b).  
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Figure 6.2  
Proliferation assay to determine piperacillin-
specificity of T-cell clones. 
PBMCs (1.5 × 105 cells in 100 μL) from 
hypersensitive patient 1 (a) and 2 (b) were 
incubated with graded concentrations of 
piperacillin (0.125-4 mM in 100 μL) in 96-well U-
bottom plates. Plates were incubated at 37°C 
under an atmosphere of 5% CO2 for 48 hours. 
[3H]-thymidine (0.5 μCi/well) was added for the 
final 16 hours of incubation and T-cell 
proliferation measured using scintillation 
counting in a Beta counter. The data was 
analysed and a stimulation of index (SI) ≥ 2 
considered as an indicator for specificity. (c) 
Table of the total number of T-cell clones 
generated from both patients. 
 
 
(c) 
(a) 
 205 
 
Patient 1
Ø 0
.1
0
.5 1.
0
4
.0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0 Ø 0
.1
0
.5 1.
0
0
50000
100000
150000
200000
250000 Clone 635
Clone 669
Clone 686
Clone 695
Clone 710
Clone 715
Clone 728
Clone 742
Piperacillin (mM)
3H
-P
ro
lif
e
ra
ti
o
n
 (
cp
m
)
 
 
Ø
0
.5 1.
0
2.
0 Ø
0
.5 1.
0
2.
0 Ø
0
.5 1.
0
2.
0
0
20000
40000
60000
Clone 14
Clone 18
Clone 43
Patient 2
Piperacillin (mM)
3H
-P
ro
lif
er
at
io
n 
(c
p
m
)
 
  
 
 
   
 
 
 
 
Patient ID Pip 
specific 
clones 
CD4+ 
(%) 
CD8+ 
(%) 
 
Patient 1 
 
8 
 
100% 
 
— 
 
Patient 2 
 
3 
 
100% 
 
— 
 
(b) 
(c) 
Figure 6.3  
Dose response assay for piperacillin-
responsive T-cell clones. 
PBMCs (1.5 × 105 cells in 100 μL) from 
hypersensitive patient 1 (a) and 2 (b) 
were incubated with graded 
concentrations of piperacillin (0.1-4 mM 
in 100 μL) in 96-well U-bottom plates. 
Plates were incubated at 37°C under an 
atmosphere of 5% CO2 for 48 hours. [3H]-
thymidine (0.5 μCi/well) was added for 
the final 16 hours of incubation and T-cell 
proliferation measured using scintillation 
counting in a Beta counter. The data was 
analysed and a stimulation of index (SI) ≥ 
2 considered as an indicator for 
specificity. (c) Table of the total number 
of T cell clones generated from both 
patients. 
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6.2.3 CD4+ and CD8+ phenotyping of piperacillin-specific T-cell clones 
After assessing the piperacillin-specificity of the various T cell clones obtained from 
hypersensitive patients, we proceeded to identify the phenotype expressed by clones 
using flow cytometry analysis. Each T cell clone confirmed to be piperacillin-specific was 
counted and ≤ 5 x 105 cells of the T cell clone split equally and transferred into two FACS 
tubes. Cells were then stained with 3 µl of CD4 and CD8 fluorochrome antibodies, in the 
dark. After incubation at 40C for 20 minutes, the tubes were washed with 1 ml FACS 
buffer and the supernatant discarded. The samples were then either re-suspended in 
200µl of FACS buffer and the samples read on a FACS canto II flow cytometer. From the 
11 clones tested 9 (73 %) were CD4+, 2 (27 %) were CD8+ (Figure 6.4).  
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Figure 6.4. Flow cytometry analysis of piperacillin-specific T-cell clones.  T cell clones were generated from 
2 patients and stained with CD4 and CD8 fluorochrome antibodies to determine the phenotype (i) shows a 
dot plot representation of some piperacillin-specific T-cell clone phenotypes from patients 1 and 2 (ii) Table 
of the total number of piperacillin-specific T cell clones generated from both patients (iii) graph of the 
CD4+, CD8+ and CD4CD8 proportion of T-cell clones from the total number of clones generated from both 
patients. 
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6.2.4 Cytokine secretory profile of T-cell clones 
Coating antibodies for the anti-cytokine antibodies were diluted in sterile PBS, pH 7.4. 
Prior to the addition of these antibodies, the PVDF membrane of the ELISpot plates were 
pre-wet with ethanol and then washed using Hanks balanced salt solution (HBSS) as 
described in materials and methods. Following the addition and overnight incubation of 
the required coating antibody solution at 4-8°C, 1.5 x 105 piperacillin-specific T-cell clones 
with 5 x 104 autologous EBVs alone, and with 2 mM piperacillin. 5 g/ml PHA plates were 
incubated at 370C and 5% CO2 for 48 h in foil paper. The detection antibodies for T cell 
cytokines and a streptavidin-ALP (1:1000) substrate was employed for the development 
of the plates. Six clones were found to secrete IL-5, GB, IL-13 and IFN-γ.  Following 
stimulation with piperacillin five clones (635, 669, 695,728 and 742) secreted IL-5. 
Granzyme B was not secreted from drug-stimulated clones. In addition to IL-5, clone 742 
expressed high amounts of IL-13. IFN-γ was expressed by all the clones, though to 
different extents. A high level of IFN-γ expression was seen with clones 635, 669 and 695 
while a lower expression was seen with clones 686, 728 and 742 (Figure 6.4).   
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Figure 6.5 ELISpot Cytokine secretory profiles of hypersensitive patient 1. ELISpot plates were pre-coated 
with anti-IL-5, anti-GB, anti-IL-13, and anti-IFN-γ according to the manufacturers’ instructions and incubated 
overnight at 4oC. Cells were harvested and transferred to each well and incubated for 48 h. ELISpot plates 
were developed according to the manufacturers’ instructions and the wells left to air dry. Data were 
analysed with images captured using an AID ELISpot machine (a) and graphs plotted (b). 
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6.2.5 Proliferation assay to define the effect of antidrug antibodies on the 
piperacillin induced proliferative response of drug-specific T-cells 
 
 Three T cell clones (clones 669, 715, 742) from patients 1 and 2 were selected for the 
experiment. Clones (1.5 X 105) were cultured with autologous irradiated EBVs (5 x 104) 
and piperacillin in the presence of 1, 10 and 20 µl of plasma bearing anti-piperacillin 
antibodies from hypersensitive patients to corresponding wells to finally achieve a total 
well volume of 200 l. The plates were then incubated at 370C and 5% CO2 for 48 h. 
Proliferative responses were measured by the addition of [3H] tritriated thymidine for 
the final 16 h of the experiment. In the absence of autologous plasma piperacillin 
activated the clones with concentrations ranging 0.1 mM to 1 mM of piperacillin.  
Autologous plasma was shown to inhibit the proliferative responses of T cells in a 
concentration-dependent fashion with a clone tested with at least one concentration of 
the drug. The results reached statistical significance with 1 mM piperacillin and 20 µl of 
plasma (p = 0.0307) [figure 6.6a]. With one clone (clone 742) inhibition of piperacillin 
induced T cell proliferation was observed at the lower drug concentration of 0.01 mM 
rather than at the higher dose of 1 mM as observed with the other two clones (figure 
6.6c). The grouped data indicates a significant reduction in T cell proliferation with 
groups in which 20 µl of anti-piperacillin antibody bearing plasma were incorporated (p ≤ 
0.05) [figure 6.6d].  
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Figure 6.6 Effect of antidrug antibody bearing plasma on the T-cell proliferative responses. Three 
piperacillin-specific T-cell clones (1.5 × 105 cells in 100 μL) from hypersensitive patient 1 (a, b and c) were 
incubated with graded concentrations of piperacillin (0.01 – 1.0 mM in 100 μL) and anti-piperacillin antibody 
bearing plasma (0.01 – 20 µL in 100 μL) in 96-well U-bottom plates. Plates were incubated at 37°C under an 
atmosphere of 5% CO2 for 48 h. [3H]-thymidine (0.5 μCi/well) was added for the final 16 h of incubation and 
T-cell proliferation measured using scintillation counting in a Beta counter. The data were analysed by 
Students T test with p < 0.05 considered significant (* denotes p = 0.05 to 0.01) (d) Proliferative responses 
at 1 mM of three piperacillin-specific T-cell clones (1.5 × 105 cells in 100 μL) from hypersensitive patient 1 
were analysed by Students T test with p < 0.05 considered significant (* denotes p = 0.05 to 0.01). 
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In subsequent experiments, 1.5 x 105 piperacillin – specific T cell clones (635, 686 from 
patient 1 and 14 from patient 2) were cultured with autologous irradiated EBVs (5 x 104) 
and piperacillin in the presence of 20 µl of autologous plasma from naïve volunteers 
added to corresponding wells to finally achieve a total well volume of 200 l. The plates 
were then incubated at 370C and 5% CO2 for 48 h. Proliferative responses were measured 
by the addition of thymidine for the final 16 h of the experiment. A significant attenuation 
of drug-specific T cell clone proliferation due to 1 mM piperacillin in the presence of 
plasma was also observed (figure 6.7a, b and c).  
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Figure 6.7  
T-cell proliferation assay using T cell clones with naïve 
volunteer autologous plasma. 
Three piperacillin-specific T-cell clones (1.5 × 105 cells in 100 
μL) from hypersensitive patient 1 were incubated with 1 mM 
piperacillin in 100 μL and IgG bearing plasma (20 µL in 100 μL) 
in 96-well U-bottom plates. Plates were incubated at 37°C 
under an atmosphere of 5% CO2 for 48 hours. [3H]-thymidine 
(0.5 μCi/well) was added for the final 16 hours of incubation 
and T-cell proliferation measured using scintillation counting 
in a Beta counter. The data was analysed by Students T-test 
with p < 0.05 considered significant (* denotes p = 0.05 to 
0.01). 
 
(a) (b) 
(c) 
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6.2.6 ELISpot assay to define the effect of anti-piperacillin antibodies on 
the piperacillin induced IFN-γ secretion of drug-specific T-cells 
Experiments were also carried out to determine the effect of plasma from hypersensitive 
patients and naïve volunteers on IFN-γ secretion from drug-specific clones.  
Coating antibodies for the anti-cytokine antibody were diluted in sterile PBS, pH 7.4. Prior 
to the addition of the antibody, the PVDF membrane of the ELISpot plate was pre-wet 
with ethanol and then washed using Hanks balanced salt solution (HBSS) as described in 
materials and methods. Following the addition and overnight incubation of the required 
coating antibody solution at 4-8°C, 1.5 x 105 piperacillin-specific T-cell clones with 5 x 104 
autologous EBVs alone, and with 2 mM piperacillin and 5 g/ml PHA plates were 
incubated at 370C and 5% CO2 for 48 h. The detection antibody for IFN-γ and a 
streptavidin-ALP (1:1000) substrate was employed for the plate development. The wells 
left out to air dry and spots were visualised using an AID ELISpot reader. The 
incorporation of 20 µl naïve volunteer plasma in the T cell proliferation assay (n = 4) did 
not produce a reduction in the total IFN-γ secretion; depicted as number of spots in the 
wells, from drug-specific T cell clones when compared to the piperacillin wells alone 
(figure 6.8a). The introduction of 20 µl piperacillin hypersensitive patient plasma bearing 
antipiperacillin antibody on the other hand showed the attenuation of IFN-γ cytokine 
secretion with all but one clone (6.8b). 
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(a) Naïve volunteer plasma minus piperacillin-specific antibody. 
 
 
 
(b) Hypersensitive patient plasma containing piperacillin-specific antibody 
 
 
 
Figure 6.8 IFN-γ ELISpot using piperacillin-specific T-cell clones. ELISpot plates were pre-coated with anti-
IFN-γ according to the manufacturers’ instructions and incubated overnight at 4oC. Cells were harvested 
and transferred to each well and incubated for 48 h under the stipulated culture conditions with (a) naïve 
volunteer plasma and (b) hypersensitive patient plasma containing piperacillin-specific antibody. ELISpot 
plates were developed according to the manufacturers’ instructions and the wells left to air dry. Data were 
analysed with images captured using an AID ELISpot machine. 
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6.3  Discussion 
 
As stated in earlier chapters, B cells and secreted antibodies play a significant role in the 
immune response. Delayed hypersensitivity reactions in CF patients due to β-lactam 
administration, have been shown to involve antigen-specific T cells. However, the 
contribution of other cellular components of the immune system especially B-cells, 
immunoglobulins and antidrug antibodies to the iatrogenic disease has not been 
established.  
High levels of antigen specific IgG4 antibodies have been found to be beneficial in 
specific immunotherapy (SIT). SIT is an immune-modifying therapy that has been 
recommended for the treatment of allergic rhinitis, venom hypersensitivity, some drug 
allergies and mild bronchial asthma. The induction of immunological tolerance and of 
blocking IgG4 antibodies through repeated exposure to allergen(s) being the major 
characteristics (Holgate and Polosa 2008). 
Different attempts at explaining this association suggest that (i) high levels of IgG4 
production is indicative of Treg activation culminating in the production of anti-
inflammatory factors such as IL-10 and TGF-β; and (ii) IgG4 antibodies have the capacity 
to act as blocking antibodies. B cells have the ability to produce antibodies and cytokines 
such as IL-10 though the relationship between the production of these cytokines, 
antigen-specific IgG and the attenuation of hypersensitivity symptoms still remains 
poorly defined (Hagan, Blumenthal et al. 1991, Hussain, Poindexter et al. 1992, Aalberse 
and Platts-Mills 2004, Aalberse 2011).  
 216 
 
Plasma containing immunoglobulins and also purified IVIG alone has been shown to 
inhibit the proliferation of T cells. Whole PBMCs have been employed in the analysis of 
these effects in spite of the inherent drawbacks of coexisting functional immune cells 
(Klaesson, Ringden et al. 1993, Lee, Koh et al. 2001).  Thus, to eliminate the presence of 
auxiliary cellular components interfering with the T cell response to IVIG in a synergistic 
or otherwise manner, CD3+ cells purified from mononuclear cells have also been studied 
(Heidt, Roelen et al. 2009, Aubin, Lemieux et al. 2010) and similar inhibitory responses 
have been detected. Additionally the antibody concentration in plasma required to elicit 
that given inhibitory response has not been determined, though dose response assays 
have been carried out in vitro using IVIG (Aubin, Lemieux et al. 2010).  I hoped that 
through this study we would be able to fill this gap.  
Anti-piperacillin antibodies were detected and quantified in the plasma of piperacillin 
hypersensitive patients (see chapter 3) out of which two patients [see figure 6a (i) – (iv)] 
were selected. For the current study T-cell clones and EBV immortalized B cells were then 
generated from these two patients. Patients were selected from the cohort of 
hypersensitive patients that bore anti-piperacillin antibodies based on the ability to 
generate both immortalized B-cell lines and piperacillin-specific T cell clones.  Drug-
specific T-cell clones were generated from the hypersensitive patients and characterized 
in terms of cellular phenotype and function. All clones (both CD4 and CD8+) were 
stimulated to proliferate with piperacillin in a concentration-dependent manner.  
 Six clones (CD4+) from patient 1 secreted IFN-γ. The majority (5) of these clones also 
secreted IL-5. However, only one clone secreted IL-13. A larger proportion of clones from 
patient 2 were CD8+ when compared to patient 1, even though the Th1/Th2 archetype has 
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been used to explain the basis of different disease conditions (Wynn 2004, van 
Oosterhout and Motta 2005). Unfortunately, a large proportion of the T cell clones 
including all CD8+ clones obtained from this patient failed to proliferate properly after 
repeated re-stimulation which prevented their use in subsequent assays. For this reason 
the assays were largely based on Th2 secreting CD4+ T cell clones. If plasma from the 
patients blocked proliferative responses to piperacillin, these same clones would have 
been used to study cytokine release in the presence and absence of piperacillin-specific 
IgG. 
The proliferative responses of these clones were then assessed utilizing EBV 
immortalized B cells as antigen processing cells and different amounts of autologous 
plasma bearing antidrug antibodies. The objective of these experiments was to establish 
a limit at which T cell proliferation could be blocked.  The expectation was that a marked 
inhibition of T cell proliferation would have been observed at lower concentrations of 
plasma.  
A significant reduction in T-cell proliferation was observed with all clones from the two 
patients with 20 µl of piperacillin-specific antibody bearing plasma. This translated to 
concentrations of approximately 3.43 pg/ µl in patient 1 and 2.88 pg/ µl in patient 2 of 
piperacillin-specific IgG which presented a uniform inhibition of proliferation. Lower 
concentrations of antibody had less of an inhibitory effect. Unexpectedly, this reduction 
was not specific to piperacillin antibody bearing plasma as 20 µl of plasma from naive 
volunteers also produced the same response. The use of whole plasma rather than 
purified drug-specific antibodies present the possibility that these non-specific protein 
interactions could have been responsible for the similarities in responses obtained. 
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Therefore using the ELISA to determine if the reduction could be due to the presence of 
specific-IgG or total IgG as a whole was difficult. Following piperacillin stimulation of 
piperacillin-specific T-cell clones there was an increased secretion of IFN-γ. The 
incorporation of naïve and piperacillin antibody bearing plasma produced varying levels 
of IFN-γ secretion from T cell clones. Naïve volunteer plasma did not affect the IFN-γ 
secretion from piperacillin-specific T cell clones, while the introduction of plasma bearing 
antipiperacillin antibody produced an attenuation of cytokine secretion with all but one 
clone used in the assay.  
Though different chromatographic methods of purification of these antibodies using  
protein G Sepharose, protein A/G Sepharose, polyethylene glycol and caprylic acid-
ammonium sulphate precipitation do exist (Bergmann-Leitner, Mease et al. 2008), time 
constraints made the purification of these antibodies impossible. The seeming 
inconsistency that exists between data that was generated from the proliferation and 
cytokine release assays suggests that more work would have to be carried out to actually 
define the roles played therein. 
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7.0 Final Discussion 
 
Drug hypersensitivity reactions make up a significant proportion of ADRs and have been 
extensively studied in terms of the involvement of the immune system in the 
pathogenesis. Moreover, in recent years we are beginning to understand the chemical, 
pharmacological and genetic factors that contribute towards individual susceptibility 
(Pichler, Naisbitt et al. 2011). Cells of the innate and adaptive immune system and 
antibodies released by B cells (Antunez, Martin et al. 2006, Posadas and Pichler 2007, 
Bircher and Scherer 2010) are believed to be responsible for the elicitation of these 
reactions. T cells have been previously identified to play a significant role in the 
pathogenesis of these reactions, but the effect of B cells has yet to be defined (Whitaker, 
Naisbitt et al. 2012). 
Hypersensitivity reactions were historically classified according to the time and onset of 
clinical symptoms; i.e., immediate or delayed hypersensitivity reactions. The importance 
of B cells can be viewed from the participation of these cells or their secretions in 
patients with delayed and immediate forms of hypersensitivity. Immediate 
hypersensitivity reactions primarily involve IgE-mediated release of histamine and other 
mediators of inflammation from mast cells and basophils. Delayed reactions on the other 
hand are essentially mediated by mononuclear leukocytes with cell components playing 
different but equally important roles of antigen presentation as seen with the B cells and 
dendritic cells, immune regulation and antigen killing as observed with CD4+ and CD8+ T 
cells (Rodriguez-Pinto 2005, Zhu, Yamane et al. 2010). In addition to their roles mediators 
of immediate hypersensitivity reactions, IgA and IgG, both of which are secreted by B 
lymphocytes, have been detected in certain patients with delayed hypersensitivity 
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(Vojdani, O'Bryan et al. 2008); however, their role in elicitation/regulation has not been 
fully defined. 
Based on the roles played by B lymphocytes and their secretions an important objective 
of this thesis was to modify existing methods and eventually develop new methods to 
detect drug-specific B-cell antibody secretion using samples isolated from piperacillin 
tolerant and hypersensitive patients with CF. Piperacillin was selected for 2 reasons. First, 
it is a β-lactam antibiotic and the chemistry of antigen formation has been delineated. In 
fact, the amino acid residues modified by the drug hapten have been characterized on 
plasma albumin of patients exposed to a therapeutic treatment course (Whitaker, Meng 
et al. 2011). Secondly, piperacillin exposure is associated with a high frequency of 
hypersensitivity reactions in patients with CF (Koch, Hjelt et al. 1991, Wills, Henry et al. 
1998, Burrows, Nissen et al. 2007); thus, clinical samples were readily available for 
functional studies. We also generated and characterized piperacillin-protein adducts for 
use as antigens to detect the presence of antibodies in the hypersensitive patients. 
Finally, the methods utilized enabled us explore, the B cell-mediated regulation of drug 
antigen-specific T cell proliferation.  
An extensive search of existing literature describing the molecular basis of the immune 
response before, during and after the onset of hypersensitivity reactions provided us 
with a foundation on which to base our investigations. Our searches brought to fore the 
basic assays utilized in the confirmation of hypersensitivity (Nyfeler and Pichler 1997, 
Jurado-Palomo, Cabanas et al. 2010), and more complex characterization of cellular 
involvement with respect to the pathology and eventual clinical consequence (Gerber 
and Pichler 2004, Naisbitt, Farrell et al. 2005, Krumbholz, Pellkofer et al. 2007, Harrer, 
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Lang et al. 2010). From this literature review, a host of cell culture-, colorimetric- and 
proteomic-based assays were selected and applied to achieve the aims stipulated above. 
In the first experimental chapter I focussed on the development and optimization of cell 
culture methods for the detection of specific B cell responses to piperacillin haptens 
using samples from hypersensitive and tolerant patients with CF. I also attempted to 
apply molecular methods to assess the presence or not of piperacillin-specific IgG and 
IgG subclasses in the same cohort of patients, while aiming to develop long-lived B cell 
lines equipped with the ability to secrete drug-specific antibodies. Our initial thoughts 
being that the development of these lines was essential in producing a B cell T cell co-
culture system that closely mimics the in vivo situation to study the regulation of antigen-
specific T cell responses by B cells. 
Piperacillin hypersensitivity was confirmed in allergic patients using the lymphocyte 
transformation test. This test used [3H] thymidine to detect the proliferation of T cells 
stimulated with mitogen or tetanus toxoid (positive controls), piperacillin and medium 
alone. An increase in incorporated radioactivity after a 6 day culture period in drug-
treated wells is indicative of sensitization. The assay has been applied previously to 
diagnose a range of drug hypersensitivity reactions and a high sensitivity (positive 
response in hypersensitive patients) and specificity (negative response in tolerant 
controls) has been reported (Naisbitt, Nattrass et al. 2014). T-lymphocytes from 
piperacillin hypersensitive patients were stimulated to proliferate in a dose-dependent 
manner when cultured with the drug. In contrast, T-lymphocytes from tolerant controls 
were not specifically stimulated. Utilising similar methods, the phenotype of B-cells from 
tolerant and allergic patients was assessed in cultures in the presence and absence of 
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piperacillin. A significant increase in CD27 expression on CD19+ B cells was detected by 
flow cytometry when cells from hypersensitive patients were cultured with piperacillin. 
In contrast, an increase in CD27 expression was not detected on cells from tolerant 
controls. CD27 is a B-cell activation marker and its expression is up regulated upon IgG 
release. The increase in expression of CD19+CD27+ B cells in hypersensitive patient PBMC 
after drug stimulation in vitro gave a clear indication of the presence of immunological B-
cell memory. Marked secretion of IgG by PBMCs in response to piperacillin treatment 
was also observed with hypersensitive patients using a B cell ELIspot that detects 
secreted IgG. B cells from naïve donors or tolerant patients were not stimulated to 
secrete IgG with piperacillin. Quantification of piperacillin-specific IgG and IgG subclasses 
was not achievable by ELISA using cell culture supernatants due to the small amounts of 
antibody present therein, but was performed on whole plasma isolated directly from 
patient blood. Piperacillin hapten-specific IgG was detected in significant quantities in 
hypersensitive patient plasma. A bias for IgG2 over other subclasses was also shown.  
Three hundred and forty eight B-cell lines were generated from three hypersensitive 
patients. 10.05 % of the lines secreted IgG, but drug-specific IgG was not detected. 
Further attempts to modify the method of B cell line generation were attempted to 
explore the influence T cells have on the production of drug-specific antibodies in vivo. 
Specifically, T-cell cytokines were introduced to the B cell culture system in an attempt to 
influence B cell differentiation. This resulted in an increase in the efficiency of antibody 
production (99.2%) but similar outcomes with respect to drug-specific antibody 
production. Lines producing piperacillin hapten-specific IgG were not detected.  
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Despite the inability of our modified culture system to generate B cell lines secreting 
quantifiable amounts of drug-specific antibody we were able to confirm the validity of 
the cell culture and molecular methods used in the detection of B cell responses. In doing 
so we were able to establish a profile for the generation of piperacillin-specific IgG 
producing CD19+CD27+ cells. The absence of these cells in naïve patients and their 
marked visibility in hypersensitive patients being an initial pointer implicating the 
generation of these antibodies in the pathogenesis of piperacillin hypersensitivity. 
However, the roles they play in elicitation/regulation of the immune response and their 
influence on the proliferative capacity of T-cells still had to be characterized. 
The second experimental chapter was primarily concerned with generation and 
characterization of β-lactam protein adducts and the influence of adduct structure on the 
propagation of antibody mediated B-cell responses in hypersensitive patients. The 
covalent binding of drugs or haptens, as reactive derivatives of drugs are often referred 
to as, to endogenous proteins has been established as a precursor to the onset of 
immune activation (Naisbitt, Gordon et al. 2000, Schnyder and Pichler 2009). The in vitro 
replication of this concept known as the hapten theory of drug hypersensitivity has 
focussed in recent years on T-cell immunogenicity. β-lactam-protein adducts have been 
generated and characterized to define the nature of the amino acid residue modifications 
which lead to development of epitopes for T-cells. Drug concentration and duration of 
exposure influence the extent of drug binding as well as the sites of modification and this 
impacts on whether or not a T-cell response is detected. In the current study HSA was 
initially used as a protein carrier however unconjugated HSA resulted in high 
backgrounds in ELISA assays to detect IgG. Other authors have experienced and 
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documented similar findings (Ming Kei Chung, Jacques Riby et al. 2010, Whitaker, Meng 
et al. 2011, Ariza A, Mayorga C et al. 2015). Thus, a suitable replacement to HSA that had a 
low background in the ELISA, but also possessing the requisite lysine residues to 
facilitate β-lactam binding was sought. Eventually BSA was selected. A clear relationship 
was observed between the additive increase in conjugate molar ratio to hapten density 
and subsequently to detection of specific IgG antibodies in patient plasma. The absence 
of cross reactivity with other β-lactam-BSA adducts highlighted the specificity of the 
antibodies to piperacillin the drug hapten the patients were exposed to at the time of the 
hypersensitivity reaction. 
Even though I was successful in detecting the presence of piperacillin-specific IgG 
antibodies in plasma of hypersensitive patients, the role these antibodies play in the 
disease pathogenesis had not been explored. Hence, the next chapter utilized samples 
collected prospectively from patients exposed to multiple courses of piperacillin some of 
whom went on to develop an allergic reaction. The first priority was to characterize the 
CF patient cohort to assess the various trends including T cell proliferation, total and 
drug-specific antibody levels, and specific cytokine profiles before, during and after drug 
administration.  
A few salient points were observed from our analysis of drug-specific T cell responses. 
First, most patients classified clinically as tolerant yielded reproducible negative 
lymphocyte transformation test results with piperacillin. Thus, the assay has a high 
specificity in this patient cohort. Secondly, piperacillin-specific lymphocyte proliferative 
responses were detected in the acute phase of certain clinically diagnosed 
hypersensitivity reactions. An important component of the clinical design was to 
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incorporate a retrospective blood sample at least 1 month after resolution of 
hypersensitivity. Positive lymphocyte transformation from 45% of hypersensitive patients 
was observed even if the acute sample yielded negative results. Since sample collection 
is on-going, several retrospective samples are still to be collected; hence, it is currently 
not possible to state the percentage lymphocyte transformation test positivity in the 
hypersensitive patient group. Thirdly, a small sub-set of tolerant patients showed positive 
lymphocyte transformation test results during the final course of piperacillin, but are still 
classified clinically as tolerant to the drug. Thus, it will be interesting to observe whether 
these patients develop a hypersensitivity reaction when next exposed to the drug.  
Fourthly, not all reactions clinically diagnosed as piperacillin hypersensitivity reactions 
were confirmed using the acute or retrospective lymphocyte transformation test. This 
may be because certain reactions are mediated via non-immune mechanisms (Bernstein 
1995 , McKenna and Leiferman 2004). Alternatively, the negative result may relate to a 
misdiagnosis or a test deficiency. Finally, analysis of the drug-specific T-cell responses of 
individual patients exposed to repeated piperacillin courses revealed that there are no 
specific time-points during which reactions arise.   
Significant differences in piperacillin-specific antibody levels were found to exist between 
lymphocyte transformation test positive and negative patients. Higher levels of 
piperacillin-specific IgG were detected in the lymphocyte transformation test positive 
samples. A small number of hypersensitive patients were recruited to the study as they 
were timetabled to undergo desensitisation (graded drug challenge). Following 
desensitisation most hypersensitive patients are able to tolerate a therapeutic course of 
piperacillin. Interestingly, lower levels of piperacillin-specific IgG were detected 24h post-
desensitisation and each of these patients tolerated piperacillin. Finally, low levels of 
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piperacillin-specific antibodies were detectable irrespective of the presence or not of 
hypersensitivity diagnosis. This may be attributed to the long term management of these 
patients and exposure to repeated courses of piperacillin. To conclude, the presence of 
anti-drug antibodies alone does not seem to represent a diagnostic characteristic of 
hypersensitivity. However, their occurance in high levels does seem to relate to the 
development of a piperacillin-specific cellular immune response. Further studies need to 
be carried out to determine the clinical implications of this relationship. 
The ability of intravenous antibody formulations, specifically IVIG to inhibit T cell 
proliferation has been established. This motivated us to explore whether plasma levels of 
circulating antibodies modulate piperacillin-specific T-cell responses in vitro. Classical 
proliferation assays were employed using piperacillin-specific T cell clones from 
hypersensitive patients in the presence or absence or culture medium supplemented 
with various amounts of antibody containing plasma. The ultimate aim being the 
appraisal of the resultant ability or inability as the case may be to inhibit the proliferation 
of T cells. The initial inference was that the assay was not sensitive enough as inhibition 
of proliferation though present occurred at seemingly high volumes of plasma with lower 
concentrations being unable to facilitate any inhibition. This was quashed to some extent 
due to the fact that subsequent quantification of drug-specific antibodies in patient 
plasma used in the assays showed concentrations of 3.43 pg/ml and 2.88 pg/ml for both 
patients. These data were one of the major driving forces prompting us to attempt to 
generate B-cell lines that secrete piperacillin-specific IgG. However, as we were not 
successful in generating lines that could be used as autologous antigen presenting cells 
alongside their ability to secrete IgG, the significance of the original observations remains 
somewhat speculative.  
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The fine differences that determine whether drug exposure leads to an allergic or 
tolerant phenotype still need to be identified. To obtain a clearer picture of the role B 
cells and antibodies play, several studies have to be undertaken herein. One major 
drawback of the studies was the inability to purify drug-specific antibodies. Instead, 
whole plasma was used as a source of drug-specific antibody. Further studies should 
include antibody purification as this will enhance assessment of the functional 
differences between IgG produced from volunteers and naïve, tolerant and 
hypersensitive patients. This could also facilitate the assessment of differences between 
non-specific and drug-specific IgG and help to explain the reasons behind the presence of 
anti-drug antibodies in the absence of hypersensitivity. A cursory search at the 
downstream signalling pathways and genes up or down regulated by whole drug or 
drug-modified conjugates in the presence and absence of these antibodies could also be 
important. In the absence of purified specific antibodies, the generation of B cell lines 
with the ability to secrete not only IgG but piperacillin-specific antibodies will ensure that 
a system which closely mimics that obtained in vivo and hence mirrors those effects will 
be in place, limiting the obvious disadvantages associated with the use of whole plasma 
as a source of our drug-specific antibodies.  The characterization of conjugates formed 
during the course of therapy and their hapten density and molar quantification should 
also be performed concurrently with that of conjugates generated in vitro to ensure 
clinically relevant scenarios are reproduced in in vitro assays. This will help to ensure 
toxicity in the form of excessive dose is eliminated when conducting experiments.  
Nonetheless, I have been able to present relevant data that begins to describe the 
different molecular events and components of the drug-specific humoral and cellular 
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immune response that develops in piperacillin hypersensitive patients with CF. The 
kinetics of drug-specific B and T cell activation may be an important determinant of 
whether drug exposure leads to an immune response that results in tissue injury.  
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APPENDIX. 
APPENDIX 1  
a. Cell lines for B-cell immortalisation 
 
 
 
 
 
 
 
2 Cell culture drugs, antibodies and substrates for flow cytometry, ELISA, ELISpot 
and western blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line 
 
Source 
 
B95.8 cells 
 
1. Public Health England, Porton Down, Salisbury. 
 
 
Drugs/antibodies 
 
Source  
1. Cyclosporin A Sigma 
2. IL-2 Peprotech  
3. PHA  Sigma 
4. Cpg-dna  
5. 3H thymidine Moraveck  
6. 123 [Cs]   
7. CD3, CD4 , CD8 fluorochrome antibodies BD Biosciences 
8. CD19 , CD27 fluorochrome antibodies BD Biosciences 
9. Mouse anti-human penicillin antibody ABD Serotec 
10. Rat anti-flucloxacillin antibody  Gift from Van-pelt. 
11. HRP labelled mouse anti-human IgG1 antibody Invitrogen 
12. HRP labelled mouse anti-human IgG1 antibody Invitrogen 
13. HRP labelled mouse anti-human IgG1 antibody Invitrogen 
14. HRP labelled mouse anti-human IgG1 antibody Invitrogen 
15. human serum standard for IgG sub-classes Nordic 
16. BCIP/NBT Mabtech 
17. TMB ELISA substrate Mabtech 
18. Bovine serum albumin (BSA) Sigma 
19. Human serum albumin (HSA) Sigma 
20. Tetanus toxoid Statens serum institute 
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APPENDIX 2  
 
a. Cell culture consumables and assay kits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumable 
 
Source 
1. IFN-γ, IL-13, IL-5 and granzyme B 
ELISpot kit/substrates/antibodies 
 
Abcam 
2. Human IgG ELISA quantitation 
test 
Bethyl 
3. 96U well plates  Nunc 163320 
4. 96 flat bottom well plates Nunc 163320 
5. High binding 96 flat bottom well 
plates 
Greiner bio-one 
6. 24 well plates Nunc 142475 
7. 48 well plates  Nunc 150687 
8. Printed Filtermat A Perkin Elmer 1450-421 
9. Multilex A scintillator sheet Perkin Elmer 1450-441 
10. Sample plastic bag Perkin Elmer 1450-432 
11. 0.2µm filters Sartorius 16534 
12. 0.45µm filters Sartorius 16534 
13. 20 ml tube Sterilin 128C 
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APPENDIX 3  
 
 
b. Chemicals for SDS PAGE western blot and mass spectrometry analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical 
 
Source 
1. Tris base Fisher 
2. Skim milk powder Fluka biochemika 
3. Sodium chloride Normapur Prolabo 
4. Ultra-pure protogel National diagnostics 
5. 4 x protogel resolving buffer National diagnostics 
6. N,N,N’,N-tetramethylenediamine 
for electrophoresis (TEMED) 
National diagnostics 
7. Ammonium persulfate (APS) Sigma 
8. Methanol HPLC grade Fisher 
9. See blue MW marker Invitrogen 
10. Sequencing grade modified 
trypsin 
Promega 
11. Plus one Dithiothreitol (DTT)  Life technologies. 
12. Iodoacetamide Sigma 
13. C18 Zip tips  
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